furthermore O
rgse B-Plant
administration O
protected O
against O
cia B-Disease
induced O
oxidative O
tissue O
damage O
by O
restoring O
the O
increased O
malondialdehyde O
levels O
and O
the O
decreased O
glutathione O
levels O
and O
catalase O
activities O
almost O
to O
control O
levels O

therefore O
rgse B-Plant
may O
be O
a O
beneficial O
supplement O
which O
can O
improve O
human O
arthritis B-Disease

objectives O
to O
assess O
the O
evidence O
for O
tobacco B-Plant
smoking O
as O
a O
risk O
factor O
for O
the O
causation O
of O
chronic O
pancreatitis B-Disease

conclusions O
tobacco B-Plant
smoking O
may O
enhance O
the O
risk O
of O
developing O
chronic O
pancreatitis B-Disease

we O
have O
previously O
reported O
that O
eriobotrya B-Plant
japonica I-Plant
seed O
extract O
ese O
is O
effective O
for O
the O
treatment O
of O
various O
gastric B-Disease
mucosal I-Disease
injuries I-Disease

in O
this O
study O
we O
prepared O
dsw O
containing O
ese B-Plant
ese B-Plant
dsw O
and O
evaluated O
its O
usefulness O
for O
the O
prevention O
of O
gastric B-Disease
mucosal I-Disease
injuries I-Disease
using O
non O
steroidal O
anti O
inflammatory O
drug O
induced O
acute O
gastric B-Disease
mucosal I-Disease
injury I-Disease
models O
in O
male O
wistar O
st O
rats O

agarwood B-Plant
induced O
laxative O
effects O
via O
acetylcholine O
receptors O
on O
loperamide O
induced O
constipation B-Disease
in O
mice O

eea1 O
eea2 O
the O
main O
constituents O
of O
eeas O
mangiferin O
and O
genkwanin O
5 O
o O
primeveroside O
and O
senna B-Plant
increased O
the O
frequency O
and O
weight O
of O
stools O
in O
loperamide O
induced O
constipation B-Disease
model O
mice O

eea1 O
and O
eea2 O
did O
not O
induce O
diarrhea B-Disease
as O
a O
side O
effect O
but O
senna B-Plant
induced O
severe O
diarrhea B-Disease

cardiac B-Disease
contractile I-Disease
dysfunction I-Disease
and O
apoptosis O
in O
streptozotocin O
induced O
diabetic B-Disease
rats O
are O
ameliorated O
by O
garlic B-Plant
oil O
supplementation O

however O
the O
mechanism O
by O
which O
garlic B-Plant
oil O
protects O
diabetes B-Disease
induced O
cardiomyopathy B-Disease
is O
unclear O

in O
this O
study O
streptozotocin O
stz O
induced O
diabetic B-Disease
rats O
received O
garlic B-Plant
oil O
0 O
10 O
50 O
or O
100 O
mg O
kg O
of O
body O
weight O
by O
gastric O
gavage O
every O
2 O
days O
for O
16 O
days O

however O
these O
diabetes B-Disease
related O
cardiac O
dysfunctions O
were O
almost O
dose O
dependently O
ameliorated O
by O
garlic B-Plant
oil O

in O
conclusion O
garlic B-Plant
oil O
possesses O
significant O
potential O
for O
protecting O
hearts O
from O
diabetes B-Disease
induced O
cardiomyopathy B-Disease

argemone B-Plant
mexicana I-Plant
am B-Plant
a O
validated O
herbal O
medicine O
for O
uncomplicated O
malaria B-Disease
seems O
to O
prevent O
severe O
malaria B-Disease
without O
completely O
clearing O
parasites O
in O
most O
patients O

activity O
of O
melaleuca B-Plant
alternifolia I-Plant
tea B-Plant
tree I-Plant
oil O
on O
influenza B-Disease
virus O
a O
pr O
8 O
study O
on O
the O
mechanism O
of O
action O

our O
previous O
study O
demonstrated O
that O
melaleuca B-Plant
alternifolia I-Plant
tea B-Plant
tree I-Plant
oil O
tto B-Plant
had O
an O
interesting O
antiviral O
activity O
against O
influenza B-Disease
a I-Disease
in O
mdck O
cells O

in O
fact O
when O
we O
tested O
tto B-Plant
and O
some O
of O
its O
components O
we O
found O
that O
tto B-Plant
had O
an O
inhibitory O
effect O
on O
influenza B-Disease
virus O
replication O
at O
doses O
below O
the O
cytotoxic O
dose O
terpinen O
4 O
ol O
terpinolene O
and O
alfa O
terpineol O
were O
the O
main O
active O
components O

the O
aim O
of O
this O
study O
was O
to O
investigate O
the O
mechanism O
of O
action O
of O
tto B-Plant
and O
its O
active O
components O
against O
influenza B-Disease
a I-Disease
pr O
8 O
virus O
subtype O
h1n1 O
in O
mdck O
cells O

thus O
the O
effect O
of O
tto B-Plant
and O
its O
active O
components O
on O
different O
steps O
of O
the O
replicative O
cycle O
of O
influenza B-Disease
virus O
was O
studied O
by O
adding O
the O
test O
compounds O
at O
various O
times O
after O
infection B-Disease

these O
experiments O
revealed O
that O
viral O
replication O
was O
significantly O
inhibited O
if O
tto B-Plant
was O
added O
within O
2h O
of O
infection O
indicating O
an O
interference O
with O
an O
early O
step O
of O
the O
viral O
replicative O
cycle O
of O
influenza B-Disease
virus O

tto B-Plant
did O
not O
inhibit O
influenza B-Disease
virus O
neuraminidase O
activity O
as O
shown O
by O
the O
experiment O
measuring O
the O
amount O
of O
4 O
methylumbelliferone O
cleaved O
by O
the O
influenza B-Disease
virus O
neuraminidase O
from O
the O
fluorogenic O
substrate O
2 O
o O
4 O
methylumbelliferyl O
n O
acetylneuraminic O
acid O

green O
and O
black B-Plant
tea I-Plant
suppress O
hyperglycemia O
and O
insulin B-Disease
resistance I-Disease
by O
retaining O
the O
expression O
of O
glucose O
transporter O
4inch O
muscle O
of O
high O
fat O
diet O
fed O
c57bl O
6j O
mice O

to O
investigate O
the O
preventive O
effects O
of O
tea B-Plant
on O
hyperglycemia B-Disease
and O
insulin B-Disease
resistance I-Disease
male O
c57bl O
6j O
mice O
were O
given O
a O
high O
fat O
diet O
containing O
29 O
lard O
and O
also O
green B-Plant
or O
black B-Plant
tea I-Plant
ad O
libitum O
for O
14 O
weeks O

the O
results O
strongly O
suggest O
that O
green B-Plant
and O
black I-Plant
tea I-Plant
suppress O
high O
fat O
diet O
evoked O
hyperglycemia B-Disease
and O
insulin B-Disease
resistance I-Disease
by O
retaining O
the O
level O
of O
glut4 O
and O
increasing O
the O
level O
of O
glut4 O
on O
the O
plasma O
membrane O
in O
muscle O

zingiber B-Plant
officinale I-Plant
mitigates O
brain B-Disease
damage I-Disease
and O
improves O
memory B-Disease
impairment I-Disease
in O
focal O
cerebral B-Disease
ischemic I-Disease
rat O

in O
this O
study O
possible O
protective O
effect O
of O
zingiber B-Plant
officinale I-Plant
a O
medicinal O
plant O
reputed O
for O
neuroprotective O
effect O
against O
oxidative O
stress O
related O
brain B-Disease
damage I-Disease
on O
brain O
damage O
and O
memory O
deficit O
induced O
by O
focal O
cerebral B-Disease
ischemia I-Disease
was O

elucidated O
male O
adult O
wistar O
rats O
were O
administrated O
an O
alcoholic O
extract O
of O
ginger B-Plant
rhizome O
orally O
14 O
days O
before O
and O
21 O
days O
after O
the O
permanent O
occlusion B-Disease
of O
right O
middle O
cerebral O
artery O
mcao O

the O
results O
showed O
that O
cognitive O
function O
and O
neurons O
density O
in O
hippocampus O
of O
rats O
receiving O
ginger B-Plant
rhizome O
extract O
were O
improved O
while O
the O
brain O
infarct B-Disease
volume O
was O
decreased O

in O
conclusion O
our O
study O
demonstrated O
the O
beneficial O
effect O
of O
ginger B-Plant
rhizome O
to O
protect O
against O
focal O
cerebral B-Disease
ischemia I-Disease

new O
cancer B-Disease
treatment O
strategy O
using O
combination O
of O
green B-Plant
tea I-Plant
catechins O
and O
anti O
cancer B-Disease
drugs O

in O
one O
study O
10 O
japanese O
size O
cups O
of O
green B-Plant
tea I-Plant
daily O
supplemented O
with O
tablets O
of O
green B-Plant
tea I-Plant
extract O
limited O
the O
recurrence O
of O
colorectal B-Disease
polyps I-Disease
in O
humans O
to O
50 O

thus O
cancer B-Disease
patients O
who O
consume O
green B-Plant
tea I-Plant
and O
take O
anti O
cancer B-Disease
drugs O
will O
have O
double O
prevention O

hibiscus B-Plant
sabdariffa I-Plant
linne I-Plant
is O
a O
traditional O
chinese B-Plant
rose I-Plant
tea I-Plant
and O
has O
been O
effectively O
used O
in O
folk O
medicines O
for O
treatment O
of O
hypertension B-Disease
inflammatory B-Disease
conditions I-Disease

pca B-Plant
and O
has B-Plant
protected O
against O
oxidative B-Disease
damage I-Disease
induced O
by O
tert O
butyl O
droperoxide O
t O
bhp O
in O
rat O
primary O
hepatocytes O

in O
rabbits O
fed O
cholesterol O
and O
human O
experimental O
studies O
these O
studies O
imply O
hse B-Plant
could O
be O
pursued O
as O
atherosclerosis B-Disease
chemopreventive O
agents O
as O
they O
inhibit O
ldl O
oxidation O
foam O
cell O
formation O
as O
well O
as O
smooth O
muscle O
cell O
migration O
and O
proliferation O

has B-Plant
and O
hpe B-Plant
were O
demonstrated O
to O
cause O
cancer B-Disease
cell O
apoptosis O
especially O
in O
leukemia B-Disease
and O
gastric B-Disease
cancer I-Disease

more O
recent O
studies O
investigated O
the O
protective O
effect O
of O
hse B-Plant
and O
hpe B-Plant
in O
streptozotocin O
induced O
diabetic B-Disease
nephropathy I-Disease

from O
all O
these O
studies O
it O
is O
clear O
that O
various O
h B-Plant
sabdariffa I-Plant
extracts O
exhibit O
activities O
against O
atherosclerosis B-Disease
liver B-Disease
disease I-Disease
cancer B-Disease
diabetes B-Disease
and O
other O
metabolic B-Disease
syndromes I-Disease

association O
between O
areca B-Plant
stimulated O
vimentin O
expression O
and O
the O
progression O
of O
head B-Disease
and O
neck B-Disease
cancers I-Disease

conclusions O
areca B-Plant
nut O
chewing O
has O
a O
significant O
association O
with O
systemic B-Disease
inflammation I-Disease

the O
purpose O
of O
this O
study O
was O
to O
investigate O
the O
impacts O
of O
areca B-Plant
nut I-Plant
chewing O
on O
neoplastic O
process O
of O
head B-Disease
and O
neck B-Disease
carcinoma I-Disease

methods O
head B-Disease
and O
neck B-Disease
carcinoma I-Disease
cells O
were O
treated O
with O
areca B-Plant
nut I-Plant
extract O
to O
perceive O
the O
phenotypic O
impacts O

tumor B-Disease
tissues O
were O
analyzed O
with O
immunohistochemistry O
ihc O
to O
understand O
the O
association O
between O
areca B-Plant
associated O
molecular O
changes O
and O
clinical O
variables O

results O
upon O
treatment O
with O
areca B-Plant
nut I-Plant
extract O
carcinoma B-Disease
cells O
showed O
the O
increase O
of O
vimentin O

conclusion O
areca B-Plant
modulated O
vimentin O
expression O
enhanced O
the O
progression O
of O
head B-Disease
and O
neck B-Disease
carcinoma I-Disease

tobacco B-Plant
smoking O
and O
cutaneous B-Disease
squamous I-Disease
cell I-Disease
carcinoma I-Disease
a O
16 O
year O
longitudinal O
population O
based O
study O

background O
although O
tobacco B-Plant
smoking O
is O
commonly O
cited O
as O
a O
risk O
factor O
for O
cutaneous B-Disease
squamous I-Disease
cell I-Disease
carcinoma I-Disease
scc B-Disease
the O
evidence O
from O
previous O
clinical O
and O
case O
control O
studies O
is O
conflicting O

we O
therefore O
aimed O
to O
prospectively O
examine O
the O
role O
of O
tobacco B-Plant
smoking O
in O
the O
development O
of O
scc B-Disease
of O
the O
skin O
in O
a O
population O
based O
study O

conclusions O
in O
this O
australian O
follow O
up O
study O
tobacco B-Plant
smoking O
did O
not O
increase O
the O
risk O
of O
scc B-Disease
of O
the O
skin O

impact O
these O
prospective O
adjusted O
data O
provide O
strong O
evidence O
which O
suggests O
that O
cutaneous O
scc B-Disease
should O
not O
be O
on O
the O
list O
of O
tobacco B-Plant
related O
cancers B-Disease

lemon B-Plant
verbena I-Plant
infusion O
consumption O
attenuates O
oxidative O
stress O
in O
dextran O
sulfate O
sodium O
induced O
colitis B-Disease
in O
the O
rat O

aims O
this O
study O
evaluated O
the O
preventive O
effects O
of O
lemon B-Plant
verbena I-Plant
infusion O
consumption O
against O
mild O
to O
moderate O
dextran O
sulfate O
sodium O
dss O
induced O
colitis B-Disease
in O
rats O

conclusion O
our O
study O
shows O
that O
the O
preventive O
consumption O
of O
lemon B-Plant
verbena I-Plant
infusion O
offered O
some O
antioxidative O
protection O
during O
experimental O
colitis B-Disease
by O
stimulating O
sod O
activity O
and O
decreasing O
lipid O
peroxidation O

dietary O
wolfberry B-Plant
ameliorates O
retinal B-Disease
structure I-Disease
abnormalities I-Disease
in O
db O
mice O
at O
the O
early O
stage O
of O
diabetes B-Disease

wolfberry B-Plant
is O
a O
traditional O
asian O
fruit O
consumed O
for O
years O
to O
prevent O
aging O
eye B-Disease
diseases I-Disease
in O
asian O
contries O

here O
we O
report O
that O
dietary O
wolfberry B-Plant
ameliorated O
mouse O
retinal B-Disease
abnormality I-Disease
at O
the O
early O
stage O
of O
type B-Disease
2 I-Disease
diabetes I-Disease
in O
db O
mice O

taken O
together O
dietary O
wolfberry B-Plant
on O
retinal O
protection O
in O
diabetic B-Disease
mice O
is O
at O
least O
partially O
due O
to O
zeaxanthin O
and O
or O
lutenin O
the O
ethanol O
extract O
from O
the O
dried O
exudate O
of O
bursera B-Plant
fagaroides I-Plant
burseraceae B-Plant
showed O
significant O
cytotoxic O
activity O
in O
the O
ht O
29 O
human O
colon B-Disease
adenocarcinoma I-Disease
test O
system O

benefits O
of O
whole O
ginger B-Plant
extract O
in O
prostate B-Disease
cancer I-Disease

here O
we O
show O
that O
whole O
ginger O
extract O
ge B-Plant
exerts O
significant O
growth O
inhibitory O
and O
death O
inductory O
effects O
in O
a O
spectrum O
of O
prostate B-Disease
cancer I-Disease

comprehensive O
studies O
have O
confirmed O
that O
ge B-Plant
perturbed O
cell O
cycle O
progression O
impaired O
reproductive O
capacity O
modulated O
cell O
cycle O
and O
apoptosis O
regulatory O
molecules O
and O
induced O
a O
caspase O
driven O
mitochondrially O
mediated O
apoptosis O
in O
human O
prostate B-Disease
cancer I-Disease
cells O

remarkably O
daily O
oral O
feeding O
of O
100 O
mg O
kg O
body O
weight O
of O
ge B-Plant
inhibited O
growth O
and O
progression O
of O
pc O
3 O
xenografts O
by O
approximately O
56 O
in O
nude O
mice O
as O
shown O
by O
measurements O
of O
tumour B-Disease
volume O

tumour B-Disease
tissue O
from O
ge B-Plant
treated O
mice O
showed O
reduced O
proliferation O
index O
and O
widespread O
apoptosis O
compared O
with O
controls O
as O
determined O
by O
immunoblotting O
and O
immunohistochemical O
methods O

most O
importantly O
ge B-Plant
did O
not O
exert O
any O
detectable O
toxicity B-Disease
in O
normal O
rapidly O
dividing O
tissues O
such O
as O
gut O
and O
bone O
marrow O

to O
the O
best O
of O
our O
knowledge O
this O
is O
the O
first O
report O
to O
demonstrate O
the O
in O
vitro O
and O
in O
vivo O
anticancer O
activity O
of O
whole O
ge B-Plant
for O
the O
management O
of O
prostate B-Disease
cancer I-Disease
vision O
preservation O
during O
retinal B-Disease
inflammation I-Disease
by O
anthocyanin O
rich O
bilberry B-Plant
extract O
cellular O
and O
molecular O
mechanism O

at O
the O
cellular O
level O
we O
found O
that O
the O
eiu B-Disease
associated O
rhodopsin O
decreased O
and O
the O
shortening O
of O
outer O
segments O
in O
photoreceptor O
cells O
were O
suppressed O
in O
the O
bilberry B-Plant
extract O
treated O
animals O

in O
addition O
to O
its O
anti O
inflammatory O
effect O
the O
anthocyanin O
rich O
bilberry B-Plant
extract O
ameliorated O
the O
intracellular O
elevation O
of O
reactive O
oxygen O
species O
and O
activated O
nf O
kb O
a O
redox O
sensitive O
transcription O
factor O
in O
the O
inflamed B-Disease
retina I-Disease

our O
findings O
indicate O
that O
anthocyanin O
rich O
bilberry B-Plant
extract O
has O
a O
protective O
effect O
on O
visual O
function O
during O
retinal B-Disease
inflammation I-Disease

in O
vitro O
antioxidant O
and O
anticancer O
activity O
of O
young O
zingiber B-Plant
officinale I-Plant
against O
human O
breast B-Disease
carcinoma I-Disease
cell O
lines O

the O
present O
work O
is O
aimed O
to O
find O
out O
antioxidant O
and O
anticancer O
activities O
of O
two O
bangladeshi O
ginger B-Plant
varieties O
fulbaria O
and O
syedpuri O
at O
young O
age O
grown O
under O
ambient O
400 O
mol O
and O
elevated O
800 O
mol O
co2 O
concentrations O
against O
two O
human O
breast B-Disease
cancer I-Disease
cell O
lines O
mcf O
7 O
and O
mda O
mb O
231 O

clustering O
of O
missense O
mutations O
in O
the O
ataxia B-Disease
- I-Disease
telangiectasia I-Disease
gene O
in O
a O
sporadic B-Disease
t I-Disease
- I-Disease
cell I-Disease
leukaemia I-Disease
. O

ataxia B-Disease
- I-Disease
telangiectasia I-Disease
( O
a B-Disease
- I-Disease
t I-Disease
) O
is O
a O
recessive B-Disease
multi I-Disease
- I-Disease
system I-Disease
disorder I-Disease
caused O
by O
mutations O
in O
the O
atm O
gene O
at O
11q22 O
- O
q23 O
( O
ref O
. O
3 O
) O
. O

the O
risk O
of O
cancer B-Disease
, O
especially O
lymphoid B-Disease
neoplasias I-Disease
, O
is O
substantially O
elevated O
in O
a B-Disease
- I-Disease
t I-Disease
patients O
and O
has O
long O
been O
associated O
with O
chromosomal O
instability O
. O

by O
analysing O
tumour B-Disease
dna O
from O
patients O
with O
sporadic B-Disease
t I-Disease
- I-Disease
cell I-Disease
prolymphocytic I-Disease
leukaemia I-Disease
( O
t B-Disease
- I-Disease
pll I-Disease
) O
, O
a O
rare O
clonal B-Disease
malignancy I-Disease
with O
similarities O
to O
a O
mature B-Disease
t I-Disease
- I-Disease
cell I-Disease
leukaemia I-Disease
seen O
in O
a B-Disease
- I-Disease
t I-Disease
, O
we O
demonstrate O
a O
high O
frequency O
of O
atm O
mutations O
in O
t B-Disease
- I-Disease
pll I-Disease
. O

in O
marked O
contrast O
to O
the O
atm O
mutation O
pattern O
in O
a B-Disease
- I-Disease
t I-Disease
, O
the O
most O
frequent O
nucleotide O
changes O
in O
this O
leukaemia B-Disease
were O
missense O
mutations O
. O

these O
clustered O
in O
the O
region O
corresponding O
to O
the O
kinase O
domain O
, O
which O
is O
highly O
conserved O
in O
atm O
- O
related O
proteins O
in O
mouse O
, O
yeast O
and O
drosophila O
. O

the O
resulting O
amino O
- O
acid O
substitutions O
are O
predicted O
to O
interfere O
with O
atp O
binding O
or O
substrate O
recognition O
. O

two O
of O
seventeen O
mutated O
t B-Disease
- I-Disease
pll I-Disease
samples O
had O
a O
previously O
reported O
a B-Disease
- I-Disease
t I-Disease
allele O
. O

in O
contrast O
, O
no O
mutations O
were O
detected O
in O
the O
p53 O
gene O
, O
suggesting O
that O
this O
tumour B-Disease
suppressor O
is O
not O
frequently O
altered O
in O
this O
leukaemia B-Disease
. O

occasional O
missense O
mutations O
in O
atm O
were O
also O
found O
in O
tumour B-Disease
dna O
from O
patients O
with O
b B-Disease
- I-Disease
cell I-Disease
non I-Disease
- I-Disease
hodgkins I-Disease
lymphomas I-Disease
( O
b B-Disease
- I-Disease
nhl I-Disease
) O
and O
a O
b B-Disease
- I-Disease
nhl I-Disease
cell O
line O
. O

the O
evidence O
of O
a O
significant O
proportion O
of O
loss O
- O
of O
- O
function O
mutations O
and O
a O
complete O
absence O
of O
the O
normal O
copy O
of O
atm O
in O
the O
majority O
of O
mutated O
tumours B-Disease
establishes O
somatic O
inactivation O
of O
this O
gene O
in O
the O
pathogenesis O
of O
sporadic B-Disease
t I-Disease
- I-Disease
pll I-Disease
and O
suggests O
that O
atm O
acts O
as O
a O
tumour B-Disease
suppressor O
. O

as O
constitutional O
dna O
was O
not O
available O
, O
a O
putative O
hereditary O
predisposition O
to O
t B-Disease
- I-Disease
pll I-Disease
will O
require O
further O
investigation O
. O
. O

myotonic B-Disease
dystrophy I-Disease
protein O
kinase O
is O
involved O
in O
the O
modulation O
of O
the O
ca2 O
+ O
homeostasis O
in O
skeletal O
muscle O
cells O
. O

myotonic B-Disease
dystrophy I-Disease
( O
dm B-Disease
) O
, O
the O
most O
prevalent O
muscular B-Disease
disorder I-Disease
in O
adults O
, O
is O
caused O
by O
( O
ctg O
) O
n O
- O
repeat O
expansion O
in O
a O
gene O
encoding O
a O
protein O
kinase O
( O
dm B-Disease
protein O
kinase O
; O
dmpk O
) O
and O
involves O
changes O
in O
cytoarchitecture O
and O
ion O
homeostasis O
. O

to O
obtain O
clues O
to O
the O
normal O
biological O
role O
of O
dmpk O
in O
cellular O
ion O
homeostasis O
, O
we O
have O
compared O
the O
resting O
[ O
ca2 O
+ O
] O
i O
, O
the O
amplitude O
and O
shape O
of O
depolarization O
- O
induced O
ca2 O
+ O
transients O
, O
and O
the O
content O
of O
atp O
- O
driven O
ion O
pumps O
in O
cultured O
skeletal O
muscle O
cells O
of O
wild O
- O
type O
and O
dmpk O
[ O
- O
/ O
- O
] O
knockout O
mice O
. O

in O
vitro O
- O
differentiated O
dmpk O
[ O
- O
/ O
- O
] O
myotubes O
exhibit O
a O
higher O
resting O
[ O
ca2 O
+ O
] O
i O
than O
do O
wild O
- O
type O
myotubes O
because O
of O
an O
altered O
open O
probability O
of O
voltage O
- O
dependent O
l O
- O
type O
ca2 O
+ O
and O
na O
+ O
channels O
. O

the O
mutant O
myotubes O
exhibit O
smaller O
and O
slower O
ca2 O
+ O
responses O
upon O
triggering O
by O
acetylcholine O
or O
high O
external O
k O
+ O
. O

in O
addition O
, O
we O
observed O
that O
these O
ca2 O
+ O
transients O
partially O
result O
from O
an O
influx O
of O
extracellular O
ca2 O
+ O
through O
the O
l O
- O
type O
ca2 O
+ O
channel O
. O

neither O
the O
content O
nor O
the O
activity O
of O
na O
+ O
/ O
k O
+ O
atpase O
and O
sarcoplasmic O
reticulum O
ca2 O
+ O
- O
atpase O
are O
affected O
by O
dmpk O
absence O
. O

in O
conclusion O
, O
our O
data O
suggest O
that O
dmpk O
is O
involved O
in O
modulating O
the O
initial O
events O
of O
excitation O
- O
contraction O
coupling O
in O
skeletal O
muscle O
. O
. O

constitutional O
rb1 O
- O
gene O
mutations O
in O
patients O
with O
isolated O
unilateral B-Disease
retinoblastoma I-Disease
. O

in O
most O
patients O
with O
isolated O
unilateral B-Disease
retinoblastoma I-Disease
, O
tumor B-Disease
development O
is O
initiated O
by O
somatic O
inactivation O
of O
both O
alleles O
of O
the O
rb1 O
gene O
. O

however O
, O
some O
of O
these O
patients O
can O
transmit O
retinoblastoma B-Disease
predisposition O
to O
their O
offspring O
. O

to O
determine O
the O
frequency O
and O
nature O
of O
constitutional O
rb1 O
- O
gene O
mutations O
in O
patients O
with O
isolated O
unilateral B-Disease
retinoblastoma I-Disease
, O
we O
analyzed O
dna O
from O
peripheral O
blood O
and O
from O
tumor B-Disease
tissue O
. O

the O
analysis O
of O
tumors B-Disease
from O
54 O
( O
71 O
% O
) O
of O
76 O
informative O
patients O
showed O
loss O
of O
constitutional O
heterozygosity O
( O
loh O
) O
at O
intragenic O
loci O
. O

three O
of O
13 O
uninformative O
patients O
had O
constitutional O
deletions O
. O

for O
39 O
randomly O
selected O
tumors B-Disease
, O
sscp O
, O
hetero O
- O
duplex O
analysis O
, O
sequencing O
, O
and O
southern O
blot O
analysis O
were O
used O
to O
identify O
mutations O
. O

mutations O
were O
detected O
in O
21 O
( O
91 O
% O
) O
of O
23 O
tumors B-Disease
with O
loh O
. O

in O
6 O
( O
38 O
% O
) O
of O
16 O
tumors B-Disease
without O
loh O
, O
one O
mutation O
was O
detected O
, O
and O
in O
9 O
( O
56 O
% O
) O
of O
the O
tumors B-Disease
without O
loh O
, O
both O
mutations O
were O
found O
. O

thus O
, O
a O
total O
of O
45 O
mutations O
were O
identified O
in O
tumors B-Disease
of O
36 O
patients O
. O

thirty O
- O
nine O
of O
the O
mutations O
- O
including O
34 O
small O
mutations O
, O
2 O
large O
structural O
alterations O
, O
and O
hypermethylation O
in O
3 O
tumors O
- O
were O
not O
detected O
in O
the O
corresponding O
peripheral O
blood O
dna O
. O

in O
6 O
( O
17 O
% O
) O
of O
the O
36 O
patients O
, O
a O
mutation O
was O
detected O
in O
constitutional O
dna O
, O
and O
1 O
of O
these O
mutations O
is O
known O
to O
be O
associated O
with O
reduced O
expressivity O
. O

the O
presence O
of O
a O
constitutional O
mutation O
was O
not O
associated O
with O
an O
early O
age O
at O
treatment O
. O

in O
1 O
patient O
, O
somatic O
mosaicism O
was O
demonstrated O
by O
molecular O
analysis O
of O
dna O
and O
rna O
from O
peripheral O
blood O
. O

in O
2 O
patients O
without O
a O
detectable O
mutation O
in O
peripheral O
blood O
, O
mosaicism O
was O
suggested O
because O
1 O
of O
the O
patients O
showed O
multifocal O
tumors B-Disease
and O
the O
other O
later O
developed O
bilateral B-Disease
retinoblastoma I-Disease
. O

in O
conclusion O
, O
our O
results O
emphasize O
that O
the O
manifestation O
and O
transmissibility O
of O
retinoblastoma B-Disease
depend O
on O
the O
nature O
of O
the O
first O
mutation O
, O
its O
time O
in O
development O
, O
and O
the O
number O
and O
types O
of O
cells O
that O
are O
affected O
. O
. O

hereditary B-Disease
deficiency I-Disease
of I-Disease
the I-Disease
fifth I-Disease
component I-Disease
of I-Disease
complement I-Disease
in O
man O
. O

i O
. O

clinical O
, O
immunochemical O
, O
and O
family O
studies O
. O

the O
first O
recognized O
human O
kindred O
with O
hereditary B-Disease
deficiency I-Disease
of I-Disease
the I-Disease
fifth I-Disease
component I-Disease
of I-Disease
complement I-Disease
( O
c5 O
) O
is O
described O
. O

the O
proband O
, O
a O
20 O
- O
year O
- O
old O
black O
female O
with O
systemic B-Disease
lupus I-Disease
erythematosus I-Disease
since O
age O
11 O
, O
lacked O
serum O
hemolytic O
complement O
activity O
, O
even O
during O
remission O
. O

c5 O
was O
undetectable O
in O
her O
serum O
by O
both O
immunodiffusion O
and O
hemolytic O
assays O
. O

other O
complement O
components O
were O
normal O
during O
remission O
of O
lupus O
, O
but O
c1 O
, O
c4 O
, O
c2 O
, O
and O
c3 O
levels O
fell O
during O
exacerbations O
. O

a O
younger O
half O
- O
sister O
, O
who O
had O
no O
underlying O
disease O
, O
was O
also O
found O
to O
lack O
immunochemically O
detectable O
c5 O
. O

by O
hemolytic O
assay O
, O
she O
exhibited O
1 O
- O
2 O
% O
of O
the O
normal O
serum O
c5 O
level O
and O
normal O
concentrations O
of O
other O
complement O
components O
. O

c5 O
levels O
of O
other O
family O
members O
were O
either O
normal O
or O
approximately O
half O
- O
normal O
, O
consistent O
with O
autosomal O
codominant O
inheritance O
of O
the O
gene O
determining O
c5 B-Disease
deficiency I-Disease
. O

normal O
hemolytic O
titers O
were O
restored O
to O
both O
homozygous O
c5 B-Disease
- I-Disease
deficient I-Disease
( O
c5d B-Disease
) O
sera O
by O
addition O
of O
highly O
purified O
human O
c5 O
. O

in O
specific O
c5 O
titrations O
, O
however O
, O
it O
was O
noted O
that O
when O
limited O
amounts O
of O
c5 O
were O
assayed O
in O
the O
presence O
of O
low O
dilutions O
of O
either O
c5d B-Disease
serum O
, O
curving O
rather O
than O
linear O
dose O
- O
response O
plots O
were O
consistently O
obtained O
, O
suggesting O
some O
inhibitory O
effect O
. O

further O
studies O
suggested O
that O
low O
dilutions O
of O
c5d B-Disease
serum O
contain O
a O
factor O
( O
or O
factors O
) O
interfering O
at O
some O
step O
in O
the O
hemolytic O
assay O
of O
c5 O
, O
rather O
than O
a O
true O
c5 O
inhibitor O
or O
inactivator O
. O

of O
clinical O
interest O
are O
( O
a O
) O
the O
documentation O
of O
membranous O
glomerulonephritis B-Disease
, O
vasculitis B-Disease
, O
and O
arthritis B-Disease
in O
an O
individual O
lacking O
c5 O
( O
and O
its O
biologic O
functions O
) O
, O
and O
( O
b O
) O
a O
remarkable O
propensity O
to O
bacterial B-Disease
infections I-Disease
in O
the O
proband O
, O
even O
during O
periods O
of O
low O
- O
dose O
or O
alternate O
- O
day O
corticosteroid O
therapy O
. O

other O
observations O
indicate O
that O
the O
c5d B-Disease
state O
is O
compatible O
with O
normal O
coagulation O
function O
and O
the O
capacity O
to O
mount O
a O
neutrophilic O
leukocytosis O
during O
pyogenic B-Disease
infection I-Disease
. O
. O

susceptibility O
to O
ankylosing B-Disease
spondylitis I-Disease
in O
twins O
: O
the O
role O
of O
genes O
, O
hla O
, O
and O
the O
environment O
. O

objective O
to O
determine O
the O
relative O
effects O
of O
genetic O
and O
environmental O
factors O
in O
susceptibility O
to O
ankylosing B-Disease
spondylitis I-Disease
( O
as B-Disease
) O
. O

methods O
twins O
with O
as B-Disease
were O
identified O
from O
the O
royal O
national O
hospital O
for O
rheumatic B-Disease
diseases I-Disease
database O
. O

clinical O
and O
radiographic O
examinations O
were O
performed O
to O
establish O
diagnoses O
, O
and O
disease O
severity O
was O
assessed O
using O
a O
combination O
of O
validated O
scoring O
systems O
. O

hla O
typing O
for O
hla O
- O
b27 O
, O
hla O
- O
b60 O
, O
and O
hla O
- O
dr1 O
was O
performed O
by O
polymerase O
chain O
reaction O
with O
sequence O
- O
specific O
primers O
, O
and O
zygosity O
was O
assessed O
using O
microsatellite O
markers O
. O

genetic O
and O
environmental O
variance O
components O
were O
assessed O
with O
the O
program O
mx O
, O
using O
data O
from O
this O
and O
previous O
studies O
of O
twins O
with O
as B-Disease
. O

results O
six O
of O
8 O
monozygotic O
( O
mz O
) O
twin O
pairs O
were O
disease O
concordant O
, O
compared O
with O
4 O
of O
15 O
b27 O
- O
positive O
dizygotic O
( O
dz O
) O
twin O
pairs O
( O
27 O
% O
) O
and O
4 O
of O
32 O
dz O
twin O
pairs O
overall O
( O
12 O
. O
5 O
% O
) O
. O

nonsignificant O
increases O
in O
similarity O
with O
regard O
to O
age O
at O
disease O
onset O
and O
all O
of O
the O
disease O
severity O
scores O
assessed O
were O
noted O
in O
disease O
- O
concordant O
mz O
twins O
compared O
with O
concordant O
dz O
twins O
. O

hla O
- O
b27 O
and O
b60 O
were O
associated O
with O
the O
disease O
in O
probands O
, O
and O
the O
rate O
of O
disease O
concordance O
was O
significantly O
increased O
among O
dz O
twin O
pairs O
in O
which O
the O
co O
- O
twin O
was O
positive O
for O
both O
b27 O
and O
dr1 O
. O

additive O
genetic O
effects O
were O
estimated O
to O
contribute O
97 O
% O
of O
the O
population O
variance O
. O

conclusion O
susceptibility O
to O
as B-Disease
is O
largely O
genetically O
determined O
, O
and O
the O
environmental O
trigger O
for O
the O
disease O
is O
probably O
ubiquitous O
. O

hla O
- O
b27 O
accounts O
for O
a O
minority O
of O
the O
overall O
genetic O
susceptibility O
to O
as B-Disease
. O

cell O
cycle O
- O
dependent O
colocalization O
of O
bard1 O
and O
brca1 O
proteins O
in O
discrete O
nuclear O
domains O
. O

germ O
- O
line O
mutations O
of O
the O
brca1 O
gene O
predispose O
women O
to O
early O
- O
onset O
breast B-Disease
and I-Disease
ovarian I-Disease
cancer I-Disease
by O
compromising O
the O
genes O
presumptive O
function O
as O
a O
tumor B-Disease
suppressor O
. O

although O
the O
biochemical O
properties O
of O
brca1 O
polypeptides O
are O
not O
understood O
, O
their O
expression O
pattern O
and O
subcellular O
localization O
suggest O
a O
role O
in O
cell O
- O
cycle O
regulation O
. O

when O
resting O
cells O
are O
induced O
to O
proliferate O
, O
the O
steady O
- O
state O
levels O
of O
brca1 O
increase O
in O
late O
g1 O
and O
reach O
a O
maximum O
during O
s O
phase O
. O

moreover O
, O
in O
s O
phase O
cells O
, O
brca1 O
polypeptides O
are O
hyperphosphorylated O
and O
accumulate O
into O
discrete O
subnuclear O
foci O
termed O
" O
brca1 O
nuclear O
dots O
. O

" O
brca1 O
associates O
in O
vivo O
with O
a O
structurally O
related O
protein O
termed O
bard1 O
. O

here O
we O
show O
that O
the O
steady O
- O
state O
levels O
of O
bard1 O
, O
unlike O
those O
of O
brca1 O
, O
remain O
relatively O
constant O
during O
cell O
cycle O
progression O
. O

however O
, O
immunostaining O
revealed O
that O
bard1 O
resides O
within O
brca1 O
nuclear O
dots O
during O
s O
phase O
of O
the O
cell O
cycle O
, O
but O
not O
during O
the O
g1 O
phase O
. O

nevertheless O
, O
bard1 O
polypeptides O
are O
found O
exclusively O
in O
the O
nuclear O
fractions O
of O
both O
g1 O
- O
and O
s O
- O
phase O
cells O
. O

therefore O
, O
progression O
to O
s O
phase O
is O
accompanied O
by O
the O
aggregation O
of O
nuclear O
bard1 O
polypeptides O
into O
brca1 O
nuclear O
dots O
. O

this O
cell O
cycle O
- O
dependent O
colocalization O
of O
bard1 O
and O
brca1 O
indicates O
a O
role O
for O
bard1 O
in O
brca1 O
- O
mediated O
tumor B-Disease
suppression O
. O

ethnic O
differences O
in O
the O
hfe O
codon O
282 O
( O
cys O
/ O
tyr O
) O
polymorphism O
. O

recent O
studies O
have O
shown O
that O
hereditary B-Disease
hemochromatosis I-Disease
( O
hh B-Disease
) O
is O
likely O
to O
be O
caused O
by O
homozygosity O
for O
a O
cys282tyr O
mutation O
in O
the O
hfe O
gene O
located O
4 O
. O

5 O
mb O
telomeric O
to O
hla O
- O
a O
. O

population O
studies O
of O
this O
polymorphism O
are O
facilitated O
by O
the O
fact O
that O
the O
cys282tyr O
mutation O
creates O
a O
rsal O
restriction O
site O
. O

we O
have O
studied O
the O
codon O
282 O
( O
cys O
/ O
tyr O
) O
polymorphism O
in O
different O
ethnic O
groups O
. O

in O
agreement O
with O
previous O
observations O
the O
tyr O
allele O
appeared O
to O
be O
rare O
or O
absent O
in O
asiatic O
( O
indian O
, O
chinese O
) O
populations O
. O

the O
highest O
allele O
frequency O
( O
7 O
. O
5 O
% O
) O
was O
found O
in O
swedes O
. O

saamis O
( O
2 O
% O
) O
and O
mordvinians O
( O
1 O
. O
8 O
% O
) O
had O
significantly O
lower O
frequencies O
of O
the O
tyr O
allele O
. O

comparisons O
with O
allele O
frequencies O
based O
on O
prevalence O
estimates O
of O
hh B-Disease
showed O
some O
disagreements O
with O
the O
rflp O
data O
, O
particularly O
in O
finns O
. O

the O
newly O
described O
hfe O
marker O
provides O
a O
new O
approach O
to O
the O
screening O
of O
hh B-Disease
as O
well O
as O
studies O
of O
the O
relationship O
between O
the O
hfe O
tyr O
allele O
and O
different O
disorders O
including O
cancer B-Disease

autosomal B-Disease
dominant I-Disease
neurohypophyseal I-Disease
diabetes I-Disease
insipidus I-Disease
associated O
with O
a O
missense O
mutation O
encoding O
gly23 O
- O
- O
> O
val O
in O
neurophysin O
ii O
. O

autosomal B-Disease
dominant I-Disease
neurohypophyseal I-Disease
diabetes I-Disease
insipidus I-Disease
( O
adndi B-Disease
) O
is O
an O
inherited B-Disease
disease I-Disease
caused O
by O
progressive O
degeneration O
of O
the O
magnocellular O
neurons O
of O
the O
hypothalamus O
leading O
to O
decreased O
ability O
to O
produce O
the O
hormone O
arginine O
vasopressin O
( O
avp O
) O
. O

affected O
individuals O
are O
not O
symptomatic O
at O
birth O
, O
but O
usually O
develop O
diabetes B-Disease
insipidus I-Disease
at O
1 O
- O
6 O
yr O
of O
age O
. O

the O
genetic O
locus O
of O
the O
disease O
is O
the O
avp O
- O
neurophysin O
ii O
( O
npii O
) O
gene O
, O
and O
mutations O
that O
cause O
adndi B-Disease
have O
been O
found O
in O
both O
the O
signal O
peptide O
of O
the O
prepro O
- O
avp O
- O
npii O
precursor O
and O
within O
npii O
itself O
. O

an O
affected O
girl O
who O
presented O
at O
9 O
months O
of O
age O
and O
her O
similarly O
affected O
younger O
brother O
and O
father O
were O
all O
found O
to O
have O
a O
novel O
missense O
mutation O
( O
g1758 O
- O
- O
> O
t O
) O
encoding O
the O
amino O
acid O
substitution O
gly23 O
- O
- O
> O
val O
within O
npii O
. O

the O
mutation O
was O
confirmed O
by O
restriction O
endonuclease O
analysis O
. O

a O
t1 O
- O
weighted O
magnetic O
resonance O
imaging O
of O
the O
fathers O
pituitary O
gland O
demonstrates O
an O
attenuated O
posterior O
pituitary O
bright O
spot O
. O

this O
mutation O
may O
be O
valuable O
for O
developing O
models O
of O
dominantly B-Disease
inherited I-Disease
neurodegeneration I-Disease
, O
as O
the O
early O
age O
of O
onset O
of O
symptoms O
suggests O
that O
this O
mutation O
may O
be O
particularly O
deleterious O
to O
the O
magnocellular O
neuron O
. O
. O

frequent O
inactivation O
of O
pten O
/ O
mmac1 O
in O
primary O
prostate B-Disease
cancer I-Disease
. O

sporadic B-Disease
prostate I-Disease
carcinoma I-Disease
is O
the O
most O
common O
male B-Disease
cancer I-Disease
in O
the O
western O
world O
, O
yet O
many O
of O
the O
major O
genetic O
events O
involved O
in O
the O
progression O
of O
this O
often O
fatal O
cancer B-Disease
remain O
to O
be O
elucidated O
. O

numerous O
cytogenetic O
and O
allelotype O
studies O
have O
reported O
frequent O
loss O
of O
heterozygosity O
on O
chromosomal O
arm O
10q O
in O
sporadic B-Disease
prostate I-Disease
cancer I-Disease
. O

deletion O
mapping O
studies O
have O
unambiguously O
identified O
a O
region O
of O
chromosome O
10q23 O
to O
be O
the O
minimal O
area O
of O
loss O
. O

a O
new O
tumor B-Disease
suppressor O
gene O
, O
pten O
/ O
mmac1 O
, O
was O
isolated O
recently O
at O
this O
region O
of O
chromosome O
10q23 O
and O
found O
to O
be O
inactivated O
by O
mutation O
in O
three O
prostate B-Disease
cancer I-Disease
cell O
lines O
. O

we O
screened O
80 O
prostate B-Disease
tumors I-Disease
by O
microsatellite O
analysis O
and O
found O
chromosome O
10q23 O
to O
be O
deleted O
in O
23 O
cases O
. O

we O
then O
proceeded O
with O
sequence O
analysis O
of O
the O
entire O
pten O
/ O
mmac1 O
coding O
region O
and O
tested O
for O
homozygous O
deletion O
with O
new O
intragenic O
markers O
in O
these O
23 O
cases O
with O
10q23 O
loss O
of O
heterozygosity O
. O

the O
identification O
of O
the O
second O
mutational O
event O
in O
10 O
( O
43 O
% O
) O
tumors B-Disease
establishes O
pten O
/ O
mmac1 O
as O
a O
main O
inactivation O
target O
of O
10q O
loss O
in O
sporadic B-Disease
prostate I-Disease
cancer I-Disease
. O
. O

risk O
reversals O
in O
predictive O
testing O
for O
huntington B-Disease
disease I-Disease
. O

the O
first O
predictive O
testing O
for O
huntington B-Disease
disease I-Disease
( O
hd B-Disease
) O
was O
based O
on O
analysis O
of O
linked O
polymorphic O
dna O
markers O
to O
estimate O
the O
likelihood O
of O
inheriting O
the O
mutation O
for O
hd B-Disease
. O

limits O
to O
accuracy O
included O
recombination O
between O
the O
dna O
markers O
and O
the O
mutation O
, O
pedigree O
structure O
, O
and O
whether O
dna O
samples O
were O
available O
from O
family O
members O
. O

with O
direct O
tests O
for O
the O
hd B-Disease
mutation O
, O
we O
have O
assessed O
the O
accuracy O
of O
results O
obtained O
by O
linkage O
approaches O
when O
requested O
to O
do O
so O
by O
the O
test O
individuals O
. O

for O
six O
such O
individuals O
, O
there O
was O
significant O
disparity O
between O
the O
tests O
. O

three O
went O
from O
a O
decreased O
risk O
to O
an O
increased O
risk O
, O
while O
in O
another O
three O
the O
risk O
was O
decreased O
. O

knowledge O
of O
the O
potential O
reasons O
for O
these O
changes O
in O
results O
and O
impact O
of O
these O
risk O
reversals O
on O
both O
patients O
and O
the O
counseling O
team O
can O
assist O
in O
the O
development O
of O
strategies O
for O
the O
prevention O
and O
, O
where O
necessary O
, O
management O
of O
a O
risk O
reversal O
in O
any O
predictive O
testing O
program O
. O
. O

a O
novel O
common O
missense O
mutation O
g301c O
in O
the O
n O
- O
acetylgalactosamine O
- O
6 O
- O
sulfate O
sulfatase O
gene O
in O
mucopolysaccharidosis B-Disease
iva I-Disease
. O

mucopolysaccharidosis B-Disease
iva I-Disease
( O
mps B-Disease
iva I-Disease
) O
is O
an O
autosomal B-Disease
recessive I-Disease
lysosomal I-Disease
storage I-Disease
disorder I-Disease
caused O
by O
a O
genetic B-Disease
defect I-Disease
in O
n O
- O
acetylgalactosamine O
- O
6 O
- O
sulfate O
sulfatase O
( O
galns O
) O
. O

in O
previous O
studies O
, O
we O
have O
found O
two O
common O
mutations O
in O
caucasians O
and O
japanese O
, O
respectively O
. O

to O
characterize O
the O
mutational O
spectrum O
in O
various O
ethnic O
groups O
, O
mutations O
in O
the O
galns O
gene O
in O
colombian O
mps B-Disease
iva I-Disease
patients O
were O
investigated O
, O
and O
genetic O
backgrounds O
were O
extensively O
analyzed O
to O
identify O
racial O
origin O
, O
based O
on O
mitochondrial O
dna O
( O
mtdna O
) O
lineages O
. O

three O
novel O
missense O
mutations O
never O
identified O
previously O
in O
other O
populations O
and O
found O
in O
16 O
out O
of O
19 O
colombian O
mps B-Disease
iva I-Disease
unrelated O
alleles O
account O
for O
84 O
. O

2 O
% O
of O
the O
alleles O
in O
this O
study O
. O

the O
g301c O
and O
s162f O
mutations O
account O
for O
68 O
. O

4 O
% O
and O
10 O
. O

5 O
% O
of O
mutations O
, O
respectively O
, O
whereas O
the O
remaining O
f69v O
is O
limited O
to O
a O
single O
allele O
. O

the O
skewed O
prevalence O
of O
g301c O
in O
only O
colombian O
patients O
and O
haplotype O
analysis O
by O
restriction O
fragment O
length O
polymorphisms O
in O
the O
galns O
gene O
suggest O
that O
g301c O
originated O
from O
a O
common O
ancestor O
. O

investigation O
of O
the O
genetic O
background O
by O
means O
of O
mtdna O
lineages O
indicate O
that O
all O
our O
patients O
are O
probably O
of O
native O
american O
descent O

low O
frequency O
of O
brca1 O
germline O
mutations O
in O
45 O
german O
breast B-Disease
/ I-Disease
ovarian I-Disease
cancer I-Disease
families O
. O

in O
this O
study O
we O
investigated O
45 O
german O
breast B-Disease
/ I-Disease
ovarian I-Disease
cancer I-Disease
families O
for O
germline O
mutations O
in O
the O
brca1 O
gene O
. O

we O
identified O
four O
germline O
mutations O
in O
three O
breast B-Disease
cancer I-Disease
families O
and O
in O
one O
breast B-Disease
- I-Disease
ovarian I-Disease
cancer I-Disease
family O
. O
among O
these O
were O
one O
frameshift O
mutation O
, O
one O
nonsense O
mutation O
, O
one O
novel O
splice O
site O
mutation O
, O
and O
one O
missense O
mutation O
. O

the O
missense O
mutation O
was O
also O
found O
in O
2 O
. O

8 O
% O
of O
the O
general O
population O
, O
suggesting O
that O
it O
is O
not O
disease O
associated O
. O

the O
average O
age O
of O
disease O
onset O
in O
those O
families O
harbouring O
causative O
mutations O
was O
between O
32 O
. O

3 O
and O
37 O
. O

4 O
years O
, O
whereas O
the O
family O
harbouring O
the O
missense O
mutation O
had O
an O
average O
age O
of O
onset O
of O
51 O
. O

2 O
years O
. O

these O
findings O
show O
that O
brca1 O
is O
implicated O
in O
a O
small O
fraction O
of O
breast B-Disease
/ I-Disease
ovarian I-Disease
cancer I-Disease
families O
suggesting O
the O
involvement O
of O
another O
susceptibility O
gene O
( O
s O
) O

paternal O
transmission O
of O
congenital B-Disease
myotonic I-Disease
dystrophy I-Disease
. O

we O
report O
a O
rare O
case O
of O
paternally O
transmitted O
congenital B-Disease
myotonic I-Disease
dystrophy I-Disease
( O
dm B-Disease
) O
. O

the O
proband O
is O
a O
23 O
year O
old O
, O
mentally B-Disease
retarded I-Disease
male O
who O
suffers O
severe O
muscular B-Disease
weakness I-Disease
. O

he O
presented O
with O
respiratory O
and O
feeding O
difficulties O
at O
birth O
. O

his O
two O
sibs O
suffer O
from O
childhood O
onset O
dm B-Disease
. O

their O
late O
father O
had O
the O
adult O
type O
of O
dm B-Disease
, O
with O
onset O
around O
30 O
years O
. O

only O
six O
other O
cases O
of O
paternal O
transmission O
of O
congenital B-Disease
dm I-Disease
have O
been O
reported O
recently O
. O

we O
review O
the O
sex O
related O
effects O
on O
transmission O
of O
congenital B-Disease
dm I-Disease
. O

decreased O
fertility O
of O
males O
with O
adult O
onset O
dm B-Disease
and O
contraction O
of O
the O
repeat O
upon O
male O
transmission O
contribute O
to O
the O
almost O
absent O
occurrence O
of O
paternal O
transmission O
of O
congenital B-Disease
dm I-Disease
. O

also O
the O
fathers O
of O
the O
reported O
congenitally O
affected O
children O
showed O
, O
on O
average O
, O
shorter O
ctg O
repeat O
lengths O
and O
hence O
less O
severe O
clinical O
symptoms O
than O
the O
mothers O
of O
children O
with O
congenital B-Disease
dm I-Disease
. O

we O
conclude O
that O
paternal O
transmission O
of O
congenital B-Disease
dm I-Disease
is O
rare O
and O
preferentially O
occurs O
with O
onset O
of O
dm B-Disease
past O
30 O
years O
in O
the O
father O
. O
. O

the O
rb1 O
gene O
mutation O
in O
a O
child O
with O
ectopic B-Disease
intracranial I-Disease
retinoblastoma I-Disease
. O

the O
rb1 O
gene O
mutation O
was O
investigated O
in O
a O
child O
with O
ectopic B-Disease
intracranial I-Disease
retinoblastoma I-Disease
using O
dna O
obtained O
from O
both O
the O
pineal B-Disease
and I-Disease
retinal I-Disease
tumours I-Disease
of O
the O
patient O
. O

a O
nonsense O
mutation O
in O
exon O
17 O
( O
codon O
556 O
) O
of O
the O
rb1 O
gene O
was O
found O
to O
be O
present O
homozygously O
in O
both O
the O
retinal B-Disease
and I-Disease
the I-Disease
pineal I-Disease
tumours I-Disease
. O

the O
same O
mutation O
was O
present O
heterozygously O
in O
the O
dna O
from O
the O
constitutional O
cells O
of O
the O
patient O
, O
proving O
it O
to O
be O
of O
germline O
origin O
. O

the O
initial O
mutation O
was O
shown O
to O
have O
occurred O
in O
the O
paternally O
derived O
rb1 O
allele O
. O

the O
mutation O
is O
in O
an O
area O
of O
the O
gene O
that O
encodes O
the O
protein O
- O
binding O
region O
known O
as O
the O
pocket O
region O
and O
has O
been O
detected O
in O
other O
cases O
of O
retinoblastoma B-Disease
. O
. O

low O
levels O
of O
beta O
hexosaminidase O
a O
in O
healthy O
individuals O
with O
apparent O
deficiency O
of O
this O
enzyme O
. O

appreciable O
beta O
hexosaminidase O
a O
( O
hex O
a O
) O
activity O
has O
been O
detected O
in O
cultured O
skin O
fibroblasts O
and O
melanoma B-Disease
tissue O
from O
healthy O
individuals O
previously O
reported O
as O
having O
deficiency B-Disease
of I-Disease
hex I-Disease
a I-Disease
activity O
indistinguishable O
from O
that O
of O
patients O
with O
tay B-Disease
- I-Disease
sachs I-Disease
disease I-Disease
( O
tsd B-Disease
) O
. O

identification O
and O
quantitation O
of O
hex O
a O
, O
amounting O
to O
3 O
. O

5 O
% O
- O
6 O
. O

9 O
% O
of O
total O
beta O
hexosaminidase O
activity O
, O
has O
been O
obtained O
by O
cellulose O
acetate O
gel O
electrophoresis O
, O
deae O
- O
cellulose O
ion O
- O
exchange O
chromatography O
, O
radial O
immunodiffusion O
, O
and O
radioimmunoassay O
. O

previous O
family O
studies O
suggested O
that O
these O
individuals O
may O
be O
compound O
heterozygotes O
for O
the O
common O
mutant O
tsd B-Disease
gene O
and O
a O
rare O
( O
allelic O
) O
mutant O
gene O
. O

thus O
, O
the O
postulated O
rate O
mutant O
gene O
appears O
to O
code O
for O
the O
expression O
of O
low O
amounts O
of O
hex O
a O
. O

heterozygotes O
for O
the O
rare O
mutant O
may O
be O
indistinguishable O
from O
heterozygotes O
for O
the O
common O
tsd B-Disease
mutant O
. O

however O
, O
direct O
visualization O
and O
quantitation O
of O
hex O
a O
by O
the O
methods O
described O
may O
prevent O
false O
- O
positive O
prenatal O
diagnosis O
of O
tsd B-Disease
in O
fetuses O
having O
the O
incomplete O
hex B-Disease
a I-Disease
deficiency I-Disease
of O
the O
type O
described O
in O
the O
four O
healthy O
individuals O

the O
tumor B-Disease
suppressor O
gene O
smad4 O
/ O
dpc4 O
is O
required O
for O
gastrulation O
and O
later O
for O
anterior O
development O
of O
the O
mouse O
embryo O
. O

mutations O
in O
the O
smad4 O
/ O
dpc4 O
tumor B-Disease
suppressor O
gene O
, O
a O
key O
signal O
transducer O
in O
most O
tgfbeta O
- O
related O
pathways O
, O
are O
involved O
in O
50 O
% O
of O
pancreatic B-Disease
cancers I-Disease
. O

homozygous O
smad4 O
mutant O
mice O
die O
before O
day O
7 O
. O

5 O
of O
embryogenesis O
. O

mutant O
embryos O
have O
reduced O
size O
, O
fail O
to O
gastrulate O
or O
express O
a O
mesodermal O
marker O
, O
and O
show O
abnormal O
visceral O
endoderm O
development O
. O

growth B-Disease
retardation I-Disease
of O
the O
smad4 O
- O
deficient O
embryos O
results O
from O
reduced O
cell O
proliferation O
rather O
than O
increased O
apoptosis O
. O

aggregation O
of O
mutant O
smad4 O
es O
cells O
with O
wild O
- O
type O
tetraploid O
morulae O
rescues O
the O
gastrulation B-Disease
defect I-Disease
. O

these O
results O
indicate O
that O
smad4 O
is O
initially O
required O
for O
the O
differentiation O
of O
the O
visceral O
endoderm O
and O
that O
the O
gastrulation B-Disease
defect I-Disease
in O
the O
epiblast O
is O
secondary O
and O
non O
- O
cell O
autonomous O
. O

rescued O
embryos O
show O
severe O
anterior O
truncations O
, O
indicating O
a O
second O
important O
role O
for O
smad4 O
in O
anterior O
patterning O
during O
embryogenesis O
. O

prevalence O
of O
p16 O
and O
cdk4 O
germline O
mutations O
in O
48 O
melanoma B-Disease
- O
prone O
families O
in O
france O
. O

the O
french O
familial B-Disease
melanoma I-Disease
study O
group O
. O

germline O
mutations O
in O
the O
p16 O
and O
cdk4 O
genes O
have O
been O
reported O
in O
a O
subset O
of O
melanoma B-Disease
pedigrees O
, O
but O
their O
prevalence O
is O
not O
well O
known O
. O

we O
searched O
for O
such O
germline O
mutations O
in O
48 O
french O
melanoma B-Disease
- O
prone O
families O
selected O
according O
to O
two O
major O
criteria O
families O
with O
at O
least O
three O
affected O
members O
( O
n O
= O
20 O
) O
or O
families O
with O
two O
affected O
members O
, O
one O
of O
them O
affected O
before O
the O
age O
of O
50 O
( O
n O
= O
28 O
) O
, O
and O
one O
additional O
minor O
criterion O
. O

sixteen O
different O
p16 O
germline O
mutations O
were O
found O
in O
21 O
families O
, O
while O
one O
germline O
mutation O
, O
arg24his O
, O
was O
detected O
in O
the O
cdk4 O
gene O
. O

the O
frequency O
of O
p16 O
gene O
mutation O
in O
our O
sample O
( O
44 O
% O
) O
is O
among O
the O
highest O
rates O
yet O
reported O
and O
the O
cdk4 O
mutation O
is O
the O
second O
mutation O
detected O
in O
this O
gene O
worldwide O
. O

in O
summary O
, O
our O
results O
show O
frequent O
involvement O
of O
the O
p16 O
gene O
in O
familial B-Disease
melanoma I-Disease
and O
confirm O
the O
role O
of O
the O
cdk4 O
gene O
as O
a O
melanoma B-Disease
- O
predisposing O
gene O
. O
. O

progression O
of O
somatic O
ctg O
repeat O
length O
heterogeneity O
in O
the O
blood O
cells O
of O
myotonic B-Disease
dystrophy I-Disease
patients O
. O

the O
genetic O
basis O
of O
myotonic B-Disease
dystrophy I-Disease
( O
dm B-Disease
) O
is O
the O
expansion O
of O
an O
unstable O
ctg O
repeat O
in O
the O
34 O
utr O
of O
the O
dm B-Disease
protein O
kinase O
gene O
on O
chromosome O
19 O
. O

one O
of O
the O
principal O
features O
of O
the O
dm B-Disease
mutation O
is O
an O
extraordinarily O
high O
level O
of O
somatic O
mosaicism O
, O
due O
to O
an O
extremely O
high O
degree O
of O
somatic O
instability O
both O
within O
and O
between O
different O
tissues O
. O

this O
instability O
appears O
to O
be O
biased O
towards O
further O
expansion O
and O
continuous O
throughout O
the O
life O
of O
an O
individual O
, O
features O
that O
could O
be O
associated O
with O
the O
progressive O
nature O
of O
the O
disease O
. O

although O
increasing O
measured O
allele O
size O
between O
patients O
clearly O
correlates O
with O
an O
increased O
severity O
of O
symptoms O
and O
an O
earlier O
age O
of O
onset O
, O
this O
correlation O
is O
not O
precise O
and O
measured O
allele O
length O
cannot O
be O
used O
as O
an O
accurate O
predictor O
of O
age O
of O
onset O
. O

in O
order O
to O
further O
characterize O
the O
dynamics O
of O
dm B-Disease
ctg O
repeat O
somatic O
instability O
, O
we O
have O
studied O
repeat O
length O
changes O
over O
time O
in O
111 O
myotonic B-Disease
dystrophy I-Disease
patients O
with O
varying O
clinical O
severity O
and O
ctg O
repeat O
size O
over O
time O
intervals O
of O
1 O
- O
7 O
years O
. O

we O
have O
found O
a O
direct O
progression O
of O
the O
size O
heterogeneity O
over O
time O
related O
to O
initial O
ctg O
repeat O
size O
and O
the O
time O
interval O
and O
always O
biased O
towards O
further O
expansion O
. O

attempts O
to O
mathematically O
model O
the O
dynamics O
have O
proved O
only O
partially O
successful O
suggesting O
that O
individual O
specific O
genetic O
and O
/ O
or O
environmental O
factors O
also O
play O
a O
role O
in O
somatic O
mosaicism O
. O
. O

aspartylglucosaminuria B-Disease
among O
palestinian O
arabs O
. O

aspartylglucosaminuria B-Disease
( O
agu B-Disease
) O
is O
a O
rare O
disorder B-Disease
of I-Disease
glycoprotein I-Disease
metabolism I-Disease
caused O
by O
the O
deficiency B-Disease
of I-Disease
the I-Disease
lysosomal I-Disease
enzyme I-Disease
aspartylglucosaminidase I-Disease
( O
aga O
) O
. O

agu B-Disease
is O
inherited O
as O
an O
autosomal O
recessive O
trait O
and O
occurs O
with O
a O
high O
frequency O
in O
finland O
because O
of O
a O
founder O
effect O
. O

while O
very O
few O
patients O
with O
agu B-Disease
have O
been O
reported O
from O
non O
- O
finnish O
origin O
, O
we O
diagnosed O
the O
disorder O
in O
8 O
patients O
originating O
from O
3 O
unrelated O
families O
, O
all O
palestinian O
arabs O
from O
the O
region O
of O
jerusalem O
. O

the O
clinical O
diagnosis O
of O
agu B-Disease
is O
often O
difficult O
, O
in O
particular O
early O
in O
the O
course O
of O
the O
disease O
, O
and O
most O
of O
the O
patients O
are O
diagnosed O
after O
the O
age O
of O
5 O
years O
. O

however O
, O
since O
these O
patients O
excrete O
early O
large O
amounts O
of O
aspartylglucosamine O
in O
urine O
, O
biochemical O
screening O
is O
easy O
by O
urine O
chromatography O
. O
. O

detection O
of O
heterozygous O
carriers O
of O
the O
ataxia B-Disease
- I-Disease
telangiectasia I-Disease
( O
atm O
) O
gene O
by O
g2 O
phase O
chromosomal O
radiosensitivity O
of O
peripheral O
blood O
lymphocytes O
. O

in O
ataxia B-Disease
- I-Disease
telangiectasia I-Disease
( O
a B-Disease
- I-Disease
t I-Disease
) O
patients O
, O
mutations O
in O
a O
single O
gene O
, O
atm O
, O
result O
in O
an O
autosomal B-Disease
recessive I-Disease
syndrome I-Disease
that O
embraces O
a O
variety O
of O
clinical O
features O
and O
manifests O
extreme O
radiosensitivity O
and O
a O
strong O
pre O
- O
disposition O
to O
malignancy B-Disease
. O

heterozygotes O
for O
the O
atm O
gene O
have O
no O
clinical O
expression O
of O
a B-Disease
- I-Disease
t I-Disease
but O
may O
be O
cancer B-Disease
prone O
with O
a O
moderate O
increase O
in O
in O
vitro O
radiosensitivity O
. O

we O
performed O
a O
blind O
chromosomal O
analysis O
on O
g2 O
- O
phase O
lymphocytes O
from O
7 O
unrelated O
a B-Disease
- I-Disease
t I-Disease
patients O
, O
13 O
obligate O
a B-Disease
- I-Disease
t I-Disease
heterozygotes O
( O
parents O
of O
the O
patients O
) O
, O
and O
14 O
normal O
controls O
following O
x O
- O
irradiation O
with O
1 O
gy O
in O
order O
to O
evaluate O
this O
cytogenetic O
method O
as O
a O
tool O
for O
detection O
of O
atm O
carriers O
. O

both O
a B-Disease
- I-Disease
t I-Disease
homozygotes O
and O
heterozygotes O
showed O
significantly O
increased O
levels O
of O
radiation O
- O
induced O
chromatid O
damage O
relative O
to O
that O
of O
normal O
controls O
. O

these O
results O
show O
that O
the O
g2 O
- O
phase O
chromosomal O
radiosensitivity O
assay O
can O
be O
used O
for O
the O
detection O
of O
a B-Disease
- I-Disease
t I-Disease
heterozygotes O
. O

in O
combination O
with O
molecular O
genetic O
analyses O
, O
this O
test O
may O
be O
of O
value O
in O
studies O
of O
familial B-Disease
and I-Disease
sporadic I-Disease
cancers I-Disease
aimed O
at O
determination O
of O
the O
potential O
involvement O
of O
atm O
mutations O
in O
tumor B-Disease
risk O
or O
development O
. O
. O

ataxia B-Disease
- I-Disease
telangiectasia I-Disease
: O
identification O
and O
detection O
of O
founder O
- O
effect O
mutations O
in O
the O
atm O
gene O
in O
ethnic O
populations O
. O

to O
facilitate O
the O
evaluation O
of O
atm O
heterozygotes O
for O
susceptibility O
to O
other O
diseases O
, O
such O
as O
breast B-Disease
cancer I-Disease
, O
we O
have O
attempted O
to O
define O
the O
most O
common O
mutations O
and O
their O
frequencies O
in O
ataxia B-Disease
- I-Disease
telangiectasia I-Disease
( O
a B-Disease
- I-Disease
t I-Disease
) O
homozygotes O
from O
10 O
ethnic O
populations O
. O

both O
genomic O
mutations O
and O
their O
effects O
on O
cdna O
were O
characterized O
. O

protein O
- O
truncation O
testing O
of O
the O
entire O
atm O
cdna O
detected O
92 O
( O
66 O
% O
) O
truncating O
mutations O
in O
140 O
mutant O
alleles O
screened O
. O

the O
haplotyping O
of O
patients O
with O
identical O
mutations O
indicates O
that O
almost O
all O
of O
these O
represent O
common O
ancestry O
and O
that O
very O
few O
spontaneously O
recurring O
atm O
mutations O
exist O
. O

assays O
requiring O
minimal O
amounts O
of O
genomic O
dna O
were O
designed O
to O
allow O
rapid O
screening O
for O
common O
ethnic O
mutations O
. O

these O
rapid O
assays O
detected O
mutations O
in O
76 O
% O
of O
costa O
rican O
patients O
( O
3 O
) O
, O
50 O
% O
of O
norwegian O
patients O
( O
1 O
) O
, O
25 O
% O
of O
polish O
patients O
( O
4 O
) O
, O
and O
14 O
% O
of O
italian O
patients O
( O
1 O
) O
, O
as O
well O
as O
in O
patients O
of O
amish O
/ O
mennonite O
and O
irish O
english O
backgrounds O
. O

additional O
mutations O
were O
observed O
in O
japanese O
, O
utah O
mormon O
, O
and O
african O
american O
patients O
. O

these O
assays O
should O
facilitate O
screening O
for O
a B-Disease
- I-Disease
t I-Disease
heterozygotes O
in O
the O
populations O
studied O
. O
. O

the O
von B-Disease
hippel I-Disease
- I-Disease
lindau I-Disease
tumor I-Disease
suppressor O
gene O
is O
required O
for O
cell O
cycle O
exit O
upon O
serum O
withdrawal O
. O

the O
inactivation O
of O
the O
von B-Disease
hippel I-Disease
- I-Disease
lindau I-Disease
( I-Disease
vhl I-Disease
) I-Disease
tumor I-Disease
suppressor O
gene O
predisposes O
affected O
individuals O
to O
the O
human O
vhl B-Disease
cancer I-Disease
syndrome I-Disease
and O
is O
associated O
with O
sporadic B-Disease
renal I-Disease
cell I-Disease
carcinomas I-Disease
( O
rcc B-Disease
) O
and O
brain B-Disease
hemangioblastomas I-Disease
. O

vhl O
- O
negative O
786 O
- O
0 O
rcc B-Disease
cells O
are O
tumorigenic O
in O
nude O
mice O
which O
is O
suppressed O
by O
the O
reintroduction O
of O
vhl B-Disease
. O

remarkably O
, O
this O
occurs O
without O
affecting O
the O
growth O
rate O
and O
cell O
cycle O
profile O
of O
these O
cells O
in O
culture O
. O

the O
786 O
- O
0 O
cell O
line O
, O
like O
many O
cancer B-Disease
cells O
, O
fails O
to O
exit O
the O
cell O
cycle O
upon O
serum O
withdrawal O
. O

here O
, O
it O
is O
shown O
that O
reintroduction O
of O
the O
wild O
- O
type O
vhl B-Disease
gene O
restores O
the O
ability O
of O
vhl O
- O
negative O
rcc B-Disease
cancer I-Disease
cells O
to O
exit O
the O
cell O
cycle O
and O
enter O
g0 O
/ O
quiescence O
in O
low O
serum O
. O

both O
vhl O
- O
positive O
and O
vhl O
- O
negative O
rcc B-Disease
cells O
exit O
the O
cell O
cycle O
by O
contact O
inhibition O
. O

the O
cyclin O
- O
dependent O
kinase O
inhibitor O
, O
p27 O
, O
accumulates O
upon O
serum O
withdrawal O
, O
only O
in O
the O
presence O
of O
vhl B-Disease
, O
as O
a O
result O
of O
the O
stabilization O
of O
the O
protein O
. O

we O
propose O
that O
the O
loss O
of O
wild O
- O
type O
vhl B-Disease
gene O
results O
in O
a O
specific O
cellular O
defect O
in O
serum O
- O
dependent O
growth O
control O
, O
which O
may O
initiate O
tumor B-Disease
formation O
. O

this O
is O
corrected O
by O
the O
reintroduction O
of O
wild O
- O
type O
vhl B-Disease
, O
implicating O
vhl B-Disease
as O
the O
first O
tumor B-Disease
suppressor O
involved O
in O
the O
regulation O
of O
cell O
cycle O
exit O
, O
which O
is O
consistent O
with O
its O
gatekeeper O
function O
in O
the O
kidney O
. O
. O

piebaldism B-Disease
with O
deafness B-Disease
: O
molecular O
evidence O
for O
an O
expanded O
syndrome O
. O

in O
a O
south O
african O
girl O
of O
xhosa O
stock O
with O
severe O
piebaldism B-Disease
and O
profound O
congenital O
sensorineural B-Disease
deafness I-Disease
we O
identified O
a O
novel O
missense O
substitution O
at O
a O
highly O
conserved O
residue O
in O
the O
intracellular O
kinase O
domain O
of O
the O
kit O
proto O
- O
oncogene O
, O
r796g O
. O

though O
auditory B-Disease
anomalies I-Disease
have O
been O
observed O
in O
mice O
with O
dominant O
white O
spotting O
( O
w O
) O
due O
to O
kit O
mutations O
, O
deafness B-Disease
is O
not O
typical O
in O
human O
piebaldism B-Disease
. O

thus O
, O
the O
occurrence O
of O
sensorineural B-Disease
deafness I-Disease
in O
this O
patient O
extends O
considerably O
the O
phenotypic O
range O
of O
piebaldism B-Disease
due O
to O
kit O
gene O
mutation O
in O
humans O
and O
tightens O
the O
clinical O
similarity O
between O
piebaldism B-Disease
and O
the O
various O
forms O
of O
waardenburg B-Disease
syndrome I-Disease
. O
. O

cycloheximide O
facilitates O
the O
identification O
of O
aberrant O
transcripts O
resulting O
from O
a O
novel O
splice O
- O
site O
mutation O
in O
col17a1 O
in O
a O
patient O
with O
generalized O
atrophic B-Disease
benign I-Disease
epidermolysis I-Disease
bullosa I-Disease
. O

patients O
with O
generalized O
atrophic B-Disease
benign I-Disease
epidermolysis I-Disease
bullosa I-Disease
often O
show O
decreased O
expression O
of O
type O
xvii O
collagen O
, O
a O
transmembrane O
hemidesmosomal O
protein O
encoded O
by O
col17a1 O
. O

this O
report O
documents O
a O
novel O
splice O
- O
site O
mutation O
in O
col17a1 O
in O
a O
patient O
with O
generalized O
atrophic B-Disease
benign I-Disease
epidermolysis I-Disease
bullosa I-Disease
, O
and O
applies O
a O
new O
methodology O
to O
define O
and O
characterize O
the O
resulting O
mrna O
splice O
variants O
. O

mutational O
analysis O
of O
col17a1 O
identified O
a O
maternally O
inherited O
g O
- O
to O
- O
t O
transversion O
at O
the O
- O
1 O
position O
of O
exon O
32 O
. O

this O
acceptor O
splice O
- O
site O
mutation O
led O
to O
the O
formation O
of O
aberrant O
transcripts O
present O
at O
extremely O
low O
levels O
. O

based O
on O
our O
recent O
finding O
that O
cycloheximide O
stabilized O
mutant O
col17a1 O
transcripts O
in O
keratinocytes O
homozygous O
for O
a O
frameshift O
mutation O
, O
the O
effects O
of O
the O
splice O
- O
site O
mutation O
on O
splicing O
of O
col17a1 O
transcripts O
were O
determined O
using O
reverse O
transcriptase O
polymerase O
chain O
reaction O
of O
total O
rna O
from O
keratinocytes O
incubated O
for O
2 O
. O

5 O
h O
in O
the O
presence O
or O
absence O
of O
10 O
microg O
cycloheximide O
per O
ml O
. O

using O
this O
approach O
, O
an O
abnormally O
spliced O
transcript O
was O
identified O
that O
contains O
an O
extra O
264 O
bases O
upstream O
from O
exon O
32 O
, O
resulting O
in O
a O
premature O
termination O
codon O
27 O
bp O
downstream O
from O
the O
cryptic O
splice O
site O
. O

three O
other O
splice O
variants O
, O
including O
one O
derived O
from O
the O
skipping O
of O
exon O
32 O
, O
were O
also O
identified O
. O

these O
results O
indicate O
the O
usefulness O
of O
cycloheximide O
treatment O
in O
evaluating O
the O
abnormal O
processing O
of O
mrna O
due O
to O
splice O
- O
site O
mutations O
, O
because O
( O
i O
) O
aberrant O
splicing O
often O
generates O
a O
premature O
termination O
codon O
, O
( O
ii O
) O
transcripts O
with O
premature O
termination O
codons O
can O
occur O
at O
low O
or O
undetectable O
levels O
due O
to O
nonsense O
- O
mediated O
mrna O
decay O
, O
and O
( O
iii O
) O
the O
levels O
of O
these O
transcripts O
can O
be O
increased O
by O
cycloheximide O
. O

a O
deletion O
mutation O
in O
col17a1 O
in O
five O
austrian O
families O
with O
generalized O
atrophic B-Disease
benign I-Disease
epidermolysis I-Disease
bullosa I-Disease
represents O
propagation O
of O
an O
ancestral O
allele O
. O

patients O
with O
generalized O
atrophic B-Disease
benign I-Disease
epidermolysis I-Disease
bullosa I-Disease
, O
a O
usually O
nonlethal O
form O
of O
junctional B-Disease
epidermolysis I-Disease
bullosa I-Disease
, O
have O
generalized O
blistering B-Disease
, O
nail B-Disease
dystrophy I-Disease
, O
patchy B-Disease
alopecia I-Disease
, O
and O
dental B-Disease
abnormalities I-Disease
. O

skin B-Disease
fragility I-Disease
in O
most O
cases O
is O
due O
to O
mutations O
in O
the O
gene O
encoding O
type O
xvii O
collagen O
( O
col17a1 O
) O
. O

recently O
, O
we O
reported O
five O
austrian O
families O
with O
generalized O
atrophic B-Disease
benign I-Disease
epidermolysis I-Disease
bullosa I-Disease
who O
share O
the O
same O
col17a1 O
mutation O
. O

affected O
individuals O
in O
three O
families O
are O
homozygous O
for O
4003deltc O
, O
whereas O
those O
in O
two O
others O
are O
compound O
heterozygotes O
. O

to O
determine O
if O
the O
occurrence O
of O
4003deltc O
in O
these O
unrelated O
families O
signifies O
propagation O
of O
an O
ancestral O
allele O
or O
a O
mutational O
hot O
spot O
, O
haplotypes O
were O
determined O
for O
polymorphisms O
both O
within O
and O
flanking O
col17a1 O
. O

five O
intragenic O
polymorphisms O
were O
chosen O
based O
on O
their O
informativeness O
. O

one O
of O
these O
, O
not O
previously O
reported O
, O
was O
2988 O
a O
or O
c O
that O
introduces O
a O
new O
restriction O
site O
for O
eco0109 O
i O
. O

all O
the O
4003deltc O
alleles O
showed O
the O
same O
haplotype O
for O
these O
five O
polymorphic O
markers O
. O

fourteen O
microsatellite O
polymorphisms O
were O
selected O
based O
on O
their O
high O
heterozygosity O
and O
their O
location O
within O
10q23 O
- O
q25 O
near O
col17a1 O
. O

three O
families O
shared O
microsatellite O
polymorphisms O
covering O
at O
most O
19 O
cm O
, O
whereas O
the O
others O
shared O
smaller O
regions O
consistent O
with O
cross O
- O
over O
events O
during O
passage O
of O
this O
mutation O
through O
several O
generations O
. O

these O
results O
indicate O
that O
4003deltc O
occurs O
on O
a O
single O
ancestral O
allele O
. O
. O

the O
haptoglobin O
- O
gene O
deletion O
responsible O
for O
anhaptoglobinemia B-Disease
. O

we O
have O
found O
an O
allelic O
deletion O
of O
the O
haptoglobin O
( O
hp O
) O
gene O
from O
an O
individual O
with O
anhaptoglobinemia B-Disease
. O

the O
hp O
gene O
cluster O
consists O
of O
coding O
regions O
of O
the O
alpha O
chain O
and O
beta O
chain O
of O
the O
haptoglobin O
gene O
( O
hp O
) O
and O
of O
the O
alpha O
chain O
and O
beta O
chain O
of O
the O
haptoglobin O
- O
related O
gene O
( O
hpr O
) O
, O
in O
tandem O
from O
the O
5 O
side O
. O

southern O
blot O
and O
pcr O
analyses O
have O
indicated O
that O
the O
individual O
with O
anhaptoglobinemia B-Disease
was O
homozygous O
for O
the O
gene O
deletion O
and O
that O
the O
gene O
deletion O
was O
included O
at O
least O
from O
the O
promoter O
region O
of O
hp O
to O
hpr O
alpha O
but O
not O
to O
hpr O
beta O
( O
hpdel O
) O
. O

in O
addition O
, O
we O
found O
seven O
individuals O
with O
hypohaptoglobinemia B-Disease
in O
three O
families O
, O
and O
the O
genotypes O
of O
six O
of O
the O
seven O
individuals O
were O
found O
to O
be O
hp2 O
/ O
hpdel O
. O

the O
phenotypes O
and O
genotypes O
in O
one O
of O
these O
three O
families O
showed O
the O
father O
to O
be O
hypohaptoglobinemic B-Disease
( O
hp2 O
) O
and O
hp2 O
/ O
hpdel O
, O
the O
mother O
to O
be O
hp2 O
- O
1 O
and O
hp1 O
/ O
hp2 O
, O
one O
of O
the O
two O
children O
to O
be O
hypohaptoglobinemic B-Disease
( O
hp2 O
) O
and O
hp2 O
/ O
hpdel O
, O
and O
the O
other O
child O
to O
be O
hp1 O
and O
hp1 O
/ O
hpdel O
, O
showing O
an O
anomalous O
inheritance O
of O
hp O
phenotypes O
in O
the O
child O
with O
hp1 O
. O

the O
hp2 O
/ O
hpdel O
individuals O
had O
an O
extremely O
low O
level O
of O
hp O
( O
mean O
+ O
/ O
- O
sd O
= O
0 O
. O
049 O
+ O
/ O
- O
0 O
. O
043 O
mg O
/ O
ml O
; O
n O
= O
6 O
) O
, O
compared O
with O
the O
level O
( O
1 O
. O
64 O
+ O
/ O
- O
1 O
. O
07 O
mg O
/ O
ml O
) O
obtained O
from O
52 O
healthy O
volunteers O
having O
phenotype O
hp2 O
, O
whereas O
the O
serum O
hp O
level O
of O
an O
individual O
with O
hp1 O
/ O
hpdel O
was O
0 O
. O

50 O
mg O
/ O
ml O
, O
which O
was O
approximately O
half O
the O
level O
of O
hp O
in O
control O
sera O
from O
the O
hp1 O
phenotype O
( O
1 O
. O
26 O
+ O
/ O
- O
0 O
. O
33 O
mg O
/ O
ml O
; O
n O
= O
9 O
) O
, O
showing O
a O
gene O
- O
dosage O
effect O
. O

the O
other O
allele O
( O
hp2 O
) O
of O
individuals O
with O
hp2 O
/ O
hpdel O
was O
found O
to O
have O
, O
in O
all O
exons O
, O
no O
mutation O
, O
by O
dna O
sequencing O
. O

on O
the O
basis O
of O
the O
present O
study O
, O
the O
mechanism O
of O
anhaptoglobinemia B-Disease
and O
the O
mechanism O
of O
anomalous O
inheritance O
of O
hp O
phenotypes O
were O
well O
explained O
. O

however O
, O
the O
mechanism O
of O
hypohaptoglobinemia B-Disease
remains O
unknown O

atm O
mutations O
and O
phenotypes O
in O
ataxia B-Disease
- I-Disease
telangiectasia I-Disease
families O
in O
the O
british O
isles O
: O
expression O
of O
mutant O
atm O
and O
the O
risk O
of O
leukemia B-Disease
, O
lymphoma B-Disease
, O
and O
breast B-Disease
cancer I-Disease
. O

we O
report O
the O
spectrum O
of O
59 O
atm O
mutations O
observed O
in O
ataxia B-Disease
- I-Disease
telangiectasia I-Disease
( O
a B-Disease
- I-Disease
t I-Disease
) O
patients O
in O
the O
british O
isles O
. O

of O
51 O
atm O
mutations O
identified O
in O
families O
native O
to O
the O
british O
isles O
, O
11 O
were O
founder O
mutations O
, O
and O
2 O
of O
these O
11 O
conferred O
a O
milder O
clinical O
phenotype O
with O
respect O
to O
both O
cerebellar B-Disease
degeneration I-Disease
and O
cellular O
features O
. O

we O
report O
, O
in O
two O
a B-Disease
- I-Disease
t I-Disease
families O
, O
an O
atm O
mutation O
( O
7271t O
- O
- O
> O
g O
) O
that O
may O
be O
associated O
with O
an O
increased O
risk O
of O
breast B-Disease
cancer I-Disease
in O
both O
homozygotes O
and O
heterozygotes O
( O
relative O
risk O
12 O
. O
7 O
; O
p O
= O
. O
0025 O
) O
, O
although O
there O
is O
a O
less O
severe O
a B-Disease
- I-Disease
t I-Disease
phenotype O
in O
terms O
of O
the O
degree O
of O
cerebellar B-Disease
degeneration I-Disease
. O

this O
mutation O
( O
7271t O
- O
- O
> O
g O
) O
also O
allows O
expression O
of O
full O
- O
length O
atm O
protein O
at O
a O
level O
comparable O
with O
that O
in O
unaffected O
individuals O
. O

in O
addition O
, O
we O
have O
studied O
18 O
a B-Disease
- I-Disease
t I-Disease
patients O
, O
in O
15 O
families O
, O
who O
developed O
leukemia B-Disease
, O
lymphoma B-Disease
, O
preleukemic O
t O
- O
cell O
proliferation O
, O
or O
hodgkin B-Disease
lymphoma I-Disease
, O
mostly O
in O
childhood O
. O

a O
wide O
variety O
of O
atm O
mutation O
types O
, O
including O
missense O
mutations O
and O
in O
- O
frame O
deletions O
, O
were O
seen O
in O
these O
patients O
. O

we O
also O
show O
that O
25 O
% O
of O
all O
a B-Disease
- I-Disease
t I-Disease
patients O
carried O
in O
- O
frame O
deletions O
or O
missense O
mutations O
, O
many O
of O
which O
were O
also O
associated O
with O
expression O
of O
mutant O
atm O
protein O
. O

the O
dmpk O
gene O
of O
severely O
affected O
myotonic B-Disease
dystrophy I-Disease
patients O
is O
hypermethylated O
proximal O
to O
the O
largely O
expanded O
ctg O
repeat O
. O

using O
methylation O
- O
sensitive O
restriction O
enzymes O
, O
we O
characterized O
the O
methylation O
pattern O
on O
the O
5 O
side O
of O
the O
ctg O
repeat O
in O
the O
dmpk O
gene O
of O
normal O
individuals O
and O
of O
patients O
affected O
with O
myotonic B-Disease
dystrophy I-Disease
, O
showing O
expansions O
of O
the O
repetitive O
sequence O
. O

the O
gene O
segment O
analyzed O
corresponds O
to O
the O
genomic O
saci O
- O
hindiii O
fragment O
carrying O
exons O
11 O
- O
15 O
. O

there O
is O
constitutive O
methylation O
in O
intron O
12 O
at O
restriction O
sites O
of O
sacii O
and O
hhai O
, O
localized O
1 O
, O
159 O
- O
1 O
, O
232 O
bp O
upstream O
of O
the O
ctg O
repeat O
, O
whereas O
most O
, O
if O
not O
all O
, O
of O
the O
other O
sites O
of O
sacii O
, O
hhai O
, O
and O
hpaii O
in O
this O
region O
are O
unmethylated O
, O
in O
normal O
individuals O
and O
most O
of O
the O
patients O
. O

in O
a O
number O
of O
young O
and O
severely O
affected O
patients O
, O
however O
, O
complete O
methylation O
of O
these O
restriction O
sites O
was O
found O
in O
the O
mutated O
allele O
. O

in O
most O
of O
these O
patients O
, O
the O
onset O
of O
the O
disease O
was O
congenital O
. O

preliminary O
in O
vivo O
footprinting O
data O
gave O
evidence O
for O
protein O
- O
dna O
contact O
in O
normal O
genes O
at O
an O
sp1 O
consensus O
binding O
site O
upstream O
of O
the O
ctg O
repeat O
and O
for O
a O
significant O
reduction O
of O
this O
interaction O
in O
cells O
with O
a O
hypermethylated O
dmpk O
gene O
. O
. O

the O
hemochromatosis B-Disease
gene O
product O
complexes O
with O
the O
transferrin O
receptor O
and O
lowers O
its O
affinity O
for O
ligand O
binding O
. O

we O
recently O
reported O
the O
positional O
cloning O
of O
a O
candidate O
gene O
for O
hereditary B-Disease
hemochromatosis I-Disease
called O
hfe O
. O

the O
gene O
product O
, O
a O
member O
of O
the O
major O
histocompatibility O
complex O
class O
i O
- O
like O
family O
, O
was O
found O
to O
have O
a O
mutation O
, O
cys O
- O
282 O
- O
- O
> O
tyr O
( O
c282y O
) O
, O
in O
85 O
% O
of O
patient O
chromosomes O
. O

this O
mutation O
eliminates O
the O
ability O
of O
hfe O
to O
associate O
with O
beta2 O
- O
microglobulin O
( O
beta2m O
) O
and O
prevents O
cell O
- O
surface O
expression O
. O

a O
second O
mutation O
that O
has O
no O
effect O
on O
beta2m O
association O
, O
h63d O
, O
was O
found O
in O
eight O
out O
of O
nine O
patients O
heterozygous O
for O
the O
c282y O
mutant O
. O

in O
this O
report O
, O
we O
demonstrate O
in O
cultured O
293 O
cells O
overexpressing O
wild O
- O
type O
or O
mutant O
hfe O
proteins O
that O
both O
the O
wild O
- O
type O
and O
h63d O
hfe O
proteins O
form O
stable O
complexes O
with O
the O
transferrin O
receptor O
( O
tfr O
) O
. O

the O
c282y O
mutation O
nearly O
completely O
prevents O
the O
association O
of O
the O
mutant O
hfe O
protein O
with O
the O
tfr O
. O

studies O
on O
cell O
- O
associated O
transferrin O
at O
37 O
degrees O
c O
suggest O
that O
the O
overexpressed O
wild O
- O
type O
hfe O
protein O
decreases O
the O
affinity O
of O
the O
tfr O
for O
transferrin O
. O

the O
overexpressed O
h63d O
protein O
does O
not O
have O
this O
effect O
, O
providing O
the O
first O
direct O
evidence O
for O
a O
functional O
consequence O
of O
the O
h63d O
mutation O
. O

addition O
of O
soluble O
wild O
- O
type O
hfe O
/ O
beta2m O
heterodimers O
to O
cultured O
cells O
also O
decreased O
the O
apparent O
affinity O
of O
the O
tfr O
for O
its O
ligand O
under O
steady O
- O
state O
conditions O
, O
both O
in O
293 O
cells O
and O
in O
hela O
cells O
. O

furthermore O
, O
at O
4 O
degrees O
c O
, O
the O
added O
soluble O
complex O
of O
hfe O
/ O
beta2m O
inhibited O
binding O
of O
transferrin O
to O
hela O
cell O
tfr O
in O
a O
concentration O
- O
dependent O
manner O
. O

scatchard O
plots O
of O
these O
data O
indicate O
that O
the O
added O
heterodimer O
substantially O
reduced O
the O
affinity O
of O
tfr O
for O
transferrin O
. O

these O
results O
establish O
a O
molecular O
link O
between O
hfe O
and O
a O
key O
protein O
involved O
in O
iron O
transport O
, O
the O
tfr O
, O
and O
raise O
the O
possibility O
that O
alterations O
in O
this O
regulatory O
mechanism O
may O
play O
a O
role O
in O
the O
pathogenesis O
of O
hereditary B-Disease
hemochromatosis I-Disease
. O
. O

genomic O
organization O
of O
the O
ube3a O
/ O
e6 O
- O
ap O
gene O
and O
related O
pseudogenes O
. O

the O
ube3a O
gene O
encodes O
the O
e6 O
- O
ap O
ubiquitin O
- O
protein O
ligase O
and O
has O
recently O
been O
shown O
to O
be O
mutated O
in O
angelman B-Disease
syndrome I-Disease
patients O
who O
lack O
15q11 O
- O
q13 O
deletions O
or O
chromosome O
15 O
paternal O
uniparental B-Disease
disomy I-Disease
. O

previous O
ube3a O
cdna O
analysis O
has O
shown O
a O
coding O
region O
of O
approximately O
2 O
. O

6 O
kb O
and O
a O
3 O
- O
untranslated O
region O
( O
utr O
) O
of O
< O
50 O
bp O
, O
whereas O
northern O
analysis O
has O
indicated O
mrna O
sizes O
of O
5 O
- O
8 O
kb O
. O

we O
have O
analyzed O
additional O
cdna O
clones O
and O
provide O
evidence O
for O
an O
additional O
0 O
. O

5 O
kb O
of O
5 O
- O
utr O
and O
> O
2 O
kb O
of O
3 O
- O
utr O
. O

we O
have O
established O
the O
genomic O
organization O
of O
ube3a O
and O
the O
sequence O
of O
intron O
- O
exon O
borders O
. O

we O
have O
also O
mapped O
two O
highly O
homologous O
processed O
pseudogenes O
, O
ube3ap1 O
and O
ube3ap2 O
, O
to O
chromosomes O
2 O
and O
21 O
, O
respectively O
, O
and O
determined O
their O
genomic O
organization O
. O

these O
results O
will O
form O
the O
basis O
for O
studies O
of O
mutation O
and O
imprinting O
of O
ube3a O
. O

mutation O
spectrum O
and O
genotype O
- O
phenotype O
analyses O
in O
cowden B-Disease
disease I-Disease
and O
bannayan B-Disease
- I-Disease
zonana I-Disease
syndrome I-Disease
, O
two O
hamartoma B-Disease
syndromes I-Disease
with O
germline O
pten O
mutation O
. O

the O
tumour B-Disease
suppressor O
gene O
pten O
, O
which O
maps O
to O
10q23 O
. O

3 O
and O
encodes O
a O
403 O
amino O
acid O
dual O
specificity O
phosphatase O
( O
protein O
tyrosine O
phosphatase O
; O
ptpase O
) O
, O
was O
shown O
recently O
to O
play O
a O
broad O
role O
in O
human O
malignancy B-Disease
. O

somatic O
pten O
deletions O
and O
mutations O
were O
observed O
in O
sporadic B-Disease
breast I-Disease
, I-Disease
brain I-Disease
, I-Disease
prostate I-Disease
and I-Disease
kidney I-Disease
cancer I-Disease
cell O
lines O
and O
in O
several O
primary O
tumours B-Disease
such O
as O
endometrial B-Disease
carcinomas I-Disease
, O
malignant B-Disease
melanoma I-Disease
and O
thyroid B-Disease
tumours I-Disease
. O

in O
addition O
, O
pten O
was O
identified O
as O
the O
susceptibility O
gene O
for O
two O
hamartoma B-Disease
syndromes I-Disease
cowden B-Disease
disease I-Disease
( O
cd B-Disease
; O
mim O
158350 O
) O
and O
bannayan B-Disease
- I-Disease
zonana I-Disease
( I-Disease
bzs I-Disease
) I-Disease
or I-Disease
ruvalcaba I-Disease
- I-Disease
riley I-Disease
- I-Disease
smith I-Disease
syndrome I-Disease
( O
mim O
153480 O
) O
. O

constitutive O
dna O
from O
37 O
cd B-Disease
families O
and O
seven O
bzs B-Disease
families O
was O
screened O
for O
germline O
pten O
mutations O
. O

pten O
mutations O
were O
identified O
in O
30 O
of O
37 O
( O
81 O
% O
) O
cd B-Disease
families O
, O
including O
missense O
and O
nonsense O
point O
mutations O
, O
deletions O
, O
insertions O
, O
a O
deletion O
/ O
insertion O
and O
splice O
site O
mutations O
. O

these O
mutations O
were O
scattered O
over O
the O
entire O
length O
of O
pten O
, O
with O
the O
exception O
of O
the O
first O
, O
fourth O
and O
last O
exons O
. O

a O
hot O
spot O
for O
pten O
mutation O
in O
cd B-Disease
was O
identified O
in O
exon O
5 O
that O
contains O
the O
ptpase O
core O
motif O
, O
with O
13 O
of O
30 O
( O
43 O
% O
) O
cd B-Disease
mutations O
identified O
in O
this O
exon O
. O

seven O
of O
30 O
( O
23 O
% O
) O
were O
within O
the O
core O
motif O
, O
the O
majority O
( O
five O
of O
seven O
) O
of O
which O
were O
missense O
mutations O
, O
possibly O
pointing O
to O
the O
functional O
significance O
of O
this O
region O
. O

germline O
pten O
mutations O
were O
identified O
in O
four O
of O
seven O
( O
57 O
% O
) O
bzs B-Disease
families O
studied O
. O

interestingly O
, O
none O
of O
these O
mutations O
was O
observed O
in O
the O
ptpase O
core O
motif O
. O

it O
is O
also O
worthy O
of O
note O
that O
a O
single O
nonsense O
point O
mutation O
, O
r233x O
, O
was O
observed O
in O
the O
germline O
dna O
from O
two O
unrelated O
cd B-Disease
families O
and O
one O
bzs B-Disease
family O
. O

genotype O
- O
phenotype O
studies O
were O
not O
performed O
on O
this O
small O
group O
of O
bzs B-Disease
families O
. O

however O
, O
genotype O
- O
phenotype O
analysis O
inthe O
group O
of O
cd B-Disease
families O
revealed O
two O
possible O
associations O
worthy O
of O
follow O
- O
up O
in O
independent O
analyses O
. O

the O
first O
was O
an O
association O
noted O
in O
the O
group O
of O
cd B-Disease
families O
with O
breast B-Disease
disease I-Disease
. O

a O
correlation O
was O
observed O
between O
the O
presence O
/ O
absence O
of O
a O
pten O
mutation O
and O
the O
type O
of O
breast O
involvement O
( O
unaffected O
versus O
benign O
versus O
malignant O
) O
. O

specifically O
and O
more O
directly O
, O
an O
association O
was O
also O
observed O
between O
the O
presence O
of O
a O
pten O
mutation O
and O
malignant B-Disease
breast I-Disease
disease I-Disease
. O

secondly O
, O
there O
appeared O
to O
be O
an O
interdependent O
association O
between O
mutations O
upstream O
and O
within O
the O
ptpase O
core O
motif O
, O
the O
core O
motif O
containing O
the O
majority O
of O
missense O
mutations O
, O
and O
the O
involvement O
of O
all O
major O
organ O
systems O
( O
central O
nervous O
system O
, O
thyroid O
, O
breast O
, O
skin O
and O
gastrointestinal O
tract O
) O
. O

however O
, O
these O
observations O
would O
need O
to O
be O
confirmed O
by O
studying O
a O
larger O
number O
of O
cd B-Disease
families O
. O

molecular O
defects O
leading O
to O
human O
complement B-Disease
component I-Disease
c6 I-Disease
deficiency I-Disease
in O
an O
african O
- O
american O
family O
. O

complement B-Disease
component I-Disease
c6 I-Disease
deficiency I-Disease
( O
c6d B-Disease
) O
was O
diagnosed O
in O
a O
16 O
- O
year O
- O
old O
african O
- O
american O
male O
with O
meningococcal B-Disease
meningitis I-Disease
. O

the O
patients O
father O
and O
two O
brothers O
also O
had O
c6d B-Disease
, O
but O
gave O
no O
history O
of O
meningitis B-Disease
or O
other O
neisserial B-Disease
infection I-Disease
. O

by O
using O
exon O
- O
specific O
polymerase O
chain O
reaction O
( O
pcr O
) O
/ O
single O
- O
strand O
conformation O
polymorphism O
as O
a O
screening O
step O
and O
nucleotide O
sequencing O
of O
target O
exons O
, O
we O
determined O
that O
the O
proband O
was O
a O
compound O
heterozygote O
for O
two O
c6 O
gene O
mutations O
. O

the O
first O
, O
1195delc O
located O
in O
exon O
7 O
, O
is O
a O
novel O
mutation O
, O
while O
the O
second O
, O
1936delg O
in O
exon O
12 O
, O
has O
been O
described O
before O
to O
cause O
c6d B-Disease
in O
an O
unrelated O
african O
- O
american O
individual O
. O

both O
mutations O
result O
in O
premature O
termination O
codons O
and O
c6 O
null O
alleles O
. O

allele O
- O
specific O
pcr O
indicated O
that O
the O
probands O
two O
brothers O
also O
inherited O
the O
1195delc O
mutation O
from O
their O
heterozygous O
mother O
and O
the O
1936delg O
mutation O
from O
their O
homozygous O
father O
. O
. O

pax6 O
mutations O
reviewed O
. O

mutations O
in O
pax6 O
are O
responsible O
for O
human O
aniridia B-Disease
and O
have O
also O
been O
found O
in O
patients O
with O
peters B-Disease
anomaly I-Disease
, O
with O
congenital B-Disease
cataracts I-Disease
, O
with O
autosomal B-Disease
dominant I-Disease
keratitis I-Disease
, O
and O
with O
isolated B-Disease
foveal I-Disease
hypoplasia I-Disease
. O

no O
locus O
other O
than O
chromosome O
11p13 O
has O
been O
implicated O
in O
aniridia B-Disease
, O
and O
pax6 O
is O
clearly O
the O
major O
, O
if O
not O
only O
, O
gene O
responsible O
. O

twenty O
- O
eight O
percent O
of O
identified O
pax6 O
mutations O
are O
c O
- O
t O
changes O
at O
cpg O
dinucleotides O
, O
20 O
% O
are O
splicing O
errors O
, O
and O
more O
than O
30 O
% O
are O
deletion O
or O
insertion O
events O
. O

there O
is O
a O
noticeably O
elevated O
level O
of O
mutation O
in O
the O
paired O
domain O
compared O
with O
the O
rest O
of O
the O
gene O
. O

increased O
mutation O
in O
the O
homeodomain O
is O
accounted O
for O
by O
the O
hypermutable O
cpg O
dinucleotide O
in O
codon O
240 O
. O

very O
nearly O
all O
mutations O
appear O
to O
cause O
loss O
of O
function O
of O
the O
mutant O
allele O
, O
and O
more O
than O
80 O
% O
of O
exonic O
substitutions O
result O
in O
nonsense O
codons O
. O

in O
a O
gene O
with O
such O
extraordinarily O
high O
sequence O
conservation O
throughout O
evolution O
, O
there O
are O
presumed O
undiscovered O
missense O
mutations O
, O
these O
are O
hypothesized O
to O
exist O
in O
as O
- O
yet O
unidentified O
phenotypes O
. O
. O

genetic O
heterogeneity O
and O
penetrance O
analysis O
of O
the O
brca1 O
and O
brca2 O
genes O
in O
breast B-Disease
cancer I-Disease
families O
. O

the O
breast B-Disease
cancer I-Disease
linkage O
consortium O
. O

the O
contribution O
of O
brca1 O
and O
brca2 O
to O
inherited B-Disease
breast I-Disease
cancer I-Disease
was O
assessed O
by O
linkage O
and O
mutation O
analysis O
in O
237 O
families O
, O
each O
with O
at O
least O
four O
cases O
of O
breast B-Disease
cancer I-Disease
, O
collected O
by O
the O
breast B-Disease
cancer I-Disease
linkage O
consortium O
. O

families O
were O
included O
without O
regard O
to O
the O
occurrence O
of O
ovarian B-Disease
or I-Disease
other I-Disease
cancers I-Disease
. O

overall O
, O
disease O
was O
linked O
to O
brca1 O
in O
an O
estimated O
52 O
% O
of O
families O
, O
to O
brca2 O
in O
32 O
% O
of O
families O
, O
and O
to O
neither O
gene O
in O
16 O
% O
( O
95 O
% O
confidence O
interval O
[ O
ci O
] O
6 O
% O
- O
28 O
% O
) O
, O
suggesting O
other O
predisposition O
genes O
. O

the O
majority O
( O
81 O
% O
) O
of O
the O
breast B-Disease
- I-Disease
ovarian I-Disease
cancer I-Disease
families O
were O
due O
to O
brca1 O
, O
with O
most O
others O
( O
14 O
% O
) O
due O
to O
brca2 O
. O

conversely O
, O
the O
majority O
of O
families O
with O
male B-Disease
and I-Disease
female I-Disease
breast I-Disease
cancer I-Disease
were O
due O
to O
brca2 O
( O
76 O
% O
) O
. O

the O
largest O
proportion O
( O
67 O
% O
) O
of O
families O
due O
to O
other O
genes O
was O
found O
in O
families O
with O
four O
or O
five O
cases O
of O
female O
breast B-Disease
cancer I-Disease
only O
. O

these O
estimates O
were O
not O
substantially O
affected O
either O
by O
changing O
the O
assumed O
penetrance O
model O
for O
brca1 O
or O
by O
including O
or O
excluding O
brca1 O
mutation O
data O
. O

among O
those O
families O
with O
disease O
due O
to O
brca1 O
that O
were O
tested O
by O
one O
of O
the O
standard O
screening O
methods O
, O
mutations O
were O
detected O
in O
the O
coding O
sequence O
or O
splice O
sites O
in O
an O
estimated O
63 O
% O
( O
95 O
% O
ci O
51 O
% O
- O
77 O
% O
) O
. O

the O
estimated O
sensitivity O
was O
identical O
for O
direct O
sequencing O
and O
other O
techniques O
. O

the O
penetrance O
of O
brca2 O
was O
estimated O
by O
maximizing O
the O
lod O
score O
in O
brca2 O
- O
mutation O
families O
, O
over O
all O
possible O
penetrance O
functions O
. O

the O
estimated O
cumulative O
risk O
of O
breast B-Disease
cancer I-Disease
reached O
28 O
% O
( O
95 O
% O
ci O
9 O
% O
- O
44 O
% O
) O
by O
age O
50 O
years O
and O
84 O
% O
( O
95 O
% O
ci O
43 O
% O
- O
95 O
% O
) O
by O
age O
70 O
years O
. O

the O
corresponding O
ovarian B-Disease
cancer I-Disease
risks O
were O
0 O
. O

4 O
% O
( O
95 O
% O
ci O
0 O
% O
- O
1 O
% O
) O
by O
age O
50 O
years O
and O
27 O
% O
( O
95 O
% O
ci O
0 O
% O
- O
47 O
% O
) O
by O
age O
70 O
years O
. O

the O
lifetime O
risk O
of O
breast B-Disease
cancer I-Disease
appears O
similar O
to O
the O
risk O
in O
brca1 O
carriers O
, O
but O
there O
was O
some O
suggestion O
of O
a O
lower O
risk O
in O
brca2 O
carriers O
< O
50 O
years O
of O
age O
. O

eye B-Disease
movement I-Disease
abnormalities I-Disease
correlate O
with O
genotype O
in O
autosomal O
dominant O
cerebellar B-Disease
ataxia I-Disease
type I-Disease
i I-Disease
. O

we O
compared O
horizontal O
eye O
movements O
( O
visually O
guided O
saccades O
, O
antisaccades O
, O
and O
smooth O
pursuit O
) O
in O
control O
subjects O
( O
n O
= O
14 O
) O
and O
patients O
with O
three O
forms O
of O
autosomal O
dominant O
cerebellar B-Disease
ataxias I-Disease
type I-Disease
i I-Disease
spinocerebellar B-Disease
ataxias I-Disease
1 I-Disease
and I-Disease
2 I-Disease
( O
sca1 B-Disease
, O
n O
= O
11 O
; O
sca2 B-Disease
, O
n O
= O
10 O
) O
and O
sca3 B-Disease
/ O
machado B-Disease
- I-Disease
joseph I-Disease
disease I-Disease
( O
mjd B-Disease
) O
( O
n O
= O
16 O
) O
. O

in O
sca1 B-Disease
, O
saccade O
amplitude O
was O
significantly O
increased O
, O
resulting O
in O
hypermetria B-Disease
. O

the O
smooth O
pursuit O
gain O
was O
decreased O
. O

in O
sca2 B-Disease
, O
saccade O
velocity O
was O
markedly O
decreased O
. O

the O
percentage O
of O
errors O
in O
antisaccades O
was O
greatly O
increased O
and O
was O
significantly O
correlated O
with O
age O
at O
disease O
onset O
. O

in O
addition O
, O
a O
correlation O
between O
smooth O
pursuit O
gain O
and O
the O
number O
of O
trinucleotide O
repeats O
was O
found O
. O

in O
sca3 B-Disease
, O
gaze B-Disease
- I-Disease
evoked I-Disease
nystagmus I-Disease
was O
often O
present O
as O
was O
saccade O
hypometria O
and O
smooth O
pursuit O
gain O
was O
markedly O
decreased O
. O

three O
major O
criteria O
, O
saccade O
amplitude O
, O
saccade O
velocity O
, O
and O
presence O
of O
gaze B-Disease
- I-Disease
evoked I-Disease
nystagmus I-Disease
, O
permitted O
the O
correct O
assignment O
of O
90 O
% O
of O
the O
sca1 B-Disease
, O
90 O
% O
of O
the O
sca2 B-Disease
, O
and O
93 O
% O
of O
the O
patients O
with O
sca3 B-Disease
to O
their O
genetically O
confirmed O
patient O
group O
and O
, O
therefore O
, O
may O
help O
orient O
diagnoses O
of O
sca1 B-Disease
, O
sca2 B-Disease
, O
and O
sca3 B-Disease
at O
early O
clinical O
stages O
of O
the O
diseases O
. O
. O

genetic O
basis O
and O
molecular O
mechanism O
for O
idiopathic B-Disease
ventricular I-Disease
fibrillation I-Disease
. O

ventricular B-Disease
fibrillation I-Disease
causes O
more O
than O
300 O
, O
000 O
sudden O
deaths O
each O
year O
in O
the O
usa O
alone O
. O

in O
approximately O
5 O
- O
12 O
% O
of O
these O
cases O
, O
there O
are O
no O
demonstrable O
cardiac O
or O
non O
- O
cardiac O
causes O
to O
account O
for O
the O
episode O
, O
which O
is O
therefore O
classified O
as O
idiopathic B-Disease
ventricular I-Disease
fibrillation I-Disease
( O
ivf B-Disease
) O
. O

a O
distinct O
group O
of O
ivf B-Disease
patients O
has O
been O
found O
to O
present O
with O
a O
characteristic O
electrocardiographic O
pattern O
. O

because O
of O
the O
small O
size O
of O
most O
pedigrees O
and O
the O
high O
incidence O
of O
sudden B-Disease
death I-Disease
, O
however O
, O
molecular O
genetic O
studies O
of O
ivf B-Disease
have O
not O
yet O
been O
done O
. O

because O
ivf B-Disease
causes O
cardiac O
rhythm O
disturbance O
, O
we O
investigated O
whether O
malfunction O
of O
ion O
channels O
could O
cause O
the O
disorder O
by O
studying O
mutations O
in O
the O
cardiac O
sodium O
channel O
gene O
scn5a O
. O

we O
have O
now O
identified O
a O
missense O
mutation O
, O
a O
splice O
- O
donor O
mutation O
, O
and O
a O
frameshift O
mutation O
in O
the O
coding O
region O
of O
scn5a O
in O
three O
ivf B-Disease
families O
. O

we O
show O
that O
sodium O
channels O
with O
the O
missense O
mutation O
recover O
from O
inactivation O
more O
rapidly O
than O
normal O
and O
that O
the O
frameshift O
mutation O
causes O
the O
sodium O
channel O
to O
be O
non O
- O
functional O
. O

our O
results O
indicate O
that O
mutations O
in O
cardiac O
ion O
- O
channel O
genes O
contribute O
to O
the O
risk O
of O
developing O
ivf B-Disease
. O
. O

molecular O
heterogeneity O
in O
mucopolysaccharidosis B-Disease
iva I-Disease
in O
australia O
and O
northern O
ireland O
: O
nine O
novel O
mutations O
including O
t312s O
, O
a O
common O
allele O
that O
confers O
a O
mild O
phenotype O
. O

mucopolysaccharidosis B-Disease
iva I-Disease
( O
mps B-Disease
iva I-Disease
) O
is O
an O
autosomal B-Disease
recessive I-Disease
lysosomal I-Disease
storage I-Disease
disorder I-Disease
caused O
by O
a O
genetic B-Disease
defect I-Disease
in O
n O
- O
acetylgalactosamine O
- O
6 O
- O
sulfate O
sulfatase O
( O
galns O
) O
. O

previous O
studies O
of O
patients O
from O
a O
british O
- O
irish O
population O
showed O
that O
the O
i113f O
mutation O
is O
the O
most O
common O
single O
mutation O
among O
mps B-Disease
iva I-Disease
patients O
and O
produces O
a O
severe O
clinical O
phenotype O
. O

we O
studied O
mutations O
in O
the O
galns O
gene O
from O
23 O
additional O
mps B-Disease
iva I-Disease
patients O
( O
15 O
from O
australia O
, O
8 O
from O
northern O
ireland O
) O
, O
with O
various O
clinical O
phenotypes O
( O
severe O
, O
16 O
cases O
; O
intermediate O
, O
4 O
cases O
; O
mild O
, O
3 O
cases O
) O
. O

we O
found O
two O
common O
mutations O
that O
together O
accounted O
for O
32 O
% O
of O
the O
44 O
unrelated O
alleles O
in O
these O
patients O
. O

one O
is O
the O
t312s O
mutation O
, O
a O
novel O
mutation O
found O
exclusively O
in O
milder O
patients O
. O

the O
other O
is O
the O
previously O
described O
i113f O
that O
produces O
a O
severe O
phenotype O
. O

the O
i113f O
and O
t312s O
mutations O
accounted O
for O
8 O
( O
18 O
% O
) O
and O
6 O
( O
14 O
% O
) O
of O
44 O
unrelated O
alleles O
, O
respectively O
. O

the O
relatively O
high O
residual O
galns O
activity O
seen O
when O
the O
t312s O
mutant O
cdna O
is O
overexpressed O
in O
mutant O
cells O
provides O
an O
explanation O
for O
the O
mild O
phenotype O
in O
patients O
with O
this O
mutation O
. O

the O
distribution O
and O
relative O
frequencies O
of O
the O
i113f O
and O
t312s O
mutations O
in O
australia O
corresponded O
to O
those O
observed O
in O
northern O
ireland O
and O
are O
unique O
to O
these O
two O
populations O
, O
suggesting O
that O
both O
mutations O
were O
probably O
introduced O
to O
australia O
by O
irish O
migrants O
during O
the O
19th O
century O
. O

haplotype O
analysis O
using O
6 O
rflps O
provides O
additional O
data O
that O
the O
i113f O
mutation O
originated O
from O
a O
common O
ancestor O
. O

the O
other O
9 O
novel O
mutations O
identified O
in O
these O
23 O
patients O
were O
each O
limited O
to O
a O
single O
family O
. O

these O
data O
provide O
further O
evidence O
for O
extensive O
allelic O
heterogeneity O
in O
mps B-Disease
iva I-Disease
in O
british O
- O
irish O
patients O
and O
provide O
evidence O
for O
their O
transmission O
to O
australia O
by O
british O
- O
irish O
migrants O
. O
. O

identification O
of O
constitutional O
wt1 O
mutations O
, O
in O
patients O
with O
isolated O
diffuse B-Disease
mesangial I-Disease
sclerosis I-Disease
, O
and O
analysis O
of O
genotype O
/ O
phenotype O
correlations O
by O
use O
of O
a O
computerized O
mutation O
database O
. O

constitutional O
mutations O
of O
the O
wt1 O
gene O
, O
encoding O
a O
zinc O
- O
finger O
transcription O
factor O
involved O
in O
renal O
and O
gonadal O
development O
, O
are O
found O
in O
most O
patients O
with O
denys B-Disease
- I-Disease
drash I-Disease
syndrome I-Disease
( O
dds B-Disease
) O
, O
or O
diffuse B-Disease
mesangial I-Disease
sclerosis I-Disease
( O
dms B-Disease
) O
associated O
with O
pseudohermaphroditism B-Disease
and O
/ O
or O
wilms B-Disease
tumor I-Disease
( O
wt B-Disease
) O
. O

most O
mutations O
in O
dds B-Disease
patients O
lie O
in O
exon O
8 O
or O
exon O
9 O
, O
encoding O
zinc O
finger O
2 O
or O
zinc O
finger O
3 O
, O
respectively O
, O
with O
a O
hot O
spot O
( O
r394w O
) O
in O
exon O
9 O
. O

we O
analyzed O
a O
series O
of O
24 O
patients O
, O
10 O
with O
isolated B-Disease
dms I-Disease
( O
idms B-Disease
) O
, O
10 O
with O
dds B-Disease
, O
and O
4 O
with O
urogenital B-Disease
abnormalities I-Disease
and O
/ O
or O
wt B-Disease
. O

we O
report O
wt1 O
heterozygous O
mutations O
in O
16 O
patients O
, O
4 O
of O
whom O
presented O
with O
idms B-Disease
. O

one O
male O
and O
two O
female O
idms B-Disease
patients O
with O
wt1 O
mutations O
underwent O
normal O
puberty O
. O

two O
mutations O
associated O
with O
idms B-Disease
are O
different O
from O
those O
described O
in O
dds B-Disease
patients O
. O

no O
wt1 O
mutations O
were O
detected O
in O
the O
six O
other O
idms B-Disease
patients O
, O
suggesting O
genetic O
heterogeneity O
of O
this O
disease O
. O

we O
analyzed O
genotype O
/ O
phenotype O
correlations O
, O
on O
the O
basis O
of O
the O
constitution O
of O
a O
wt1 O
mutation O
database O
of O
84 O
germ O
- O
line O
mutations O
, O
to O
compare O
the O
distribution O
and O
type O
of O
mutations O
, O
according O
to O
the O
different O
symptoms O
. O

this O
demonstrated O
( O
1 O
) O
the O
association O
between O
mutations O
in O
exons O
8 O
and O
9 O
and O
dms B-Disease
; O
( O
2 O
) O
among O
patients O
with O
dms B-Disease
, O
a O
higher O
frequency O
of O
exon O
8 O
mutations O
among O
46 O
, O
xy O
patients O
with O
female O
phenotype O
than O
among O
46 O
, O
xy O
patients O
with O
sexual O
ambiguity O
or O
male O
phenotype O
; O
and O
( O
3 O
) O
statistically O
significant O
evidence O
that O
mutations O
in O
exons O
8 O
and O
9 O
preferentially O
affect O
amino O
acids O
with O
different O
functions O
. O
. O

the O
185delag O
brca1 O
mutation O
originated O
before O
the O
dispersion O
of O
jews O
in O
the O
diaspora O
and O
is O
not O
limited O
to O
ashkenazim O
. O

the O
185delag O
mutation O
in O
brca1 O
is O
detected O
in O
ashkenazi O
jews O
both O
in O
familial B-Disease
breast I-Disease
and I-Disease
ovarian I-Disease
cancer I-Disease
and O
in O
the O
general O
population O
. O

all O
tested O
ashkenazi O
mutation O
carriers O
share O
the O
same O
allelic O
pattern O
at O
the O
brca1 O
locus O
. O

our O
previous O
study O
showed O
that O
this O
ashkenazi O
mutation O
also O
occurs O
in O
iraqi O
jews O
with O
a O
similar O
allelic O
pattern O
. O

we O
extended O
our O
analysis O
to O
other O
non O
- O
ashkenazi O
subsets O
354 O
of O
moroccan O
origin O
, O
200 O
yemenites O
and O
150 O
iranian O
jews O
. O

heteroduplex O
analysis O
complemented O
by O
direct O
dna O
sequencing O
of O
abnormally O
migrating O
bands O
were O
employed O
. O

four O
of O
moroccan O
origin O
( O
1 O
. O
1 O
% O
) O
and O
none O
of O
the O
yemenites O
or O
iranians O
was O
a O
carrier O
of O
the O
185delag O
mutation O
. O

brca1 O
allelic O
patterns O
were O
determined O
for O
four O
of O
these O
individuals O
and O
for O
12 O
additional O
non O
- O
ashkenazi O
185delag O
mutation O
carriers O
who O
had O
breast B-Disease
/ I-Disease
ovarian I-Disease
cancer I-Disease
. O

six O
non O
- O
ashkenazi O
individuals O
shared O
the O
common O
ashkenazi O
haplotype O
, O
four O
had O
a O
closely O
related O
pattern O
, O
and O
the O
rest O
( O
n O
= O
6 O
) O
displayed O
a O
distinct O
brca1 O
allelic O
pattern O
. O

we O
conclude O
that O
the O
185delag O
brca1 O
mutation O
occurs O
in O
some O
non O
- O
ashkenazi O
populations O
at O
rates O
comparable O
with O
that O
of O
ashkenazim O
. O

the O
majority O
of O
jewish O
185delag O
mutation O
carriers O
have O
a O
common O
allelic O
pattern O
, O
supporting O
the O
founder O
effect O
notion O
, O
but O
dating O
the O
mutations O
origin O
to O
an O
earlier O
date O
than O
currently O
estimated O
. O

however O
, O
the O
different O
allelic O
pattern O
at O
the O
brca1 O
locus O
even O
in O
some O
jewish O
mutation O
carriers O
, O
might O
suggest O
that O
the O
mutation O
arose O
independently O
. O
. O

crystal O
structure O
of O
the O
hemochromatosis B-Disease
protein O
hfe O
and O
characterization O
of O
its O
interaction O
with O
transferrin O
receptor O
. O

hfe O
is O
an O
mhc O
- O
related O
protein O
that O
is O
mutated O
in O
the O
iron B-Disease
- I-Disease
overload I-Disease
disease I-Disease
hereditary B-Disease
hemochromatosis I-Disease
. O

hfe O
binds O
to O
transferrin O
receptor O
( O
tfr O
) O
and O
reduces O
its O
affinity O
for O
iron O
- O
loaded O
transferrin O
, O
implicating O
hfe O
in O
iron O
metabolism O
. O

the O
2 O
. O

6 O
a O
crystal O
structure O
of O
hfe O
reveals O
the O
locations O
of O
hemochromatosis B-Disease
mutations O
and O
a O
patch O
of O
histidines O
that O
could O
be O
involved O
in O
ph O
- O
dependent O
interactions O
. O

we O
also O
demonstrate O
that O
soluble O
tfr O
and O
hfe O
bind O
tightly O
at O
the O
basic O
ph O
of O
the O
cell O
surface O
, O
but O
not O
at O
the O
acidic O
ph O
of O
intracellular O
vesicles O
. O

tfr O
hfe O
stoichiometry O
( O
2 O
1 O
) O
differs O
from O
tfr O
transferrin O
stoichiometry O
( O
2 O
2 O
) O
, O
implying O
a O
different O
mode O
of O
binding O
for O
hfe O
and O
transferrin O
to O
tfr O
, O
consistent O
with O
our O
demonstration O
that O
hfe O
, O
transferrin O
, O
and O
tfr O
form O
a O
ternary O
complex O
. O

identification O
of O
three O
novel O
mutations O
and O
a O
high O
frequency O
of O
the O
arg778leu O
mutation O
in O
korean O
patients O
with O
wilson B-Disease
disease I-Disease
. O

four O
mutations O
- O
- O
r778l O
, O
a874v O
, O
l1083f O
, O
and O
2304delc O
- O
- O
in O
the O
copper O
- O
transporting O
enzyme O
, O
p O
- O
type O
atpase O
( O
atp7b O
) O
, O
were O
identified O
in O
korean O
patients O
with O
wilson B-Disease
disease I-Disease
. O

arg778leu O
, O
the O
most O
frequently O
reported O
mutation O
of O
this O
enzyme O
, O
was O
found O
in O
six O
of O
eight O
unrelated O
patients O
studied O
, O
an O
allele O
frequency O
of O
37 O
. O

5 O
% O
, O
which O
is O
considerably O
higher O
than O
those O
in O
other O
asian O
populations O
. O

the O
novel O
single O
nucleotide O
deletion O
, O
2304delc O
, O
was O
found O
in O
one O
patient O
. O

since O
a O
mutation O
at O
cdna O
nucleotide O
2302 O
( O
2302insc O
) O
had O
been O
previously O
described O
, O
this O
region O
of O
the O
atp7b O
gene O
may O
be O
susceptible O
to O
gene O
rearrangements O
causing O
wilson B-Disease
disease I-Disease
. O

disruption O
of O
splicing O
regulated O
by O
a O
cug O
- O
binding O
protein O
in O
myotonic B-Disease
dystrophy I-Disease
. O

myotonic B-Disease
dystrophy I-Disease
( O
dm B-Disease
) O
is O
caused O
by O
a O
ctg O
expansion O
in O
the O
3 O
untranslated O
region O
of O
the O
dm B-Disease
gene O
. O

one O
model O
of O
dm B-Disease
pathogenesis O
suggests O
that O
rnas O
from O
the O
expanded O
allele O
create O
a O
gain O
- O
of O
- O
function O
mutation O
by O
the O
inappropriate O
binding O
of O
proteins O
to O
the O
cug O
repeats O
. O

data O
presented O
here O
indicate O
that O
the O
conserved O
heterogeneous O
nuclear O
ribonucleoprotein O
, O
cug O
- O
binding O
protein O
( O
cug O
- O
bp O
) O
, O
may O
mediate O
the O
trans O
- O
dominant O
effect O
of O
the O
rna O
. O

cug O
- O
bp O
was O
found O
to O
bind O
to O
the O
human O
cardiac O
troponin O
t O
( O
ctnt O
) O
pre O
- O
messenger O
rna O
and O
regulate O
its O
alternative O
splicing O
. O

splicing O
of O
ctnt O
was O
disrupted O
in O
dm B-Disease
striated O
muscle O
and O
in O
normal O
cells O
expressing O
transcripts O
that O
contain O
cug O
repeats O
. O

altered O
expression O
of O
genes O
regulated O
posttranscriptionally O
by O
cug O
- O
bp O
therefore O
may O
contribute O
to O
dm B-Disease
pathogenesis O
. O
. O

identification O
of O
a O
novel O
nonsense O
mutation O
and O
a O
missense O
substitution O
in O
the O
vasopressin O
- O
neurophysin O
ii O
gene O
in O
two O
spanish O
kindreds O
with O
familial B-Disease
neurohypophyseal I-Disease
diabetes I-Disease
insipidus I-Disease
. O

familial B-Disease
neurohypophyseal I-Disease
diabetes I-Disease
insipidus I-Disease
( O
fndi B-Disease
) O
is O
an O
autosomal B-Disease
dominant I-Disease
disease I-Disease
caused O
by O
deficiency O
in O
the O
antidiuretic O
hormone O
arginine O
vasopressin O
( O
avp O
) O
encoded O
by O
the O
avp O
- O
neurophysin O
ii O
( O
avp O
- O
npii O
) O
gene O
on O
chromosome O
20p13 O
. O

in O
this O
study O
, O
we O
analyzed O
two O
families O
with O
fndi B-Disease
using O
direct O
automated O
fluorescent O
, O
solid O
phase O
, O
single O
- O
stranded O
dna O
sequencing O
of O
pcr O
- O
amplified O
avp O
- O
npii O
dna O
. O

in O
one O
of O
the O
families O
, O
affected O
individuals O
presented O
a O
novel O
nonsense O
mutation O
in O
exon O
3 O
of O
the O
gene O
, O
consisting O
in O
a O
g O
to O
t O
transition O
at O
nucleotide O
2101 O
, O
which O
produces O
a O
stop O
signal O
in O
codon O
82 O
( O
glu O
) O
of O
npii O
. O

the O
premature O
termination O
eliminates O
part O
of O
the O
c O
- O
terminal O
domain O
of O
npii O
, O
including O
a O
cysteine O
residue O
in O
position O
85 O
, O
which O
could O
be O
involved O
in O
the O
correct O
folding O
of O
the O
prohormone O
. O

in O
the O
second O
family O
, O
a O
g279a O
substitution O
at O
position O
- O
1 O
of O
the O
signal O
peptide O
was O
observed O
in O
all O
affected O
individuals O
. O

this O
missense O
mutation O
, O
which O
replaces O
ala O
with O
thr O
, O
is O
frequent O
among O
fndi B-Disease
patients O
and O
is O
thought O
to O
reduce O
the O
efficiency O
of O
cleavage O
by O
signal O
peptidases O
. O
. O

genetic O
heterogeneity O
of O
saethre B-Disease
- I-Disease
chotzen I-Disease
syndrome I-Disease
, O
due O
to O
twist O
and O
fgfr O
mutations O
. O

thirty O
- O
two O
unrelated O
patients O
with O
features O
of O
saethre B-Disease
- I-Disease
chotzen I-Disease
syndrome I-Disease
, O
a O
common O
autosomal B-Disease
dominant I-Disease
condition I-Disease
of O
craniosynostosis B-Disease
and O
limb B-Disease
anomalies I-Disease
, O
were O
screened O
for O
mutations O
in O
twist O
, O
fgfr2 O
, O
and O
fgfr3 O
. O

nine O
novel O
and O
three O
recurrent O
twist O
mutations O
were O
found O
in O
12 O
families O
. O

seven O
families O
were O
found O
to O
have O
the O
fgfr3 O
p250r O
mutation O
, O
and O
one O
individual O
was O
found O
to O
have O
an O
fgfr2 O
vv269 O
- O
270 O
deletion O
. O

to O
date O
, O
our O
detection O
rate O
for O
twist O
or O
fgfr O
mutations O
is O
68 O
% O
in O
our O
saethre B-Disease
- I-Disease
chotzen I-Disease
syndrome I-Disease
patients O
, O
including O
our O
five O
patients O
elsewhere O
reported O
with O
twist O
mutations O
. O

more O
than O
35 O
different O
twist O
mutations O
are O
now O
known O
in O
the O
literature O
. O

the O
most O
common O
phenotypic O
features O
, O
present O
in O
more O
than O
a O
third O
of O
our O
patients O
with O
twist O
mutations O
, O
are O
coronal B-Disease
synostosis I-Disease
, O
brachycephaly B-Disease
, O
low B-Disease
frontal I-Disease
hairline I-Disease
, O
facial B-Disease
asymmetry I-Disease
, O
ptosis B-Disease
, O
hypertelorism B-Disease
, O
broad B-Disease
great I-Disease
toes I-Disease
, O
and O
clinodactyly B-Disease
. O

significant O
intra O
- O
and O
interfamilial O
phenotypic O
variability O
is O
present O
for O
either O
twist O
mutations O
or O
fgfr O
mutations O
. O

the O
overlap O
in O
clinical O
features O
and O
the O
presence O
, O
in O
the O
same O
genes O
, O
of O
mutations O
for O
more O
than O
one O
craniosynostotic B-Disease
condition I-Disease
- O
such O
as O
saethre B-Disease
- I-Disease
chotzen I-Disease
, I-Disease
crouzon I-Disease
, I-Disease
and I-Disease
pfeiffer I-Disease
syndromes I-Disease
- O
support O
the O
hypothesis O
that O
twist O
and O
fgfrs O
are O
components O
of O
the O
same O
molecular O
pathway O
involved O
in O
the O
modulation O
of O
craniofacial O
and O
limb O
development O
in O
humans O
. O
. O

mutation O
analysis O
of O
ube3a O
in O
angelman B-Disease
syndrome I-Disease
patients O
. O

angelman B-Disease
syndrome I-Disease
( O
as B-Disease
) O
is O
caused O
by O
chromosome O
15q11 O
- O
q13 O
deletions O
of O
maternal O
origin O
, O
by O
paternal O
uniparental B-Disease
disomy I-Disease
( O
upd B-Disease
) O
15 O
, O
by O
imprinting O
defects O
, O
and O
by O
mutations O
in O
the O
ube3a O
gene O
. O

ube3a O
encodes O
a O
ubiquitin O
- O
protein O
ligase O
and O
shows O
brain O
- O
specific O
imprinting O
. O

here O
we O
describe O
ube3a O
coding O
- O
region O
mutations O
detected O
by O
sscp O
analysis O
in O
13 O
as B-Disease
individuals O
or O
families O
. O

two O
identical O
de O
novo O
5 O
- O
bp O
duplications O
in O
exon O
16 O
were O
found O
. O

among O
the O
other O
11 O
unique O
mutations O
, O
8 O
were O
small O
deletions O
or O
insertions O
predicted O
to O
cause O
frameshifts O
, O
1 O
was O
a O
mutation O
to O
a O
stop O
codon O
, O
1 O
was O
a O
missense O
mutation O
, O
and O
1 O
was O
predicted O
to O
cause O
insertion O
of O
an O
isoleucine O
in O
the O
hect O
domain O
of O
the O
ube3a O
protein O
, O
which O
functions O
in O
e2 O
binding O
and O
ubiquitin O
transfer O
. O

eight O
of O
the O
cases O
were O
familial O
, O
and O
five O
were O
sporadic O
. O

in O
two O
familial O
cases O
and O
one O
sporadic O
case O
, O
mosaicism O
for O
ube3a O
mutations O
was O
detected O
in O
the O
mother O
of O
three O
as B-Disease
sons O
, O
in O
the O
maternal O
grandfather O
of O
two O
as B-Disease
first O
cousins O
, O
and O
in O
the O
mother O
of O
an O
as B-Disease
daughter O
. O

the O
frequencies O
with O
which O
we O
detected O
mutations O
were O
5 O
( O
14 O
% O
) O
of O
35 O
in O
sporadic O
cases O
and O
8 O
( O
80 O
% O
) O
of O
10 O
in O
familial O
cases O
. O
. O

the O
hemochromatosis B-Disease
845 O
g O
- O
- O
> O
a O
and O
187 O
c O
- O
- O
> O
g O
mutations O
: O
prevalence O
in O
non O
- O
caucasian O
populations O
. O

hemochromatosis B-Disease
, O
the O
inherited B-Disease
disorder I-Disease
of I-Disease
iron I-Disease
metabolism I-Disease
, O
leads O
, O
if O
untreated O
, O
to O
progressive O
iron B-Disease
overload I-Disease
and O
premature B-Disease
death I-Disease
. O

the O
hemochromatosis B-Disease
gene O
, O
hfe O
, O
recently O
has O
been O
identified O
, O
and O
characterization O
of O
this O
gene O
has O
shown O
that O
it O
contains O
two O
mutations O
that O
result O
in O
amino O
acid O
substitutions O
- O
cdna O
nucleotides O
845 O
g O
- O
- O
> O
a O
( O
c282y O
) O
and O
187 O
c O
- O
- O
> O
g O
( O
h63d O
) O
. O

although O
hemochromatosis B-Disease
is O
common O
in O
caucasians O
, O
affecting O
> O
= O
1 O
/ O
300 O
individuals O
of O
northern O
european O
origin O
, O
it O
has O
not O
been O
recognized O
in O
other O
populations O
. O

the O
present O
study O
used O
pcr O
and O
restriction O
- O
enzyme O
digestion O
to O
analyze O
the O
frequency O
of O
the O
845 O
g O
- O
- O
> O
a O
and O
187 O
c O
- O
- O
> O
g O
mutations O
in O
hla O
- O
typed O
samples O
from O
non O
- O
caucasian O
populations O
, O
comprising O
australian O
aboriginal O
, O
chinese O
, O
and O
pacific O
islanders O
. O

results O
showed O
that O
the O
845 O
g O
- O
- O
> O
a O
mutation O
was O
present O
in O
these O
populations O
( O
allele O
frequency O
0 O
. O
32 O
% O
) O
, O
and O
, O
furthermore O
, O
it O
was O
always O
seen O
in O
conjunction O
with O
hla O
haplotypes O
common O
in O
caucasians O
, O
suggesting O
that O
845 O
g O
- O
- O
> O
a O
may O
have O
been O
introduced O
into O
these O
populations O
by O
caucasian O
admixture O
. O

187 O
c O
- O
- O
> O
g O
was O
present O
at O
an O
allele O
frequency O
of O
2 O
. O

68 O
% O
in O
the O
two O
populations O
analyzed O
( O
australian O
aboriginal O
and O
chinese O
) O
. O

in O
the O
australian O
aboriginal O
samples O
, O
187 O
c O
- O
- O
> O
g O
was O
found O
to O
be O
associated O
with O
hla O
haplotypes O
common O
in O
caucasians O
, O
suggesting O
that O
it O
was O
introduced O
by O
recent O
admixture O
. O

in O
the O
chinese O
samples O
analyzed O
, O
187 O
c O
- O
- O
> O
g O
was O
present O
in O
association O
with O
a O
wide O
variety O
of O
hla O
haplotypes O
, O
showing O
this O
mutation O
to O
be O
widespread O
and O
likely O
to O
predate O
the O
more O
genetically O
restricted O
845 O
g O
- O
- O
> O
a O
mutation O
. O

genotype O
- O
phenotype O
correlations O
in O
attenuated B-Disease
adenomatous I-Disease
polyposis I-Disease
coli I-Disease
. O

germ O
- O
line O
mutations O
of O
the O
tumor B-Disease
suppressor O
apc O
are O
implicated O
in O
attenuated B-Disease
adenomatous I-Disease
polyposis I-Disease
coli I-Disease
( O
aapc B-Disease
) O
, O
a O
variant O
of O
familial B-Disease
adenomatous I-Disease
polyposis I-Disease
( O
fap B-Disease
) O
. O

aapc B-Disease
is O
recognized O
by O
the O
occurrence O
of O
< O
100 O
colonic B-Disease
adenomas I-Disease
and O
a O
later O
onset O
of O
colorectal B-Disease
cancer I-Disease
( O
age O
> O
40 O
years O
) O
. O

the O
aim O
of O
this O
study O
was O
to O
assess O
genotype O
- O
phenotype O
correlations O
in O
aapc B-Disease
families O
. O

by O
protein O
- O
truncation O
test O
( O
ptt O
) O
assay O
, O
the O
entire O
coding O
region O
of O
the O
apc B-Disease
gene O
was O
screened O
in O
affected O
individuals O
from O
11 O
aapc B-Disease
kindreds O
, O
and O
their O
phenotypic O
differences O
were O
examined O
. O

five O
novel O
germ O
- O
line O
apc B-Disease
mutations O
were O
identified O
in O
seven O
kindreds O
. O

mutations O
were O
located O
in O
three O
different O
regions O
of O
the O
apc B-Disease
gene O
( O
1 O
) O
at O
the O
5 O
end O
spanning O
exons O
4 O
and O
5 O
, O
( O
2 O
) O
within O
exon O
9 O
, O
and O
( O
3 O
) O
at O
the O
3 O
distal O
end O
of O
the O
gene O
. O

variability O
in O
the O
number O
of O
colorectal B-Disease
adenomas I-Disease
was O
most O
apparent O
in O
individuals O
with O
mutations O
in O
region O
1 O
, O
and O
upper O
- O
gastrointestinal O
manifestations O
were O
more O
severe O
in O
them O
. O

in O
individuals O
with O
mutations O
in O
either O
region O
2 O
or O
region O
3 O
, O
the O
average O
number O
of O
adenomas B-Disease
tended O
to O
be O
lower O
than O
those O
in O
individuals O
with O
mutations O
in O
region O
1 O
, O
although O
age O
at O
diagnosis O
was O
similar O
. O

in O
all O
aapc B-Disease
kindreds O
, O
a O
predominance O
of O
right O
- O
sided O
colorectal B-Disease
adenomas I-Disease
and O
rectal B-Disease
polyp I-Disease
sparing O
was O
observed O
. O

no O
desmoid B-Disease
tumors I-Disease
were O
found O
in O
these O
kindreds O
. O

our O
data O
suggest O
that O
, O
in O
aapc B-Disease
families O
, O
the O
location O
of O
the O
apc B-Disease
mutation O
may O
partially O
predict O
specific O
phenotypic O
expression O
. O

this O
should O
help O
in O
the O
design O
of O
tailored O
clinical O
- O
management O
protocols O
in O
this O
subset O
of O
fap B-Disease
patients O
. O
. O

wilms B-Disease
' I-Disease
tumor I-Disease
1 O
and O
dax O
- O
1 O
modulate O
the O
orphan O
nuclear O
receptor O
sf O
- O
1 O
in O
sex O
- O
specific O
gene O
expression O
. O

products O
of O
steroidogenic O
factor O
1 O
( O
sf O
- O
1 O
) O
and O
wilms B-Disease
tumor I-Disease
1 O
( O
wt1 O
) O
genes O
are O
essential O
for O
mammalian O
gonadogenesis O
prior O
to O
sexual O
differentiation O
. O

in O
males O
, O
sf O
- O
1 O
participates O
in O
sexual O
development O
by O
regulating O
expression O
of O
the O
polypeptide O
hormone O
mullerian O
inhibiting O
substance O
( O
mis O
) O
. O

here O
, O
we O
show O
that O
wt1 O
- O
kts O
isoforms O
associate O
and O
synergize O
with O
sf O
- O
1 O
to O
promote O
mis O
expression O
. O

in O
contrast O
, O
wt1 O
missense O
mutations O
, O
associated O
with O
male B-Disease
pseudohermaphroditism I-Disease
in O
denys B-Disease
- I-Disease
drash I-Disease
syndrome I-Disease
, O
fail O
to O
synergize O
with O
sf O
- O
1 O
. O

additionally O
, O
the O
x O
- O
linked O
, O
candidate O
dosage O
- O
sensitive O
sex O
- O
reversal O
gene O
, O
dax O
- O
1 O
, O
antagonizes O
synergy O
between O
sf O
- O
1 O
and O
wt1 O
, O
most O
likely O
through O
a O
direct O
interaction O
with O
sf O
- O
1 O
. O

we O
propose O
that O
wt1 O
and O
dax O
- O
1 O
functionally O
oppose O
each O
other O
in O
testis O
development O
by O
modulating O
sf O
- O
1 O
- O
mediated O
transactivation O
. O
. O

a O
mouse O
model O
for O
prader B-Disease
- I-Disease
willi I-Disease
syndrome I-Disease
imprinting O
- O
centre O
mutations O
. O

imprinting O
in O
the O
15q11 O
- O
q13 O
region O
involves O
an O
imprinting O
centre O
( O
ic O
) O
, O
mapping O
in O
part O
to O
the O
promoter O
and O
first O
exon O
of O
snrpn O
. O

deletion O
of O
this O
ic O
abolishes O
local O
paternally O
derived O
gene O
expression O
and O
results O
in O
prader B-Disease
- I-Disease
willi I-Disease
syndrome I-Disease
( O
pws B-Disease
) O
. O

we O
have O
created O
two O
deletion O
mutations O
in O
mice O
to O
understand O
pws B-Disease
and O
the O
mechanism O
of O
this O
ic O
. O

mice O
harbouring O
an O
intragenic O
deletion O
in O
snrpn O
are O
phenotypically O
normal O
, O
suggesting O
that O
mutations O
of O
snrpn O
are O
not O
sufficient O
to O
induce O
pws B-Disease
. O

mice O
with O
a O
larger O
deletion O
involving O
both O
snrpn O
and O
the O
putative O
pws O
- O
ic O
lack O
expression O
of O
the O
imprinted O
genes O
zfp127 O
( O
mouse O
homologue O
of O
znf127 O
) O
, O
ndn O
and O
ipw O
, O
and O
manifest O
several O
phenotypes O
common O
to O
pws B-Disease
infants O
. O

these O
data O
demonstrate O
that O
both O
the O
position O
of O
the O
ic O
and O
its O
role O
in O
the O
coordinate O
expression O
of O
genes O
is O
conserved O
between O
mouse O
and O
human O
, O
and O
indicate O
that O
the O
mouse O
is O
a O
suitable O
model O
system O
in O
which O
to O
investigate O
the O
molecular O
mechanisms O
of O
imprinting O
in O
this O
region O
of O
the O
genome O
. O
. O

mutations O
of O
the O
atm O
gene O
detected O
in O
japanese O
ataxia B-Disease
- I-Disease
telangiectasia I-Disease
patients O
: O
possible O
preponderance O
of O
the O
two O
founder O
mutations O
4612del165 O
and O
7883del5 O
. O

the O
atm O
( O
a O
- O
t O
, O
mutated O
) O
gene O
on O
human O
chromosome O
11q22 O
. O

3 O
has O
recently O
been O
identified O
as O
the O
gene O
responsible O
for O
the O
human O
recessive B-Disease
disease I-Disease
ataxia B-Disease
- I-Disease
telangiectasia I-Disease
( O
a B-Disease
- I-Disease
t I-Disease
) O
. O

in O
order O
to O
define O
the O
types O
of O
disease O
- O
causing O
atm O
mutations O
in O
japanese O
a B-Disease
- I-Disease
t I-Disease
patients O
as O
well O
as O
to O
look O
for O
possible O
mutational O
hotspots O
, O
reverse O
- O
transcribed O
rna O
derived O
from O
ten O
patients O
belonging O
to O
eight O
unrelated O
japanese O
a B-Disease
- I-Disease
t I-Disease
families O
was O
analyzed O
for O
mutations O
by O
the O
restriction O
endonuclease O
fingerprinting O
method O
. O

as O
has O
been O
reported O
by O
others O
, O
mutations O
that O
lead O
to O
exon O
skipping O
or O
premature O
protein O
truncation O
were O
also O
predominant O
in O
our O
mutants O
. O

six O
different O
mutations O
were O
identified O
on O
12 O
of O
the O
16 O
alleles O
examined O
. O

four O
were O
deletions O
involving O
a O
loss O
of O
a O
single O
exon O
exon O
7 O
, O
exon O
16 O
, O
exon O
33 O
or O
exon O
35 O
. O

the O
others O
were O
minute O
deletions O
, O
4649dela O
in O
exon O
33 O
and O
7883del5 O
in O
exon O
55 O
. O

the O
mutations O
4612del165 O
and O
7883del5 O
were O
found O
in O
more O
than O
two O
unrelated O
families O
; O
44 O
% O
( O
7 O
of O
16 O
) O
of O
the O
mutant O
alleles O
had O
one O
of O
the O
two O
mutations O
. O

the O
4612del165 O
mutations O
in O
three O
different O
families O
were O
all O
ascribed O
to O
the O
same O
t O
- O
- O
> O
a O
substitution O
at O
the O
splice O
donor O
site O
in O
intron O
33 O
. O

microsatellite O
genotyping O
around O
the O
atm O
locus O
also O
indicated O
that O
a O
common O
haplotype O
was O
shared O
by O
the O
mutant O
alleles O
in O
both O
mutations O
. O

this O
suggests O
that O
these O
two O
founder O
mutations O
may O
be O
predominant O
among O
japanese O
atm O
mutant O
alleles O
. O

w474c O
amino O
acid O
substitution O
affects O
early O
processing O
of O
the O
alpha O
- O
subunit O
of O
beta O
- O
hexosaminidase O
a O
and O
is O
associated O
with O
subacute O
g B-Disease
( I-Disease
m2 I-Disease
) I-Disease
gangliosidosis I-Disease
. O

mutations O
in O
the O
hexa O
gene O
, O
encoding O
the O
alpha O
- O
subunit O
of O
beta O
- O
hexosaminidase O
a O
( O
hex O
a O
) O
, O
that O
abolish O
hex O
a O
enzyme O
activity O
cause O
tay B-Disease
- I-Disease
sachs I-Disease
disease I-Disease
( O
tsd B-Disease
) O
, O
the O
fatal O
infantile B-Disease
form I-Disease
of I-Disease
g I-Disease
( I-Disease
m2 I-Disease
) I-Disease
gangliosidosis I-Disease
, I-Disease
type I-Disease
1 I-Disease
. O

less O
severe O
, O
subacute O
( O
juvenile O
- O
onset O
) O
and O
chronic O
( O
adult O
- O
onset O
) O
variants O
are O
characterized O
by O
a O
broad O
spectrum O
of O
clinical O
manifestations O
and O
are O
associated O
with O
residual O
levels O
of O
hex O
a O
enzyme O
activity O
. O

we O
identified O
a O
1422 O
g O
- O
- O
> O
c O
( O
amino O
acid O
w474c O
) O
substitution O
in O
the O
first O
position O
of O
exon O
13 O
of O
hexa O
of O
a O
non O
- O
jewish O
proband O
who O
manifested O
a O
subacute O
variant O
of O
g B-Disease
( I-Disease
m2 I-Disease
) I-Disease
gangliosidosis I-Disease
. O

on O
the O
second O
maternally O
inherited O
allele O
, O
we O
identified O
the O
common O
infantile O
disease O
- O
causing O
4 O
- O
bp O
insertion O
, O
+ O
tatc O
1278 O
, O
in O
exon O
11 O
. O

pulse O
- O
chase O
analysis O
using O
proband O
fibroblasts O
revealed O
that O
the O
w474c O
- O
containing O
alpha O
- O
subunit O
precursor O
was O
normally O
synthesized O
, O
but O
not O
phosphorylated O
or O
secreted O
, O
and O
the O
mature O
lysosomal O
alpha O
- O
subunit O
was O
not O
detected O
. O

when O
the O
w474c O
- O
containing O
alpha O
- O
subunit O
was O
transiently O
co O
- O
expressed O
with O
the O
beta O
- O
subunit O
to O
produce O
hex O
a O
( O
alphabeta O
) O
in O
cos O
- O
7 O
cells O
, O
the O
mature O
alpha O
- O
subunit O
was O
present O
, O
but O
its O
level O
was O
much O
lower O
than O
that O
from O
normal O
alpha O
- O
subunit O
transfections O
, O
although O
higher O
than O
in O
those O
cells O
transfected O
with O
an O
alpha O
- O
subunit O
associated O
with O
infantile O
tsd B-Disease
. O

furthermore O
, O
the O
precursor O
level O
of O
the O
w474c O
alpha O
- O
subunit O
was O
found O
to O
accumulate O
in O
comparison O
to O
the O
normal O
alpha O
- O
subunit O
precursor O
levels O
. O

we O
conclude O
that O
the O
1422 O
g O
- O
- O
> O
c O
mutation O
is O
the O
cause O
of O
hex B-Disease
a I-Disease
enzyme I-Disease
deficiency I-Disease
in O
the O
proband O
. O

the O
resulting O
w474c O
substitution O
clearly O
interferes O
with O
alpha O
- O
subunit O
processing O
, O
but O
because O
the O
base O
substitution O
falls O
at O
the O
first O
position O
of O
exon O
13 O
, O
aberrant O
splicing O
may O
also O
contribute O
to O
hex B-Disease
a I-Disease
deficiency I-Disease
in O
this O
proband O
. O
. O

two O
frequent O
missense O
mutations O
in O
pendred B-Disease
syndrome I-Disease
. O

pendred B-Disease
syndrome I-Disease
is O
an O
autosomal B-Disease
recessive I-Disease
disorder I-Disease
characterized O
by O
early O
childhood O
deafness B-Disease
and O
goiter B-Disease
. O

a O
century O
after O
its O
recognition O
as O
a O
syndrome O
by O
vaughan O
pendred O
, O
the O
disease O
gene O
( O
pds O
) O
was O
mapped O
to O
chromosome O
7q22 O
- O
q31 O
. O

1 O
and O
, O
recently O
, O
found O
to O
encode O
a O
putative O
sulfate O
transporter O
. O

we O
performed O
mutation O
analysis O
of O
the O
pds B-Disease
gene O
in O
patients O
from O
14 O
pendred B-Disease
families O
originating O
from O
seven O
countries O
and O
identified O
all O
mutations O
. O

the O
mutations O
include O
three O
single O
base O
deletions O
, O
one O
splice O
site O
mutation O
and O
10 O
missense O
mutations O
. O

one O
missense O
mutation O
( O
l236p O
) O
was O
found O
in O
a O
homozygous O
state O
in O
two O
consanguineous O
families O
and O
in O
a O
heterozygous O
state O
in O
five O
additional O
non O
- O
consanguineous O
families O
. O

another O
missense O
mutation O
( O
t416p O
) O
was O
found O
in O
a O
homozygous O
state O
in O
one O
family O
and O
in O
a O
heterozygous O
state O
in O
four O
families O
. O

pendred B-Disease
patients O
in O
three O
non O
- O
consanguineous O
families O
were O
shown O
to O
be O
compound O
heterozygotes O
for O
l236p O
and O
t416p O
. O

in O
total O
, O
one O
or O
both O
of O
these O
mutations O
were O
found O
in O
nine O
of O
the O
14 O
families O
analyzed O
. O

the O
identification O
of O
two O
frequent O
pds B-Disease
mutations O
will O
facilitate O
the O
molecular O
diagnosis O
of O
pendred B-Disease
syndrome I-Disease
. O

insertional O
mutation O
by O
transposable O
element O
, O
l1 O
, O
in O
the O
dmd B-Disease
gene O
results O
in O
x B-Disease
- I-Disease
linked I-Disease
dilated I-Disease
cardiomyopathy I-Disease
. O

x B-Disease
- I-Disease
linked I-Disease
dilated I-Disease
cardiomyopathy I-Disease
( O
xldcm B-Disease
) O
is O
a O
clinical O
phenotype O
of O
dystrophinopathy B-Disease
which O
is O
characterized O
by O
preferential O
myocardial B-Disease
involvement I-Disease
without O
any O
overt O
clinical O
signs O
of O
skeletal B-Disease
myopathy I-Disease
. O

to O
date O
, O
several O
mutations O
in O
the O
duchenne B-Disease
muscular I-Disease
dystrophy I-Disease
gene O
, O
dmd O
, O
have O
been O
identified O
in O
patients O
with O
xldcm B-Disease
, O
but O
a O
pathogenic O
correlation O
of O
these O
cardiospecific O
mutations O
in O
dmd O
with O
the O
xldcm B-Disease
phenotype O
has O
remained O
to O
be O
elucidated O
. O

we O
report O
here O
the O
identification O
of O
a O
unique O
de O
novo O
l1 O
insertion O
in O
the O
muscle O
exon O
1 O
in O
dmd O
in O
three O
xldcm B-Disease
patients O
from O
two O
unrelated O
japanese O
families O
. O

the O
insertion O
was O
a O
5 O
- O
truncated O
form O
of O
human O
l1 O
inversely O
integrated O
in O
the O
5 O
- O
untranslated O
region O
in O
the O
muscle O
exon O
1 O
, O
which O
affected O
the O
transcription O
or O
the O
stability O
of O
the O
muscle O
form O
of O
dystrophin O
transcripts O
but O
not O
that O
of O
the O
brain O
or O
purkinje O
cell O
form O
, O
probably O
due O
to O
its O
unique O
site O
of O
integration O
. O

we O
speculate O
that O
this O
insertion O
of O
an O
l1 O
sequence O
in O
dmd O
is O
responsible O
for O
some O
of O
the O
population O
of O
japanese O
patients O
with O
xldcm B-Disease
. O
. O

severe O
early O
- O
onset O
obesity B-Disease
, O
adrenal B-Disease
insufficiency I-Disease
and O
red O
hair O
pigmentation O
caused O
by O
pomc O
mutations O
in O
humans O
. O

sequential O
cleavage O
of O
the O
precursor O
protein O
pre O
- O
pro O
- O
opiomelanocortin O
( O
pomc O
) O
generates O
the O
melanocortin O
peptides O
adrenocorticotrophin O
( O
acth O
) O
, O
melanocyte O
- O
stimulating O
hormones O
( O
msh O
) O
alpha O
, O
beta O
and O
gamma O
as O
well O
as O
the O
opioid O
- O
receptor O
ligand O
beta O
- O
endorphin O
. O

while O
a O
few O
cases O
of O
isolated O
acth B-Disease
deficiency I-Disease
have O
been O
reported O
( O
omim O
201400 O
) O
, O
an O
inherited O
pomc O
defect O
has O
not O
been O
described O
so O
far O
. O

recent O
studies O
in O
animal O
models O
elucidated O
a O
central O
role O
of O
alpha O
- O
msh O
in O
the O
regulation O
of O
food O
intake O
by O
activation O
of O
the O
brain O
melanocortin O
- O
4 O
- O
receptor O
( O
mc4 O
- O
r O
; O
refs O
3 O
- O
5 O
) O
and O
the O
linkage O
of O
human O
obesity B-Disease
to O
chromosome O
2 O
in O
close O
proximity O
to O
the O
pomc O
locus O
, O
led O
to O
the O
proposal O
of O
an O
association O
of O
pomc O
with O
human O
obesity B-Disease
. O

the O
dual O
role O
of O
alpha O
- O
msh O
in O
regulating O
food O
intake O
and O
influencing O
hair O
pigmentation O
predicts O
that O
the O
phenotype O
associated O
with O
a O
defect O
in O
pomc O
function O
would O
include O
obesity B-Disease
, O
alteration O
in O
pigmentation O
and O
acth B-Disease
deficiency I-Disease
. O

the O
observation O
of O
these O
symptoms O
in O
two O
probands O
prompted O
us O
to O
search O
for O
mutations O
within O
their O
pomc O
genes O
. O

patient O
1 O
was O
found O
to O
be O
a O
compound O
heterozygote O
for O
two O
mutations O
in O
exon O
3 O
( O
g7013t O
, O
c7133delta O
) O
which O
interfere O
with O
appropriate O
synthesis O
of O
acth O
and O
alpha O
- O
msh O
. O

patient O
2 O
was O
homozygous O
for O
a O
mutation O
in O
exon O
2 O
( O
c3804a O
) O
which O
abolishes O
pomc O
translation O
. O

these O
findings O
represent O
the O
first O
examples O
of O
a O
genetic B-Disease
defect I-Disease
within O
the O
pomc O
gene O
and O
define O
a O
new O
monogenic B-Disease
endocrine I-Disease
disorder I-Disease
resulting O
in O
early O
- O
onset O
obesity B-Disease
, O
adrenal B-Disease
insufficiency I-Disease
and O
red O
hair O
pigmentation O
. O
. O

a O
european O
multicenter O
study O
of O
phenylalanine B-Disease
hydroxylase I-Disease
deficiency I-Disease
: O
classification O
of O
105 O
mutations O
and O
a O
general O
system O
for O
genotype O
- O
based O
prediction O
of O
metabolic O
phenotype O
. O

phenylketonuria B-Disease
( O
pku B-Disease
) O
and O
mild B-Disease
hyperphenylalaninemia I-Disease
( O
mhp B-Disease
) O
are O
allelic B-Disease
disorders I-Disease
caused O
by O
mutations O
in O
the O
gene O
encoding O
phenylalanine O
hydroxylase O
( O
pah O
) O
. O

previous O
studies O
have O
suggested O
that O
the O
highly O
variable O
metabolic O
phenotypes O
of O
pah B-Disease
deficiency I-Disease
correlate O
with O
pah O
genotypes O
. O

we O
identified O
both O
causative O
mutations O
in O
686 O
patients O
from O
seven O
european O
centers O
. O

on O
the O
basis O
of O
the O
phenotypic O
characteristics O
of O
297 O
functionally O
hemizygous O
patients O
, O
105 O
of O
the O
mutations O
were O
assigned O
to O
one O
of O
four O
arbitrary O
phenotype O
categories O
. O

we O
proposed O
and O
tested O
a O
simple O
model O
for O
correlation O
between O
genotype O
and O
phenotypic O
outcome O
. O

the O
observed O
phenotype O
matched O
the O
predicted O
phenotype O
in O
79 O
% O
of O
the O
cases O
, O
and O
in O
only O
5 O
of O
184 O
patients O
was O
the O
observed O
phenotype O
more O
than O
one O
category O
away O
from O
that O
expected O
. O

among O
the O
seven O
contributing O
centers O
, O
the O
proportion O
of O
patients O
for O
whom O
the O
observed O
phenotype O
did O
not O
match O
the O
predicted O
phenotype O
was O
4 O
% O
- O
23 O
% O
( O
p O
< O
. O
0001 O
) O
, O
suggesting O
that O
differences O
in O
methods O
used O
for O
mutation O
detection O
or O
phenotype O
classification O
may O
account O
for O
a O
considerable O
proportion O
of O
genotype O
- O
phenotype O
inconsistencies O
. O

our O
data O
indicate O
that O
the O
pah O
- O
mutation O
genotype O
is O
the O
main O
determinant O
of O
metabolic O
phenotype O
in O
most O
patients O
with O
pah B-Disease
deficiency I-Disease
. O

in O
the O
present O
study O
, O
the O
classification O
of O
105 O
pah O
mutations O
may O
allow O
the O
prediction O
of O
the O
biochemical O
phenotype O
in O
> O
10 O
, O
000 O
genotypes O
, O
which O
may O
be O
useful O
for O
the O
management O
of O
hyperphenylalaninemia B-Disease
in O
newborns O
. O

somatic O
instability O
of O
the O
ctg O
repeat O
in O
mice O
transgenic O
for O
the O
myotonic B-Disease
dystrophy I-Disease
region O
is O
age O
dependent O
but O
not O
correlated O
to O
the O
relative O
intertissue O
transcription O
levels O
and O
proliferative O
capacities O
. O

a O
( O
ctg O
) O
nexpansion O
in O
the O
3 O
- O
untranslated O
region O
( O
utr O
) O
of O
the O
dm O
protein O
kinase O
gene O
( O
dmpk O
) O
is O
responsible O
for O
causing O
myotonic B-Disease
dystrophy I-Disease
( O
dm B-Disease
) O
. O

major O
instability O
, O
with O
very O
large O
expansions O
between O
generations O
and O
high O
levels O
of O
somatic O
mosaicism O
, O
is O
observed O
in O
patients O
. O

there O
is O
a O
good O
correlation O
between O
repeat O
size O
( O
at O
least O
in O
leucocytes O
) O
, O
clinical O
severity O
and O
age O
of O
onset O
. O

the O
trinucleotide O
repeat O
instability O
mechanisms O
involved O
in O
dm B-Disease
and O
other O
human O
genetic B-Disease
diseases I-Disease
are O
unknown O
. O

we O
studied O
somatic O
instability O
by O
measuring O
the O
ctg O
repeat O
length O
at O
several O
ages O
in O
various O
tissues O
of O
transgenic O
mice O
carrying O
a O
( O
ctg O
) O
55expansion O
surrounded O
by O
45 O
kb O
of O
the O
human O
dm B-Disease
region O
, O
using O
small O
- O
pool O
pcr O
. O

these O
mice O
have O
been O
shown O
to O
reproduce O
the O
intergenerational O
and O
somatic O
instability O
of O
the O
55 O
ctg O
repeat O
suggesting O
that O
surrounding O
sequences O
and O
the O
chromatin O
environment O
are O
involved O
in O
instability O
mechanisms O
. O

as O
observed O
in O
some O
of O
the O
tissues O
of O
dm B-Disease
patients O
, O
there O
is O
a O
tendency O
for O
repeat O
length O
and O
somatic O
mosaicism O
to O
increase O
with O
the O
age O
of O
the O
mouse O
. O

furthermore O
, O
we O
observed O
no O
correlation O
between O
the O
somatic O
mutation O
rate O
and O
tissue O
proliferation O
capacity O
. O

the O
somatic O
mutation O
rates O
in O
different O
tissues O
were O
also O
not O
correlated O
to O
the O
relative O
inter O
- O
tissue O
difference O
in O
transcriptional O
levels O
of O
the O
three O
genes O
( O
dmahp O
, O
dmpk O
and O
59 O
) O
surrounding O
the O
repeat O
. O
. O

a O
novel O
missense O
mutation O
in O
patients O
from O
a O
retinoblastoma B-Disease
pedigree O
showing O
only O
mild O
expression O
of O
the O
tumor B-Disease
phenotype O
. O

we O
have O
used O
single O
strand O
conformation O
polymorphism O
analysis O
to O
study O
the O
27 O
exons O
of O
the O
rb1 O
gene O
in O
individuals O
from O
a O
family O
showing O
mild O
expression O
of O
the O
retinoblastoma B-Disease
phenotype O
. O

in O
this O
family O
affected O
individuals O
developed O
unilateral B-Disease
tumors I-Disease
and O
, O
as O
a O
result O
of O
linkage O
analysis O
, O
unaffected O
mutation O
carriers O
were O
also O
identified O
within O
the O
pedigree O
. O

a O
single O
band O
shift O
using O
sscp O
was O
identified O
in O
exon O
21 O
which O
resulted O
in O
a O
missense O
mutation O
converting O
a O
cys O
- O
- O
> O
arg O
at O
nucleotide O
position O
28 O
in O
the O
exon O
. O

the O
mutation O
destroyed O
an O
ndei O
restriction O
enzyme O
site O
. O

analysis O
of O
all O
family O
members O
demonstrated O
that O
the O
missense O
mutation O
co O
- O
segregated O
with O
patients O
with O
tumors B-Disease
or O
who O
, O
as O
a O
result O
of O
linkage O
analysis O
had O
been O
predicted O
to O
carry O
the O
predisposing O
mutation O
. O

these O
observations O
point O
to O
another O
region O
of O
the O
rb1 O
gene O
where O
mutations O
only O
modify O
the O
function O
of O
the O
gene O
and O
raise O
important O
questions O
for O
genetic O
counseling O
in O
families O
with O
these O
distinctive O
phenotypes O
. O
. O

maternal B-Disease
disomy I-Disease
and O
prader B-Disease
- I-Disease
willi I-Disease
syndrome I-Disease
consistent O
with O
gamete O
complementation O
in O
a O
case O
of O
familial O
translocation O
( O
3 O
; O
15 O
) O
( O
p25 O
; O
q11 O
. O
2 O
) O
. O

maternal B-Disease
uniparental I-Disease
disomy I-Disease
( I-Disease
upd I-Disease
) I-Disease
for I-Disease
chromosome I-Disease
15 I-Disease
is O
responsible O
for O
an O
estimated O
30 O
% O
of O
cases O
of O
prader B-Disease
- I-Disease
willi I-Disease
syndrome I-Disease
( O
pws B-Disease
) O
. O

we O
report O
on O
an O
unusual O
case O
of O
maternal B-Disease
disomy I-Disease
15 I-Disease
in O
pws B-Disease
that O
is O
most O
consistent O
with O
adjacent O
- O
1 O
segregation O
of O
a O
paternal O
t O
( O
3 O
; O
15 O
) O
( O
p25 O
; O
q11 O
. O
2 O
) O
with O
simultaneous O
maternal O
meiotic O
nondisjunction O
for O
chromosome O
15 O
. O

the O
patient O
( O
j O
. O
b O
. O
) O
, O
a O
17 O
- O
year O
- O
old O
white O
male O
with O
pws B-Disease
, O
was O
found O
to O
have O
47 O
chromosomes O
with O
a O
supernumerary O
, O
paternal O
der O
( O
15 O
) O
consisting O
of O
the O
short O
arm O
and O
the O
proximal O
long O
arm O
of O
chromosome O
15 O
, O
and O
distal O
chromosome O
arm O
3p O
. O

the O
t O
( O
3 O
; O
15 O
) O
was O
present O
in O
the O
balanced O
state O
in O
the O
patients O
father O
and O
a O
sister O
. O

fluorescent O
in O
situ O
hybridization O
analysis O
demonstrated O
that O
the O
pws B-Disease
critical O
region O
resided O
on O
the O
derivative O
chromosome O
3 O
and O
that O
there O
was O
no O
deletion O
of O
the O
pws B-Disease
region O
on O
the O
normal O
pair O
of O
15s O
present O
in O
j O
. O

b O
. O

methylation O
analysis O
at O
exon O
alpha O
of O
the O
small O
nuclear O
ribonucleoprotein O
- O
associated O
polypeptide O
n O
( O
snrpn O
) O
gene O
showed O
a O
pattern O
characteristic O
of O
only O
the O
maternal O
chromosome O
15 O
in O
j O
. O

b O
. O

maternal B-Disease
disomy I-Disease
was O
confirmed O
by O
polymerase O
chain O
reaction O
analysis O
of O
microsatellite O
repeats O
at O
the O
gamma O
- O
aminobutyric O
acid O
receptor O
beta3 O
subunit O
( O
gabrb3 O
) O
locus O
. O

a O
niece O
( O
b O
. O
b O
. O
) O
with O
45 O
chromosomes O
and O
the O
derivative O
3 O
but O
without O
the O
der O
( O
15 O
) O
demonstrated O
a O
phenotype O
consistent O
with O
that O
reported O
for O
haploinsufficiency O
of O
distal O
3 O
p O
. O

uniparental B-Disease
disomy I-Disease
associated O
with O
unbalanced O
segregation O
of O
non O
- O
robertsonian O
translocations O
has O
been O
reported O
previously O
but O
has O
not O
, O
to O
our O
knowledge O
, O
been O
observed O
in O
a O
case O
of O
pws B-Disease
. O

furthermore O
, O
our O
findings O
are O
best O
interpreted O
as O
true O
gamete O
complementation O
resulting O
in O
maternal B-Disease
upd I-Disease
15 I-Disease
and O
pws B-Disease

schwartz B-Disease
- I-Disease
jampel I-Disease
syndrome I-Disease
type I-Disease
2 I-Disease
and O
stuve B-Disease
- I-Disease
wiedemann I-Disease
syndrome I-Disease
: O
a O
case O
for O
" O
lumping O
" O
. O

recent O
studies O
demonstrated O
the O
existence O
of O
a O
genetically O
distinct O
, O
usually O
lethal O
form O
of O
the O
schwartz B-Disease
- I-Disease
jampel I-Disease
syndrome I-Disease
( O
sjs B-Disease
) O
of O
myotonia B-Disease
and O
skeletal B-Disease
dysplasia I-Disease
, O
which O
we O
called O
sjs B-Disease
type I-Disease
2 I-Disease
. O

this O
disorder O
is O
reminiscent O
of O
another O
rare O
condition O
, O
the O
stuve B-Disease
- I-Disease
wiedemann I-Disease
syndrome I-Disease
( O
sws B-Disease
) O
, O
which O
comprises O
campomelia B-Disease
at O
birth O
with O
skeletal B-Disease
dysplasia I-Disease
, O
contractures B-Disease
, O
and O
early B-Disease
death I-Disease
. O

to O
test O
for O
possible O
nosologic O
identity O
between O
these O
disorders O
, O
we O
reviewed O
the O
literature O
and O
obtained O
a O
follow O
- O
up O
of O
the O
only O
two O
surviving O
patients O
, O
one O
with O
sjs B-Disease
type I-Disease
2 I-Disease
at O
age O
10 O
years O
and O
another O
with O
sws B-Disease
at O
age O
7 O
years O
. O

patients O
reported O
as O
having O
either O
neonatal O
sjs B-Disease
or O
sws B-Disease
presented O
a O
combination O
of O
a O
severe O
, O
prenatal O
- O
onset O
neuromuscular B-Disease
disorder I-Disease
( O
with O
congenital B-Disease
joint I-Disease
contractures I-Disease
, O
respiratory O
and O
feeding O
difficulties O
, O
tendency O
to O
hyperthermia B-Disease
, O
and O
frequent O
death O
in O
infancy O
) O
with O
a O
distinct O
campomelic B-Disease
- I-Disease
metaphyseal I-Disease
skeletal I-Disease
dysplasia I-Disease
. O

the O
similarity O
of O
the O
clinical O
and O
radiographic O
findings O
is O
so O
extensive O
that O
these O
disorders O
appear O
to O
be O
a O
single O
entity O
. O

the O
follow O
- O
up O
observation O
of O
an O
identical O
and O
unique O
pattern O
of O
progressive O
bone B-Disease
dysplasia I-Disease
in O
the O
two O
patients O
( O
one O
with O
sjs B-Disease
type I-Disease
2 I-Disease
, O
one O
with O
sws B-Disease
) O
surviving O
beyond O
infancy O
adds O
to O
the O
evidence O
in O
favor O
of O
identity O
. O

the O
hypothesis O
that O
sws B-Disease
and O
sjs B-Disease
type I-Disease
2 I-Disease
are O
the O
same O
disorder O
should O
be O
testable O
by O
molecular O
methods O
. O
. O

a O
mouse O
model O
of O
severe O
von B-Disease
willebrand I-Disease
disease I-Disease
: O
defects O
in O
hemostasis O
and O
thrombosis B-Disease
. O

von B-Disease
willebrand I-Disease
factor I-Disease
( I-Disease
vwf I-Disease
) I-Disease
deficiency I-Disease
causes O
severe O
von B-Disease
willebrand I-Disease
disease I-Disease
in O
humans O
. O

we O
generated O
a O
mouse O
model O
for O
this O
disease O
by O
using O
gene O
targeting O
. O

vwf B-Disease
- I-Disease
deficient I-Disease
mice O
appeared O
normal O
at O
birth O
; O
they O
were O
viable O
and O
fertile O
. O

neither O
vwf O
nor O
vwf O
propolypeptide O
( O
von B-Disease
willebrand I-Disease
antigen O
ii O
) O
were O
detectable O
in O
plasma O
, O
platelets O
, O
or O
endothelial O
cells O
of O
the O
homozygous O
mutant O
mice O
. O

the O
mutant O
mice O
exhibited O
defects O
in O
hemostasis O
with O
a O
highly O
prolonged O
bleeding O
time O
and O
spontaneous O
bleeding O
events O
in O
approximately O
10 O
% O
of O
neonates O
. O

as O
in O
the O
human O
disease O
, O
the O
factor O
viii O
level O
in O
these O
mice O
was O
reduced O
strongly O
as O
a O
result O
of O
the O
lack O
of O
protection O
provided O
by O
vwf O
. O

defective O
thrombosis B-Disease
in O
mutant O
mice O
was O
also O
evident O
in O
an O
in O
vivo O
model O
of O
vascular B-Disease
injury I-Disease
. O

in O
this O
model O
, O
the O
exteriorized O
mesentery O
was O
superfused O
with O
ferric O
chloride O
and O
the O
accumulation O
of O
fluorescently O
labeled O
platelets O
was O
observed O
by O
intravital O
microscopy O
. O

we O
conclude O
that O
these O
mice O
very O
closely O
mimic O
severe O
human O
von B-Disease
willebrand I-Disease
disease I-Disease
and O
will O
be O
very O
useful O
for O
investigating O
the O
role O
of O
vwf O
in O
normal O
physiology O
and O
in O
disease O
models O
. O
. O

oral O
contraceptives O
and O
the O
risk O
of O
hereditary B-Disease
ovarian I-Disease
cancer I-Disease
. O

hereditary B-Disease
ovarian I-Disease
cancer I-Disease
clinical O
study O
group O
. O

background O
women O
with O
mutations O
in O
either O
the O
brca1 O
or O
the O
brca2 O
gene O
have O
a O
high O
lifetime O
risk O
of O
ovarian B-Disease
cancer I-Disease
. O

oral O
contraceptives O
protect O
against O
ovarian B-Disease
cancer I-Disease
in O
general O
, O
but O
it O
is O
not O
known O
whether O
they O
also O
protect O
against O
hereditary B-Disease
forms I-Disease
of I-Disease
ovarian I-Disease
cancer I-Disease
. O

methods O
we O
enrolled O
207 O
women O
with O
hereditary B-Disease
ovarian I-Disease
cancer I-Disease
and O
161 O
of O
their O
sisters O
as O
controls O
in O
a O
case O
- O
control O
study O
. O

all O
the O
patients O
carried O
a O
pathogenic O
mutation O
in O
either O
brca1 O
( O
179 O
women O
) O
or O
brca2 O
( O
28 O
women O
) O
. O

the O
control O
women O
were O
enrolled O
regardless O
of O
whether O
or O
not O
they O
had O
either O
mutation O
. O

lifetime O
histories O
of O
oral O
- O
contraceptive O
use O
were O
obtained O
by O
interview O
or O
by O
written O
questionnaire O
and O
were O
compared O
between O
patients O
and O
control O
women O
, O
after O
adjustment O
for O
year O
of O
birth O
and O
parity O
. O

results O
the O
adjusted O
odds O
ratio O
for O
ovarian B-Disease
cancer I-Disease
associated O
with O
any O
past O
use O
of O
oral O
contraceptives O
was O
0 O
. O

5 O
( O
95 O
percent O
confidence O
interval O
, O
0 O
. O
3 O
to O
0 O
. O
8 O
) O
. O

the O
risk O
decreased O
with O
increasing O
duration O
of O
use O
( O
p O
for O
trend O
, O
< O
0 O
. O
001 O
) O
; O
use O
for O
six O
or O
more O
years O
was O
associated O
with O
a O
60 O
percent O
reduction O
in O
risk O
. O

oral O
- O
contraceptive O
use O
protected O
against O
ovarian B-Disease
cancer I-Disease
both O
for O
carriers O
of O
the O
brca1 O
mutation O
( O
odds O
ratio O
, O
0 O
. O
5 O
; O
95 O
percent O
confidence O
interval O
, O
0 O
. O
3 O
to O
0 O
. O
9 O
) O
and O
for O
carriers O
of O
the O
brca2 O
mutation O
( O
odds O
ratio O
, O
0 O
. O
4 O
; O
95 O
percent O
confidence O
interval O
, O
0 O
. O
2 O
to O
1 O
. O
1 O
) O
. O

conclusions O
oral O
- O
contraceptive O
use O
may O
reduce O
the O
risk O
of O
ovarian B-Disease
cancer I-Disease
in O
women O
with O
pathogenic O
mutations O
in O
the O
brca1 O
or O
brca2 O
gene O

a O
japanese O
family O
with O
adrenoleukodystrophy B-Disease
with O
a O
codon O
291 O
deletion O
: O
a O
clinical O
, O
biochemical O
, O
pathological O
, O
and O
genetic O
report O
. O

we O
report O
a O
japanese O
family O
with O
adrenoleukodystrophy B-Disease
( O
ald B-Disease
) O
with O
a O
three O
base O
pair O
deletion O
( O
delgag O
291 O
) O
in O
the O
ald B-Disease
gene O
. O

a O
variety O
of O
phenotypes O
were O
observed O
within O
this O
family O
. O

while O
the O
proband O
( O
patient O
1 O
) O
was O
classified O
as O
having O
a O
rare O
intermediate O
type O
of O
adult O
cerebral O
and O
cerebello O
- O
brain O
stem O
forms O
, O
his O
younger O
brother O
( O
patient O
2 O
) O
and O
nephew O
( O
patient O
3 O
) O
had O
a O
childhood O
ald B-Disease
type O
. O

another O
nephew O
( O
patient O
4 O
) O
of O
patient O
1 O
was O
classified O
as O
having O
an O
adolescent O
form O
. O

the O
tau O
level O
in O
the O
cerebrospinal O
fluid O
( O
csf O
) O
in O
patient O
1 O
was O
as O
high O
as O
that O
of O
patients O
with O
alzheimers B-Disease
disease I-Disease
( O
ad B-Disease
) O
. O

his O
brain O
magnetic O
resonance O
image O
( O
mri O
) O
showed O
abnormalities B-Disease
in I-Disease
the I-Disease
bilateral I-Disease
cerebellar I-Disease
hemispheres I-Disease
and O
brain O
stem O
, O
but O
not O
in O
the O
cerebral O
white O
matter O
, O
where O
marked O
reductions O
of O
the O
cerebral O
blood O
flow O
and O
oxygen O
metabolism O
were O
clearly O
demonstrated O
by O
positron O
emission O
tomography O
( O
pet O
) O
. O

in O
patients O
2 O
and O
3 O
, O
the O
autopsy O
findings O
showed O
massive O
demyelination B-Disease
of I-Disease
the I-Disease
cerebral I-Disease
white I-Disease
matter I-Disease
with O
sparing O
of O
the O
u O
- O
fibers O
, O
compatible O
with O
the O
findings O
of O
childhood O
ald B-Disease
. O

oleic O
and O
erucic O
acids O
( O
lorenzos O
oil O
) O
were O
administered O
to O
patients O
1 O
and O
4 O
, O
but O
sufficient O
effectiveness O
was O
not O
obtained O
. O

the O
findings O
in O
this O
family O
suggest O
that O
delgag291 O
is O
part O
of O
the O
cause O
of O
japanese O
ald B-Disease
with O
phenotypic O
variations O
. O

moreover O
, O
although O
the O
scale O
of O
the O
study O
is O
limited O
, O
there O
is O
a O
possibility O
that O
pet O
can O
detect O
an O
insidious B-Disease
lesion I-Disease
which O
is O
undetectable O
by O
computed O
tomogram O
( O
ct O
) O
or O
mri O
analysis O
, O
and O
that O
the O
higher O
level O
of O
tau O
reflects O
the O
process O
of O
neuronal B-Disease
degeneration I-Disease
in O
ald B-Disease
. O

lorenzos O
oil O
should O
be O
given O
in O
the O
early O
stage O
. O
. O

nonsense O
mutation O
in O
exon O
4 O
of O
human O
complement O
c9 O
gene O
is O
the O
major O
cause O
of O
japanese O
complement B-Disease
c9 I-Disease
deficiency I-Disease
. O

deficiency B-Disease
of I-Disease
the I-Disease
ninth I-Disease
component I-Disease
of I-Disease
human I-Disease
complement I-Disease
( O
c9 O
) O
is O
the O
most O
common O
complement B-Disease
deficiency I-Disease
in O
japan O
but O
is O
rare O
in O
other O
countries O
. O

we O
studied O
the O
molecular O
basis O
of O
c9 B-Disease
deficiency I-Disease
in O
four O
japanese O
c9 B-Disease
- I-Disease
deficient I-Disease
patients O
who O
had O
suffered O
from O
meningococcal B-Disease
meningitis I-Disease
. O

direct O
sequencing O
of O
amplified O
c9 O
cdna O
and O
dna O
revealed O
a O
nonsense O
substitution O
( O
cga O
- O
- O
> O
tga O
) O
at O
codon O
95 O
in O
exon O
4 O
in O
the O
four O
c9 B-Disease
- I-Disease
deficient I-Disease
individuals O
. O

an O
allele O
- O
specific O
polymerase O
chain O
reaction O
system O
designed O
to O
detect O
exclusively O
only O
one O
of O
the O
normal O
and O
mutant O
alleles O
indicated O
that O
all O
the O
four O
patients O
were O
homozygous O
for O
the O
mutation O
in O
exon O
4 O
and O
that O
the O
parents O
of O
patient O
2 O
were O
heterozygous O
. O

the O
common O
mutation O
at O
codon O
95 O
in O
exon O
4 O
might O
be O
responsible O
for O
most O
japanese O
c9 B-Disease
deficiency I-Disease
. O
. O

brca1 O
required O
for O
transcription O
- O
coupled O
repair O
of O
oxidative O
dna O
damage O
. O

the O
breast B-Disease
and I-Disease
ovarian I-Disease
cancer I-Disease
susceptibility O
gene O
brca1 O
encodes O
a O
zinc O
finger O
protein O
of O
unknown O
function O
. O

association O
of O
the O
brca1 O
protein O
with O
the O
dna O
repair O
protein O
rad51 O
and O
changes O
in O
the O
phosphorylation O
and O
cellular O
localization O
of O
the O
protein O
after O
exposure O
to O
dna O
- O
damaging O
agents O
are O
consistent O
with O
a O
role O
for O
brca1 O
in O
dna O
repair O
. O

here O
, O
it O
is O
shown O
that O
mouse O
embryonic O
stem O
cells O
deficient B-Disease
in I-Disease
brca1 I-Disease
are O
defective O
in O
the O
ability O
to O
carry O
out O
transcription O
- O
coupled O
repair O
of O
oxidative O
dna O
damage O
, O
and O
are O
hypersensitive O
to O
ionizing O
radiation O
and O
hydrogen O
peroxide O
. O

these O
results O
suggest O
that O
brca1 O
participates O
, O
directly O
or O
indirectly O
, O
in O
transcription O
- O
coupled O
repair O
of O
oxidative O
dna O
damage O
. O
. O

truncation O
mutations O
in O
the O
transactivation O
region O
of O
pax6 O
result O
in O
dominant O
- O
negative O
mutants O
. O

pax6 O
is O
a O
transcription O
factor O
with O
two O
dna O
- O
binding O
domains O
( O
paired O
box O
and O
homeobox O
) O
and O
a O
proline O
- O
serine O
- O
threonine O
( O
pst O
) O
- O
rich O
transactivation O
domain O
. O

pax6 O
regulates O
eye O
development O
in O
animals O
ranging O
from O
jellyfish O
to O
drosophila O
to O
humans O
. O

heterozygous O
mutations O
in O
the O
human O
pax6 O
gene O
result O
in O
various O
phenotypes O
, O
including O
aniridia B-Disease
, O
peters B-Disease
anomaly I-Disease
, O
autosomal B-Disease
dominant I-Disease
keratitis I-Disease
, O
and O
familial B-Disease
foveal I-Disease
dysplasia I-Disease
. O

it O
is O
believed O
that O
the O
mutated O
allele O
of O
pax6 O
produces O
an O
inactive O
protein O
and O
aniridia B-Disease
is O
caused O
due O
to O
genetic O
haploinsufficiency O
. O

however O
, O
several O
truncation O
mutations O
have O
been O
found O
to O
occur O
in O
the O
c O
- O
terminal O
half O
of O
pax6 O
in O
patients O
with O
aniridia B-Disease
resulting O
in O
mutant O
proteins O
that O
retain O
the O
dna O
- O
binding O
domains O
but O
have O
lost O
most O
of O
the O
transactivation O
domain O
. O

it O
is O
not O
clear O
whether O
such O
mutants O
really O
behave O
as O
loss O
- O
of O
- O
function O
mutants O
as O
predicted O
by O
haploinsufficiency O
. O

contrary O
to O
this O
theory O
, O
our O
data O
showed O
that O
these O
mutants O
are O
dominant O
- O
negative O
in O
transient O
transfection O
assays O
when O
they O
are O
coexpressed O
with O
wild O
- O
type O
pax6 O
. O

we O
found O
that O
the O
dominant O
- O
negative O
effects O
result O
from O
the O
enhanced O
dna O
binding O
ability O
of O
these O
mutants O
. O

kinetic O
studies O
of O
binding O
and O
dissociation O
revealed O
that O
various O
truncation O
mutants O
have O
3 O
- O
5 O
- O
fold O
higher O
affinity O
to O
various O
dna O
- O
binding O
sites O
when O
compared O
with O
the O
wild O
- O
type O
pax6 O
. O

these O
results O
provide O
a O
new O
insight O
into O
the O
role O
of O
mutant O
pax6 O
in O
causing O
aniridia B-Disease
. O
. O

reversal O
of O
severe O
hypertrophic B-Disease
cardiomyopathy I-Disease
and O
excellent O
neuropsychologic O
outcome O
in O
very B-Disease
- I-Disease
long I-Disease
- I-Disease
chain I-Disease
acyl I-Disease
- I-Disease
coenzyme I-Disease
a I-Disease
dehydrogenase I-Disease
deficiency I-Disease
. O

very B-Disease
- I-Disease
long I-Disease
- I-Disease
chain I-Disease
acyl I-Disease
- I-Disease
coenzyme I-Disease
a I-Disease
dehydrogenase I-Disease
( I-Disease
vlcad I-Disease
) I-Disease
deficiency I-Disease
is O
a O
disorder O
of O
fatty O
acid O
beta O
oxidation O
that O
reportedly O
has O
high O
rates O
of O
morbidity O
and O
mortality O
. O

we O
describe O
the O
outcome O
of O
a O
5 O
- O
year O
- O
old O
girl O
with O
vlcad B-Disease
deficiency I-Disease
who O
was O
first O
seen O
at O
5 O
months O
of O
age O
with O
severe O
hypertrophic B-Disease
cardiomyopathy I-Disease
, O
hepatomegaly B-Disease
, O
encephalopathy B-Disease
, O
and O
hypotonia B-Disease
. O

biochemical O
studies O
indicated O
vlcad B-Disease
deficiency I-Disease
caused O
by O
a O
stable O
yet O
inactive O
enzyme O
. O

molecular O
genetic O
analysis O
of O
her O
vlcad O
gene O
revealed O
a O
t1372c O
( O
f458l O
) O
missense O
mutation O
and O
a O
1668 O
acag O
1669 O
splice O
site O
mutation O
. O

after O
initial O
treatment O
with O
intravenous O
glucose O
and O
carnitine O
, O
the O
patient O
has O
thrived O
on O
a O
low O
- O
fat O
diet O
supplemented O
with O
medium O
- O
chain O
triglyceride O
oil O
and O
carnitine O
and O
avoidance O
of O
fasting O
. O

her O
ventricular O
hypertrophy O
resolved O
significantly O
over O
1 O
year O
, O
and O
cognitively O
, O
she O
is O
in O
the O
superior O
range O
for O
age O
. O

clinical O
recognition O
of O
vlcad B-Disease
deficiency I-Disease
is O
important O
because O
it O
is O
one O
of O
the O
few O
directly O
treatable O
causes O
of O
cardiomyopathy B-Disease
in O
children O
. O
. O

cloning O
of O
a O
novel O
member O
of O
the O
low O
- O
density O
lipoprotein O
receptor O
family O
. O

a O
gene O
encoding O
a O
novel O
transmembrane O
protein O
was O
identified O
by O
dna O
sequence O
analysis O
within O
the O
insulin B-Disease
- I-Disease
dependent I-Disease
diabetes I-Disease
mellitus I-Disease
( O
iddm B-Disease
) O
locus O
iddm4 O
on O
chromosome O
11q13 O
. O

based O
on O
its O
chromosomal O
position O
, O
this O
gene O
is O
a O
candidate O
for O
conferring O
susceptibility O
to O
diabetes B-Disease
. O

the O
gene O
, O
termed O
low O
- O
density O
lipoprotein O
receptor O
related O
protein O
5 O
( O
lrp5 O
) O
, O
encodes O
a O
protein O
of O
1615 O
amino O
acids O
that O
contains O
conserved O
modules O
which O
are O
characteristic O
of O
the O
low O
- O
density O
lipoprotein O
( O
ldl O
) O
receptor O
family O
. O

these O
modules O
include O
a O
putative O
signal O
peptide O
for O
protein O
export O
, O
four O
epidermal O
growth O
factor O
( O
egf O
) O
repeats O
with O
associated O
spacer O
domains O
, O
three O
ldl O
- O
receptor O
( O
ldlr O
) O
repeats O
, O
a O
single O
transmembrane O
spanning O
domain O
, O
and O
a O
cytoplasmic O
domain O
. O

the O
encoded O
protein O
has O
a O
unique O
organization O
of O
egf O
and O
ldlr O
repeats O
; O
therefore O
, O
lrp5 O
likely O
represents O
a O
new O
category O
of O
the O
ldlr O
family O
. O

both O
human O
and O
mouse O
lrp5 O
cdnas O
have O
been O
isolated O
and O
the O
encoded O
mature O
proteins O
are O
95 O
% O
identical O
, O
indicating O
a O
high O
degree O
of O
evolutionary O
conservation O
. O
. O

the O
apc B-Disease
variants O
i1307k O
and O
e1317q O
are O
associated O
with O
colorectal B-Disease
tumors I-Disease
, O
but O
not O
always O
with O
a O
family O
history O
. O

classical O
familial B-Disease
adenomatous I-Disease
polyposis I-Disease
( O
fap B-Disease
) O
is O
a O
high O
- O
penetrance O
autosomal B-Disease
dominant I-Disease
disease I-Disease
that O
predisposes O
to O
hundreds O
or O
thousands O
of O
colorectal B-Disease
adenomas I-Disease
and I-Disease
carcinoma I-Disease
and O
that O
results O
from O
truncating O
mutations O
in O
the O
apc B-Disease
gene O
. O

a O
variant O
of O
fap B-Disease
is O
attenuated B-Disease
adenomatous I-Disease
polyposis I-Disease
coli I-Disease
, O
which O
results O
from O
germ O
- O
line O
mutations O
in O
the O
5 O
and O
3 O
regions O
of O
the O
apc B-Disease
gene O
. O

attenuated B-Disease
adenomatous I-Disease
polyposis I-Disease
coli I-Disease
patients O
have O
" O
multiple O
" O
colorectal B-Disease
adenomas I-Disease
( O
typically O
fewer O
than O
100 O
) O
without O
the O
florid O
phenotype O
of O
classical O
fap B-Disease
. O

another O
group O
of O
patients O
with O
multiple O
adenomas B-Disease
has O
no O
mutations O
in O
the O
apc B-Disease
gene O
, O
and O
their O
phenotype O
probably O
results O
from O
variation O
at O
a O
locus O
, O
or O
loci O
, O
elsewhere O
in O
the O
genome O
. O

recently O
, O
however O
, O
a O
missense O
variant O
of O
apc B-Disease
( O
i1307k O
) O
was O
described O
that O
confers O
an O
increased O
risk O
of O
colorectal B-Disease
tumors I-Disease
, O
including O
multiple O
adenomas B-Disease
, O
in O
ashkenazim O
. O

we O
have O
studied O
a O
set O
of O
164 O
patients O
with O
multiple O
colorectal B-Disease
adenomas I-Disease
and I-Disease
/ I-Disease
or I-Disease
carcinoma I-Disease
and O
analyzed O
codons O
1263 O
- O
1377 O
( O
exon O
15g O
) O
of O
the O
apc B-Disease
gene O
for O
germ O
- O
line O
variants O
. O

three O
patients O
with O
the O
i1307k O
allele O
were O
detected O
, O
each O
of O
ashkenazi O
descent O
. O

four O
patients O
had O
a O
germ O
- O
line O
e1317q O
missense O
variant O
of O
apc O
that O
was O
not O
present O
in O
controls O
; O
one O
of O
these O
individuals O
had O
an O
unusually O
large O
number O
of O
metaplastic B-Disease
polyps I-Disease
of I-Disease
the I-Disease
colorectum I-Disease
. O

there O
is O
increasing O
evidence O
that O
there O
exist O
germ O
- O
line O
variants O
of O
the O
apc B-Disease
gene O
that O
predispose O
to O
the O
development O
of O
multiple O
colorectal B-Disease
adenomas I-Disease
and I-Disease
carcinoma I-Disease
, O
but O
without O
the O
florid O
phenotype O
of O
classical O
fap B-Disease
, O
and O
possibly O
with O
importance O
for O
colorectal B-Disease
cancer I-Disease
risk O
in O
the O
general O
population O
. O
. O

genomic O
structure O
of O
the O
human O
congenital B-Disease
chloride I-Disease
diarrhea I-Disease
( O
cld B-Disease
) O
gene O
. O

congenital B-Disease
chloride I-Disease
diarrhea I-Disease
( O
cld B-Disease
) O
is O
caused O
by O
mutations O
in O
a O
gene O
which O
encodes O
an O
intestinal O
anion O
transporter O
. O

we O
report O
here O
the O
complete O
genomic O
organization O
of O
the O
human O
cld B-Disease
gene O
which O
spans O
approximately O
39kb O
, O
and O
comprises O
21 O
exons O
. O

all O
exon O
/ O
intron O
boundaries O
conform O
to O
the O
gt O
/ O
ag O
rule O
. O

an O
analysis O
of O
the O
putative O
promoter O
region O
sequence O
shows O
a O
putative O
tata O
box O
and O
predicts O
multiple O
transcription O
factor O
binding O
sites O
. O

the O
genomic O
structure O
was O
determined O
using O
dna O
from O
several O
sources O
including O
multiple O
large O
- O
insert O
libaries O
and O
genomic O
dna O
from O
finnish O
cld B-Disease
patients O
and O
controls O
. O

exon O
- O
specific O
primers O
developed O
in O
this O
study O
will O
facilitate O
mutation O
screening O
studies O
of O
patients O
with O
the O
disease O
. O

genomic O
sequencing O
of O
a O
bac O
clone O
h O
_ O
rg364p16 O
revealed O
the O
presence O
of O
another O
, O
highly O
homologous O
gene O
3 O
of O
the O
cld B-Disease
gene O
, O
with O
a O
similar O
genomic O
structure O
, O
recently O
identified O
as O
the O
pendred B-Disease
syndrome I-Disease
gene O
( O
pds B-Disease
) O
. O
. O

the O
apci1307k O
allele O
and O
cancer B-Disease
risk O
in O
a O
community O
- O
based O
study O
of O
ashkenazi O
jews O
. O

mutations O
in O
apc O
are O
classically O
associated O
with O
familial B-Disease
adenomatous I-Disease
polyposis I-Disease
( O
fap B-Disease
) O
, O
a O
highly O
penetrant O
autosomal B-Disease
dominant I-Disease
disorder I-Disease
characterized O
by O
multiple O
intestinal O
polyps B-Disease
and O
, O
without O
surgical O
intervention O
, O
the O
development O
of O
colorectal B-Disease
cancer I-Disease
( O
crc B-Disease
) O
. O

apc B-Disease
is O
a O
tumour O
- O
suppressor O
gene O
, O
and O
somatic O
loss O
occurs O
in O
tumours B-Disease
. O

the O
germline O
t O
- O
to O
- O
a O
transversion O
responsible O
for O
the O
apc O
i1307k O
allele O
converts O
the O
wild O
- O
type O
sequence O
to O
a O
homopolymer O
tract O
( O
a8 O
) O
that O
is O
genetically O
unstable O
and O
prone O
to O
somatic O
mutation O
. O

the O
i1307k O
allele O
was O
found O
in O
6 O
. O

1 O
% O
of O
unselected O
ashkenazi O
jews O
and O
higher O
proportions O
of O
ashkenazim O
with O
family O
or O
personal O
histories O
of O
crc B-Disease
( O
ref O
. O
2 O
) O
. O

to O
evaluate O
the O
role O
of O
i1307k O
in O
cancer B-Disease
, O
we O
genotyped O
5 O
, O
081 O
ashkenazi O
volunteers O
in O
a O
community O
survey O
. O

risk O
of O
developing O
colorectal B-Disease
, I-Disease
breast I-Disease
and I-Disease
other I-Disease
cancers I-Disease
were O
compared O
between O
genotyped O
i1307k O
carriers O
and O
non O
- O
carriers O
and O
their O
first O
- O
degree O
relatives O
. O

sperm O
dna O
analysis O
in O
a O
friedreich B-Disease
ataxia I-Disease
premutation O
carrier O
suggests O
both O
meiotic O
and O
mitotic O
expansion O
in O
the O
frda B-Disease
gene O
. O

friedreich B-Disease
ataxia I-Disease
is O
usually O
caused O
by O
an O
expansion O
of O
a O
gaa O
trinucleotide O
repeat O
in O
intron O
1 O
of O
the O
frda B-Disease
gene O
. O

occasionally O
, O
a O
fully O
expanded O
allele O
has O
been O
found O
to O
arise O
from O
a O
premutation O
of O
100 O
or O
less O
triplet O
repeats O
. O

we O
have O
examined O
the O
sperm O
dna O
of O
a O
premutation O
carrier O
. O

this O
mans O
leucocyte O
dna O
showed O
one O
normal O
allele O
and O
one O
allele O
of O
approximately O
100 O
repeats O
. O

his O
sperm O
showed O
an O
expanded O
allele O
in O
a O
tight O
range O
centering O
on O
a O
size O
of O
approximately O
320 O
trinucleotide O
repeats O
. O

his O
affected O
son O
has O
repeat O
sizes O
of O
1040 O
and O
540 O
. O

these O
data O
suggest O
that O
expansion O
occurs O
in O
two O
stages O
, O
the O
first O
during O
meiosis O
followed O
by O
a O
second O
mitotic O
expansion O
. O

we O
also O
show O
that O
in O
all O
informative O
carrier O
father O
to O
affected O
child O
transmissions O
, O
with O
the O
notable O
exception O
of O
the O
premutation O
carrier O
, O
the O
expansion O
size O
decreases O
. O
. O

the O
r496h O
mutation O
of O
arylsulfatase O
a O
does O
not O
cause O
metachromatic B-Disease
leukodystrophy I-Disease
. O

deficiency B-Disease
of I-Disease
arylsulfatase I-Disease
a I-Disease
( O
arsa O
) O
enzyme O
activity O
causes O
metachromatic B-Disease
leukodystrophy I-Disease
( O
mld B-Disease
) O
. O

a O
number O
of O
arsa O
gene O
mutations O
responsible O
for O
mld B-Disease
have O
been O
identified O
. O

recently O
, O
the O
r496h O
mutation O
of O
arsa O
was O
proposed O
to O
be O
a O
cause O
of O
mld B-Disease
( O
draghia O
et O
al O
. O
, O
1997 O
) O
. O

we O
have O
investigated O
the O
r496h O
mutation O
and O
found O
this O
mutation O
at O
a O
relatively O
high O
frequency O
in O
an O
african O
american O
population O
( O
f O
= O
0 O
. O
09 O
, O
n O
= O
61 O
subjects O
) O
. O

the O
arsa O
enzyme O
activity O
in O
subjects O
with O
and O
without O
the O
r496h O
mutation O
was O
determined O
and O
found O
to O
be O
normal O
. O

it O
is O
therefore O
concluded O
that O
the O
r496h O
mutation O
of O
arsa O
does O
not O
negatively O
influence O
the O
activity O
of O
arsa O
and O
is O
not O
a O
cause O
of O
mld B-Disease

down O
- O
regulation O
of O
transmembrane O
carbonic O
anhydrases O
in O
renal B-Disease
cell I-Disease
carcinoma I-Disease
cell O
lines O
by O
wild O
- O
type O
von B-Disease
hippel I-Disease
- I-Disease
lindau I-Disease
transgenes O
. O

to O
discover O
genes O
involved O
in O
von B-Disease
hippel I-Disease
- I-Disease
lindau I-Disease
( O
vhl B-Disease
) O
- O
mediated O
carcinogenesis O
, O
we O
used O
renal B-Disease
cell I-Disease
carcinoma I-Disease
cell O
lines O
stably O
transfected O
with O
wild O
- O
type O
vhl O
- O
expressing O
transgenes O
. O

large O
- O
scale O
rna O
differential O
display O
technology O
applied O
to O
these O
cell O
lines O
identified O
several O
differentially O
expressed O
genes O
, O
including O
an O
alpha O
carbonic O
anhydrase O
gene O
, O
termed O
ca12 O
. O

the O
deduced O
protein O
sequence O
was O
classified O
as O
a O
one O
- O
pass O
transmembrane O
ca O
possessing O
an O
apparently O
intact O
catalytic O
domain O
in O
the O
extracellular O
ca O
module O
. O

reintroduced O
wild O
- O
type O
vhl B-Disease
strongly O
inhibited O
the O
overexpression O
of O
the O
ca12 O
gene O
in O
the O
parental O
renal B-Disease
cell I-Disease
carcinoma I-Disease
cell O
lines O
. O

similar O
results O
were O
obtained O
with O
ca9 O
, O
encoding O
another O
transmembrane O
ca O
with O
an O
intact O
catalytic O
domain O
. O

although O
both O
domains O
of O
the O
vhl B-Disease
protein O
contribute O
to O
regulation O
of O
ca12 O
expression O
, O
the O
elongin O
binding O
domain O
alone O
could O
effectively O
regulate O
ca9 O
expression O
. O

we O
mapped O
ca12 O
and O
ca9 O
loci O
to O
chromosome O
bands O
15q22 O
and O
17q21 O
. O

2 O
respectively O
, O
regions O
prone O
to O
amplification O
in O
some O
human O
cancers B-Disease
. O

additional O
experiments O
are O
needed O
to O
define O
the O
role O
of O
ca O
ix O
and O
ca O
xii O
enzymes O
in O
the O
regulation O
of O
ph O
in O
the O
extracellular O
microenvironment O
and O
its O
potential O
impact O
on O
cancer B-Disease
cell O
growth O
. O

a O
gene O
encoding O
a O
transmembrane O
protein O
is O
mutated O
in O
patients O
with O
diabetes B-Disease
mellitus I-Disease
and O
optic B-Disease
atrophy I-Disease
( O
wolfram B-Disease
syndrome I-Disease
) O
. O

wolfram B-Disease
syndrome I-Disease
( O
wfs B-Disease
; O
omim O
222300 O
) O
is O
an O
autosomal B-Disease
recessive I-Disease
neurodegenerative I-Disease
disorder I-Disease
defined O
by O
young O
- O
onset O
non O
- O
immune O
insulin B-Disease
- I-Disease
dependent I-Disease
diabetes I-Disease
mellitus I-Disease
and O
progressive O
optic B-Disease
atrophy I-Disease
. O

linkage O
to O
markers O
on O
chromosome O
4p O
was O
confirmed O
in O
five O
families O
. O

on O
the O
basis O
of O
meiotic O
recombinants O
and O
disease O
- O
associated O
haplotypes O
, O
the O
wfs B-Disease
gene O
was O
localized O
to O
a O
bac O
/ O
p1 O
contig O
of O
less O
than O
250 O
kb O
. O

mutations O
in O
a O
novel O
gene O
( O
wfs1 O
) O
encoding O
a O
putative O
transmembrane O
protein O
were O
found O
in O
all O
affected O
individuals O
in O
six O
wfs B-Disease
families O
, O
and O
these O
mutations O
were O
associated O
with O
the O
disease O
phenotype O
. O

wfs1 O
appears O
to O
function O
in O
survival O
of O
islet O
beta O
- O
cells O
and O
neurons O
. O
. O

stable O
interaction O
between O
the O
products O
of O
the O
brca1 O
and O
brca2 O
tumor B-Disease
suppressor O
genes O
in O
mitotic O
and O
meiotic O
cells O
. O

brca1 O
and O
brca2 O
account O
for O
most O
cases O
of O
familial O
, O
early O
onset O
breast B-Disease
and I-Disease
/ I-Disease
or I-Disease
ovarian I-Disease
cancer I-Disease
and O
encode O
products O
that O
each O
interact O
with O
hrad51 O
. O

results O
presented O
here O
show O
that O
brca1 O
and O
brca2 O
coexist O
in O
a O
biochemical O
complex O
and O
colocalize O
in O
subnuclear O
foci O
in O
somatic O
cells O
and O
on O
the O
axial O
elements O
of O
developing O
synaptonemal O
complexes O
. O

like O
brca1 O
and O
rad51 O
, O
brca2 O
relocates O
to O
pcna O
+ O
replication O
sites O
following O
exposure O
of O
s O
phase O
cells O
to O
hydroxyurea O
or O
uv O
irradiation O
. O

thus O
, O
brca1 O
and O
brca2 O
participate O
, O
together O
, O
in O
a O
pathway O
( O
s O
) O
associated O
with O
the O
activation O
of O
double O
- O
strand O
break O
repair O
and O
/ O
or O
homologous O
recombination O
. O

dysfunction O
of O
this O
pathway O
may O
be O
a O
general O
phenomenon O
in O
the O
majority O
of O
cases O
of O
hereditary B-Disease
breast I-Disease
and I-Disease
/ I-Disease
or I-Disease
ovarian I-Disease
cancer I-Disease
. O
. O

a O
novel O
arg362ser O
mutation O
in O
the O
sterol O
27 O
- O
hydroxylase O
gene O
( O
cyp27 O
) O
: O
its O
effects O
on O
pre O
- O
mrna O
splicing O
and O
enzyme O
activity O
. O

a O
novel O
c O
to O
a O
mutation O
in O
the O
sterol O
27 O
- O
hydroxylase O
gene O
( O
cyp27 O
) O
was O
identified O
by O
sequencing O
amplified O
cyp27 O
gene O
products O
from O
a O
patient O
with O
cerebrotendinous B-Disease
xanthomatosis I-Disease
( O
ctx B-Disease
) O
. O

the O
mutation O
changed O
the O
adrenodoxin O
cofactor O
binding O
residue O
362arg O
to O
362ser O
( O
cgt O
362arg O
to O
agt O
362ser O
) O
, O
and O
was O
responsible O
for O
deficiency O
in O
the O
sterol O
27 O
- O
hydroxylase O
activity O
, O
as O
confirmed O
by O
expression O
of O
mutant O
cdna O
into O
cos O
- O
1 O
cells O
. O

quantitative O
analysis O
showed O
that O
the O
expression O
of O
cyp27 O
gene O
mrna O
in O
the O
patient O
represented O
52 O
. O

5 O
% O
of O
the O
normal O
level O
. O

as O
the O
mutation O
occurred O
at O
the O
penultimate O
nucleotide O
of O
exon O
6 O
( O
- O
2 O
position O
of O
exon O
6 O
- O
intron O
6 O
splice O
site O
) O
of O
the O
gene O
, O
we O
hypothesized O
that O
the O
mutation O
may O
partially O
affect O
the O
normal O
splicing O
efficiency O
in O
exon O
6 O
and O
cause O
alternative O
splicing O
elsewhere O
, O
which O
resulted O
in O
decreased O
transcript O
in O
the O
patient O
. O

transfection O
of O
constructed O
minigenes O
, O
with O
or O
without O
the O
mutation O
, O
into O
cos O
- O
1 O
cells O
confirmed O
that O
the O
mutant O
minigene O
was O
responsible O
for O
a O
mrna O
species O
alternatively O
spliced O
at O
an O
activated O
cryptic O
5 O
splice O
site O
88 O
bp O
upstream O
from O
the O
3 O
end O
of O
exon O
6 O
. O

our O
data O
suggest O
that O
the O
c O
to O
a O
mutation O
at O
the O
penultimate O
nucleotide O
of O
exon O
6 O
of O
the O
cyp27 O
gene O
not O
only O
causes O
the O
deficiency B-Disease
in I-Disease
the I-Disease
sterol I-Disease
27 I-Disease
- I-Disease
hydroxylase I-Disease
activity I-Disease
, O
but O
also O
partially O
leads O
to O
alternative O
pre O
- O
mrna O
splicing O
of O
the O
gene O
. O

to O
our O
knowledge O
, O
this O
is O
the O
first O
report O
regarding O
effects O
on O
pre O
- O
mrna O
splicing O
of O
a O
mutation O
at O
the O
- O
2 O
position O
of O
a O
5 O
splice O
site O
. O

atm O
germline O
mutations O
in O
classical O
ataxia B-Disease
- I-Disease
telangiectasia I-Disease
patients O
in O
the O
dutch O
population O
. O

germline O
mutations O
in O
the O
atm O
gene O
are O
responsible O
for O
the O
autosomal B-Disease
recessive I-Disease
disorder I-Disease
ataxia B-Disease
- I-Disease
telangiectasia I-Disease
( O
a B-Disease
- I-Disease
t I-Disease
) O
. O

in O
our O
study O
, O
we O
have O
determined O
the O
atm O
mutation O
spectrum O
in O
19 O
classical O
a B-Disease
- I-Disease
t I-Disease
patients O
, O
including O
some O
immigrant O
populations O
, O
as O
well O
as O
12 O
of O
dutch O
ethnic O
origin O
. O

both O
the O
protein O
truncation O
test O
( O
ptt O
) O
and O
the O
restriction O
endonuclease O
fingerprinting O
( O
ref O
) O
method O
were O
used O
and O
compared O
for O
their O
detection O
efficiency O
, O
identifying O
76 O
% O
and O
60 O
% O
of O
the O
mutations O
, O
respectively O
. O

most O
patients O
were O
found O
to O
be O
compound O
heterozygote O
. O

seventeen O
mutations O
were O
distinct O
, O
of O
which O
10 O
were O
not O
reported O
previously O
. O

mutations O
are O
small O
deletions O
or O
point O
mutations O
frequently O
affecting O
splice O
sites O
. O

moreover O
, O
a O
16 O
. O

7 O
- O
kb O
genomic O
deletion O
of O
the O
3 O
end O
of O
the O
gene O
, O
most O
likely O
a O
result O
of O
recombination O
between O
two O
line O
elements O
, O
was O
identified O
. O

the O
most O
frequently O
found O
mutation O
, O
identified O
in O
three O
unrelated O
turkish O
a B-Disease
- I-Disease
t I-Disease
individuals O
, O
was O
previously O
described O
to O
be O
a O
turkish O
a B-Disease
- I-Disease
t I-Disease
founder O
mutation O
. O

the O
presence O
of O
a O
founder O
mutation O
among O
relatively O
small O
ethnic O
population O
groups O
in O
western O
europe O
could O
indicate O
a O
high O
carrier O
frequency O
in O
such O
communities O
. O

in O
patients O
of O
dutch O
ethnic O
origin O
, O
however O
, O
no O
significant O
founder O
effect O
could O
be O
identified O
. O

the O
observed O
genetic O
heterogeneity O
including O
the O
relative O
high O
percentage O
of O
splice O
- O
site O
mutations O
had O
no O
reflection O
on O
the O
phenotype O
. O

all O
patients O
manifested O
classical O
a B-Disease
- I-Disease
t I-Disease
and O
increased O
cellular O
radioresistant O
dna O
synthesis O
. O

determination O
of O
the O
genomic O
structure O
of O
the O
col4a4 O
gene O
and O
of O
novel O
mutations O
causing O
autosomal B-Disease
recessive I-Disease
alport I-Disease
syndrome I-Disease
. O

autosomal B-Disease
recessive I-Disease
alport I-Disease
syndrome I-Disease
is O
a O
progressive O
hematuric B-Disease
glomerulonephritis I-Disease
characterized O
by O
glomerular B-Disease
basement I-Disease
membrane I-Disease
abnormalities I-Disease
and O
associated O
with O
mutations O
in O
either O
the O
col4a3 O
or O
the O
col4a4 O
gene O
, O
which O
encode O
the O
alpha3 O
and O
alpha4 O
type O
iv O
collagen O
chains O
, O
respectively O
. O

to O
date O
, O
mutation O
screening O
in O
the O
two O
genes O
has O
been O
hampered O
by O
the O
lack O
of O
genomic O
structure O
information O
. O

we O
report O
here O
the O
complete O
characterization O
of O
the O
48 O
exons O
of O
the O
col4a4 O
gene O
, O
a O
comprehensive O
gene O
screen O
, O
and O
the O
subsequent O
detection O
of O
10 O
novel O
mutations O
in O
eight O
patients O
diagnosed O
with O
autosomal B-Disease
recessive I-Disease
alport I-Disease
syndrome I-Disease
. O

furthermore O
, O
we O
identified O
a O
glycine O
to O
alanine O
substitution O
in O
the O
collagenous O
domain O
that O
is O
apparently O
silent O
in O
the O
heterozygous O
carriers O
, O
in O
11 O
. O

5 O
% O
of O
all O
control O
individuals O
, O
and O
in O
one O
control O
individual O
homozygous O
for O
this O
glycine O
substitution O
. O

there O
has O
been O
no O
previous O
finding O
of O
a O
glycine O
substitution O
that O
is O
not O
associated O
with O
any O
obvious O
phenotype O
in O
homozygous O
individuals O
. O

founder O
brca1 O
and O
brca2 O
mutations O
in O
french O
canadian O
breast B-Disease
and I-Disease
ovarian I-Disease
cancer I-Disease
families O
. O

we O
have O
identified O
four O
mutations O
in O
each O
of O
the O
breast B-Disease
cancer I-Disease
- O
susceptibility O
genes O
, O
brca1 O
and O
brca2 O
, O
in O
french O
canadian O
breast B-Disease
cancer I-Disease
and O
breast B-Disease
/ I-Disease
ovarian I-Disease
cancer I-Disease
families O
from O
quebec O
. O

to O
identify O
founder O
effects O
, O
we O
examined O
independently O
ascertained O
french O
canadian O
cancer B-Disease
families O
for O
the O
distribution O
of O
these O
eight O
mutations O
. O

mutations O
were O
found O
in O
41 O
of O
97 O
families O
. O

six O
of O
eight O
mutations O
were O
observed O
at O
least O
twice O
. O

the O
brca1 O
c4446t O
mutation O
was O
the O
most O
common O
mutation O
found O
, O
followed O
by O
the O
brca2 O
8765delag O
mutation O
. O

together O
, O
these O
mutations O
were O
found O
in O
28 O
of O
41 O
families O
identified O
to O
have O
a O
mutation O
. O

the O
odds O
of O
detection O
of O
any O
of O
the O
four O
brca1 O
mutations O
was O
18 O
. O

7x O
greater O
if O
one O
or O
more O
cases O
of O
ovarian B-Disease
cancer I-Disease
were O
also O
present O
in O
the O
family O
. O

the O
odds O
of O
detection O
of O
any O
of O
the O
four O
brca2 O
mutations O
was O
5 O
. O

3x O
greater O
if O
there O
were O
at O
least O
five O
cases O
of O
breast B-Disease
cancer I-Disease
in O
the O
family O
. O

interestingly O
, O
the O
presence O
of O
a O
breast B-Disease
cancer I-Disease
case O
< O
36 O
years O
of O
age O
was O
strongly O
predictive O
of O
the O
presence O
of O
any O
of O
the O
eight O
mutations O
screened O
. O

carriers O
of O
the O
same O
mutation O
, O
from O
different O
families O
, O
shared O
similar O
haplotypes O
, O
indicating O
that O
the O
mutant O
alleles O
were O
likely O
to O
be O
identical O
by O
descent O
for O
a O
mutation O
in O
the O
founder O
population O
. O

the O
identification O
of O
common O
brca1 O
and O
brca2 O
mutations O
will O
facilitate O
carrier O
detection O
in O
french O
canadian O
breast B-Disease
cancer I-Disease
and O
breast B-Disease
/ I-Disease
ovarian I-Disease
cancer I-Disease
families O
. O

are O
dp71 O
and O
dp140 O
brain O
dystrophin O
isoforms O
related O
to O
cognitive B-Disease
impairment I-Disease
in O
duchenne B-Disease
muscular I-Disease
dystrophy I-Disease
? O

molecular O
study O
and O
neuropsychological O
analysis O
were O
performed O
concurrently O
on O
49 O
patients O
with O
duchenne B-Disease
muscular I-Disease
dystrophy I-Disease
( O
dmd B-Disease
) O
in O
order O
to O
find O
a O
molecular O
explanation O
for O
the O
cognitive B-Disease
impairment I-Disease
observed O
in O
most O
dmd B-Disease
patients O
. O

complete O
analysis O
of O
the O
dystrophin O
gene O
was O
performed O
to O
define O
the O
localization O
of O
deletions O
and O
duplications O
in O
relation O
to O
the O
different O
dmd B-Disease
promoters O
. O

qualitative O
analysis O
of O
the O
dp71 O
transcript O
and O
testing O
for O
the O
specific O
first O
exon O
of O
dp140 O
were O
also O
carried O
out O
. O

neuropsychological O
analysis O
assessed O
verbal O
and O
visuospatial O
intelligence O
, O
verbal O
memory O
, O
and O
reading O
skills O
. O

comparison O
of O
molecular O
and O
psychometric O
findings O
demonstrated O
that O
deletions O
and O
duplications O
that O
were O
localized O
in O
the O
distal O
part O
of O
the O
gene O
seemed O
to O
be O
preferentially O
associated O
with O
cognitive B-Disease
impairment I-Disease
. O

two O
altered O
dp71 O
transcripts O
and O
two O
deleted O
dp140 O
dna O
sequences O
were O
found O
in O
four O
patients O
with O
severe O
cerebral B-Disease
dysfunction I-Disease
. O

these O
findings O
suggest O
that O
some O
sequences O
located O
in O
the O
distal O
part O
of O
the O
gene O
and O
, O
in O
particular O
, O
some O
dmd B-Disease
isoforms O
expressed O
in O
the O
brain O
may O
be O
related O
to O
the O
cognitive B-Disease
impairment I-Disease
associated O
with O
dmd B-Disease
. O
. O

i1307k O
apc O
and O
hmlh1 O
mutations O
in O
a O
non O
- O
jewish O
family O
with O
hereditary B-Disease
non I-Disease
- I-Disease
polyposis I-Disease
colorectal I-Disease
cancer I-Disease
. O

we O
describe O
a O
french O
canadian O
hereditary B-Disease
non I-Disease
- I-Disease
polyposis I-Disease
colorectal I-Disease
cancer I-Disease
( O
hnpcc B-Disease
) O
kindred O
which O
carries O
a O
novel O
truncating O
mutation O
in O
hmlh1 O
. O

interestingly O
, O
the O
i1307k O
apc O
polymorphism O
, O
associated O
with O
an O
increased O
risk O
of O
colorectal B-Disease
cancer I-Disease
, O
is O
also O
present O
in O
this O
family O
. O

the O
i1307k O
polymorphism O
has O
previously O
only O
been O
identified O
in O
individuals O
of O
self O
- O
reported O
ashkenazi O
jewish O
origins O
. O

in O
addition O
, O
in O
this O
family O
, O
there O
appears O
to O
be O
no O
relationship O
between O
the O
i1307k O
polymorphism O
and O
the O
presence O
or O
absence O
of O
cancer B-Disease
. O
. O

identification O
of O
a O
novel O
mutation O
of O
the O
cpo O
gene O
in O
a O
japanese O
hereditary B-Disease
coproporphyria I-Disease
family O
. O

hereditary B-Disease
coproporphyria I-Disease
( O
hcp B-Disease
) O
is O
an O
autosomal B-Disease
dominant I-Disease
disease I-Disease
characterized O
by O
a O
deficiency B-Disease
of I-Disease
coproporphyrinogen I-Disease
oxidase I-Disease
( O
cpo O
) O
caused O
by O
a O
mutation O
in O
the O
cpo O
gene O
. O

only O
11 O
mutations O
of O
the O
gene O
have O
been O
reported O
in O
hcp B-Disease
patients O
. O

we O
report O
another O
mutation O
in O
a O
japanese O
family O
. O

polymerase O
chain O
reaction O
- O
single O
strand O
conformational O
polymorphism O
and O
direct O
sequence O
analyses O
demonstrated O
a O
c O
to O
t O
substitution O
in O
exon O
1 O
of O
the O
cpo O
gene O
at O
nucleotide O
position O
85 O
, O
which O
lies O
in O
the O
putative O
presequence O
for O
targeting O
to O
mitochondria O
. O

this O
mutation O
changes O
the O
codon O
for O
glutamine O
to O
a O
termination O
codon O
at O
amino O
acid O
position O
29 O
. O

maei O
restriction O
analysis O
showed O
two O
other O
carriers O
in O
the O
family O
. O

the O
c O
- O
t O
mutation O
is O
located O
within O
a O
recently O
proposed O
putative O
alternative O
translation O
initiation O
codon O
( O
tic O
- O
1 O
) O
, O
supporting O
that O
tic O
- O
1 O
is O
the O
real O
tic O
rather O
than O
tic O
- O
2 O
. O
. O

human B-Disease
complement I-Disease
factor I-Disease
h I-Disease
deficiency I-Disease
associated O
with O
hemolytic B-Disease
uremic I-Disease
syndrome I-Disease
. O

this O
study O
reports O
on O
six O
cases O
of O
deficiency B-Disease
in I-Disease
the I-Disease
human I-Disease
complement I-Disease
regulatory I-Disease
protein I-Disease
factor I-Disease
h I-Disease
( O
fh O
) O
in O
the O
context O
of O
an O
acute B-Disease
renal I-Disease
disease I-Disease
. O

five O
of O
the O
cases O
were O
observed O
in O
children O
presenting O
with O
idiopathic O
hemolytic B-Disease
uremic I-Disease
syndrome I-Disease
( O
hus B-Disease
) O
. O

two O
of O
the O
children O
exhibited O
a O
homozygous O
deficiency O
characterized O
by O
the O
absence O
of O
the O
150 O
- O
kd O
form O
of O
factor O
h O
and O
the O
presence O
, O
upon O
immunoblotting O
, O
of O
the O
42 O
- O
kd O
factor O
h O
- O
like O
protein O
1 O
( O
fhl O
- O
1 O
) O
and O
other O
fh O
- O
related O
protein O
( O
fhr O
) O
bands O
. O

southern O
blot O
and O
pcr O
analysis O
of O
dna O
of O
one O
patient O
with O
homozygous O
deficiency O
ruled O
out O
the O
presence O
of O
a O
large O
deletion O
of O
the O
fh O
gene O
as O
the O
underlying O
defect O
for O
the O
deficiency O
. O

the O
other O
four O
children O
presented O
with O
heterozygous O
deficiency O
and O
exhibited O
a O
normal O
immunoblotting O
pattern O
of O
proteins O
of O
the O
fh O
family O
. O

factor B-Disease
h I-Disease
deficiency I-Disease
is O
the O
only O
complement B-Disease
deficiency I-Disease
associated O
with O
hus B-Disease
. O

these O
observations O
suggest O
a O
role O
for O
fh O
and O
/ O
or O
fh O
receptors O
in O
the O
pathogenesis O
of O
idiopathic O
hus B-Disease
. O
. O

further O
evidence O
for O
a O
major O
ancient O
mutation O
underlying O
myotonic B-Disease
dystrophy I-Disease
from O
linkage O
disequilibrium O
studies O
in O
the O
japanese O
population O
. O

the O
myotonic B-Disease
dystrophy I-Disease
( O
dm B-Disease
) O
mutation O
is O
an O
unstable O
( O
ctg O
) O
n O
repeat O
, O
present O
at O
a O
copy O
number O
of O
5 O
- O
37 O
repeats O
on O
normal O
chromosomes O
but O
amplified O
to O
50 O
- O
3000 O
copies O
on O
dm B-Disease
chromosomes O
. O

previous O
findings O
in O
caucasian O
populations O
of O
a O
dm B-Disease
founder O
chromosome O
raise O
a O
question O
about O
the O
molecular O
events O
involved O
in O
the O
expansion O
mutation O
. O

to O
investigate O
whether O
a O
founder O
chromosome O
for O
the O
dm B-Disease
mutation O
exists O
in O
the O
japanese O
population O
, O
we O
genotyped O
families O
using O
polymorphic O
markers O
near O
the O
( O
ctg O
) O
n O
repeat O
region O
and O
constructed O
haplotypes O
. O

six O
different O
haplotypes O
were O
found O
and O
dm B-Disease
alleles O
were O
always O
haplotype O
a O
. O

to O
find O
an O
origin O
of O
the O
( O
ctg O
) O
n O
repeat O
mutation O
and O
to O
investigate O
the O
mechanism O
of O
the O
expansion O
mutation O
in O
the O
japanese O
population O
we O
have O
studied O
90 O
japanese O
dm B-Disease
families O
comprising O
190 O
affected O
and O
130 O
unaffected O
members O
. O

the O
results O
suggest O
that O
a O
few O
common O
ancestral O
mutations O
in O
both O
caucasian O
and O
japanese O
populations O
have O
originated O
by O
expansion O
of O
an O
ancestral O
n O
= O
5 O
repeat O
to O
n O
= O
19 O
- O
37 O
copies O
. O

these O
data O
support O
multistep O
models O
of O
triplet O
repeat O
expansion O
that O
have O
been O
proposed O
for O
both O
dm B-Disease
and O
friedreichs B-Disease
ataxia I-Disease
. O
. O

the O
molecular O
basis O
of O
c6 B-Disease
deficiency I-Disease
in O
the O
western O
cape O
, O
south O
africa O
. O

deficiency B-Disease
of I-Disease
the I-Disease
sixth I-Disease
component I-Disease
of I-Disease
human I-Disease
complement I-Disease
( O
c6 O
) O
has O
been O
reported O
in O
a O
number O
of O
families O
from O
the O
western O
cape O
, O
south O
africa O
. O

meningococcal B-Disease
disease I-Disease
is O
endemic O
in O
the O
cape O
and O
almost O
all O
pedigrees O
of O
total O
c6 B-Disease
deficiency I-Disease
( O
c6q0 O
) O
have O
been O
ascertained O
because O
of O
recurrent O
disease O
. O

we O
have O
sequenced O
the O
expressed O
exons O
of O
the O
c6 O
gene O
from O
selected O
cases O
and O
have O
found O
three O
molecular O
defects O
leading O
to O
total O
deficiency O
879delg O
, O
which O
is O
the O
common O
defect O
in O
the O
cape O
and O
hitherto O
unreported O
, O
and O
1195delc O
and O
1936delg O
, O
which O
have O
been O
previously O
reported O
in O
african O
- O
americans O
. O

we O
also O
show O
that O
the O
879delg O
and O
1195delc O
defects O
are O
associated O
with O
characteristic O
c6 O
/ O
c7 O
region O
dna O
marker O
haplotypes O
, O
although O
small O
variations O
were O
observed O
. O

the O
1936delg O
defect O
was O
observed O
only O
once O
in O
the O
cape O
, O
but O
its O
associated O
haplotype O
could O
be O
deduced O
. O

the O
data O
from O
the O
haplotypes O
indicate O
that O
these O
three O
molecular O
defects O
account O
for O
the O
defects O
in O
all O
the O
38 O
unrelated O
c6q0 O
individuals O
we O
have O
studied O
from O
the O
cape O
. O

we O
have O
also O
observed O
the O
879delg O
defect O
in O
two O
dutch O
c6 B-Disease
- I-Disease
deficient I-Disease
kindreds O
, O
but O
the O
879delg O
defect O
in O
the O
cape O
probably O
did O
not O
come O
from O
the O
netherlands O
. O
. O

complement B-Disease
c7 I-Disease
deficiency I-Disease
: O
seven O
further O
molecular O
defects O
and O
their O
associated O
marker O
haplotypes O
. O

seven O
further O
molecular O
bases O
of O
c7 B-Disease
deficiency I-Disease
are O
described O
. O

all O
these O
new O
molecular O
defects O
involve O
single O
- O
nucleotide O
events O
, O
deletions O
and O
substitutions O
, O
some O
of O
which O
alter O
splice O
sites O
, O
and O
others O
codons O
. O

they O
are O
distributed O
along O
the O
c7 O
gene O
, O
but O
predominantly O
towards O
the O
3 O
end O
. O

all O
were O
found O
in O
compound O
heterozygous O
individuals O
. O

the O
c6 O
/ O
c7 O
marker O
haplotypes O
associated O
with O
most O
c7 B-Disease
defects I-Disease
are O
tabulated O
. O
. O

a O
genome O
- O
wide O
search O
for O
chromosomal O
loci O
linked O
to O
mental O
health O
wellness O
in O
relatives O
at O
high O
risk O
for O
bipolar B-Disease
affective I-Disease
disorder I-Disease
among O
the O
old O
order O
amish O
. O

bipolar B-Disease
affective I-Disease
disorder I-Disease
( O
bpad B-Disease
; O
manic B-Disease
- I-Disease
depressive I-Disease
illness I-Disease
) O
is O
characterized O
by O
episodes O
of O
mania B-Disease
and O
/ O
or O
hypomania B-Disease
interspersed O
with O
periods O
of O
depression B-Disease
. O

compelling O
evidence O
supports O
a O
significant O
genetic O
component O
in O
the O
susceptibility O
to O
develop O
bpad B-Disease
. O

to O
date O
, O
however O
, O
linkage O
studies O
have O
attempted O
only O
to O
identify O
chromosomal O
loci O
that O
cause O
or O
increase O
the O
risk O
of O
developing O
bpad B-Disease
. O

to O
determine O
whether O
there O
could O
be O
protective O
alleles O
that O
prevent O
or O
reduce O
the O
risk O
of O
developing O
bpad B-Disease
, O
similar O
to O
what O
is O
observed O
in O
other O
genetic B-Disease
disorders I-Disease
, O
we O
used O
mental O
health O
wellness O
( O
absence O
of O
any O
psychiatric B-Disease
disorder I-Disease
) O
as O
the O
phenotype O
in O
our O
genome O
- O
wide O
linkage O
scan O
of O
several O
large O
multigeneration O
old O
order O
amish O
pedigrees O
exhibiting O
an O
extremely O
high O
incidence O
of O
bpad B-Disease
. O

we O
have O
found O
strong O
evidence O
for O
a O
locus O
on O
chromosome O
4p O
at O
d4s2949 O
( O
maximum O
genehunter O
- O
plus O
nonparametric O
linkage O
score O
= O
4 O
. O
05 O
, O
p O
= O
5 O
. O
22 O
x O
10 O
( O
- O
4 O
) O
; O
sibpal O
pempirical O
value O
< O
3 O
x O
10 O
( O
- O
5 O
) O
) O
and O
suggestive O
evidence O
for O
a O
locus O
on O
chromosome O
4q O
at O
d4s397 O
( O
maximum O
genehunter O
- O
plus O
nonparametric O
linkage O
score O
= O
3 O
. O
29 O
, O
p O
= O
2 O
. O
57 O
x O
10 O
( O
- O
3 O
) O
; O
sibpal O
pempirical O
value O
< O
1 O
x O
10 O
( O
- O
3 O

) O
) O
that O
are O
linked O
to O
mental O
health O
wellness O
. O

these O
findings O
are O
consistent O
with O
the O
hypothesis O
that O
certain O
alleles O
could O
prevent O
or O
modify O
the O
clinical O
manifestations O
of O
bpad B-Disease
and O
perhaps O
other O
related O
affective B-Disease
disorders I-Disease
. O

segregation O
distortion O
in O
myotonic B-Disease
dystrophy I-Disease
. O

myotonic B-Disease
dystrophy I-Disease
( O
dm B-Disease
) O
is O
an O
autosomal B-Disease
dominant I-Disease
disease I-Disease
which O
, O
in O
the O
typical O
pedigree O
, O
shows O
a O
three O
generation O
anticipation O
cascade O
. O

this O
results O
in O
infertility B-Disease
and O
congenital B-Disease
myotonic I-Disease
dystrophy I-Disease
( O
cdm B-Disease
) O
with O
the O
disappearance O
of O
dm B-Disease
in O
that O
pedigree O
. O

the O
concept O
of O
segregation O
distortion O
, O
where O
there O
is O
preferential O
transmission O
of O
the O
larger O
allele O
at O
the O
dm B-Disease
locus O
, O
has O
been O
put O
forward O
to O
explain O
partially O
the O
maintenance O
of O
dm B-Disease
in O
the O
population O
. O

in O
a O
survey O
of O
dm B-Disease
in O
northern O
ireland O
, O
59 O
pedigrees O
were O
ascertained O
. O

sibships O
where O
the O
status O
of O
all O
the O
members O
had O
been O
identified O
were O
examined O
to O
determine O
the O
transmission O
of O
the O
dm B-Disease
expansion O
from O
affected O
parents O
to O
their O
offspring O
. O

where O
the O
transmitting O
parent O
was O
male O
, O
58 O
. O

3 O
% O
of O
the O
offspring O
were O
affected O
, O
and O
in O
the O
case O
of O
a O
female O
transmitting O
parent O
, O
68 O
. O

7 O
% O
were O
affected O
. O

studies O
on O
meiotic O
drive O
in O
dm B-Disease
have O
shown O
increased O
transmission O
of O
the O
larger O
allele O
at O
the O
dm B-Disease
locus O
in O
non O
- O
dm O
heterozygotes O
for O
ctgn O
. O

this O
study O
provides O
further O
evidence O
that O
the O
dm B-Disease
expansion O
tends O
to O
be O
transmitted O
preferentially O
. O

diagnosis O
of O
hemochromatosis B-Disease
. O

if O
untreated O
, O
hemochromatosis B-Disease
can O
cause O
serious O
illness O
and O
early B-Disease
death I-Disease
, O
but O
the O
disease O
is O
still O
substantially O
under O
- O
diagnosed O
. O

the O
cornerstone O
of O
screening O
and O
case O
detection O
is O
the O
measurement O
of O
serum O
transferrin O
saturation O
and O
the O
serum O
ferritin O
level O
. O

once O
the O
diagnosis O
is O
suspected O
, O
physicians O
must O
use O
serum O
ferritin O
levels O
and O
hepatic O
iron O
stores O
on O
liver O
biopsy O
specimens O
to O
assess O
patients O
for O
the O
presence O
of O
iron B-Disease
overload I-Disease
. O

liver O
biopsy O
is O
also O
used O
to O
establish O
the O
presence O
or O
absence O
of O
cirrhosis B-Disease
, O
which O
can O
affect O
prognosis O
and O
management O
. O

a O
dna O
- O
based O
test O
for O
the O
hfe O
gene O
is O
commercially O
available O
, O
but O
its O
place O
in O
the O
diagnosis O
of O
hemochromatosis B-Disease
is O
still O
being O
evaluated O
. O

currently O
, O
the O
most O
useful O
role O
for O
this O
test O
is O
in O
the O
detection O
of O
hemochromatosis B-Disease
in O
the O
family O
members O
of O
patients O
with O
a O
proven O
case O
of O
the O
disease O
. O

it O
is O
crucial O
to O
diagnose O
hemochromatosis B-Disease
before O
hepatic B-Disease
cirrhosis I-Disease
develops O
because O
phlebotomy O
therapy O
can O
avert O
serious O
chronic O
disease O
and O
can O
even O
lead O
to O
normal O
life O
expectancy O
. O
. O

prevalence O
of O
the O
i1307k O
apc B-Disease
gene O
variant O
in O
israeli O
jews O
of O
differing O
ethnic O
origin O
and O
risk O
for O
colorectal B-Disease
cancer I-Disease
. O

background O
& O
aims O
israeli O
jews O
of O
european O
birth O
, O
i O
. O
e O
. O
, O
ashkenazim O
, O
have O
the O
highest O
colorectal B-Disease
cancer I-Disease
incidence O
of O
any O
israeli O
ethnic O
group O
. O

the O
i1307k O
apc B-Disease
gene O
variant O
was O
found O
in O
6 O
. O

1 O
% O
of O
american O
jews O
, O
28 O
% O
of O
their O
familial O
colorectal B-Disease
cancer I-Disease
cases O
, O
but O
not O
in O
non O
- O
jews O
. O

we O
assessed O
the O
i1307k O
prevalence O
in O
israeli O
jews O
of O
differing O
ethnic O
origin O
and O
risk O
for O
colorectal B-Disease
cancer I-Disease
. O

methods O
dna O
samples O
from O
500 O
unrelated O
jews O
of O
european O
or O
non O
- O
european O
origin O
, O
with O
or O
without O
a O
personal O
and O
/ O
or O
family O
history O
of O
neoplasia B-Disease
, O
were O
examined O
for O
the O
i1307k O
variant O
by O
the O
allele O
- O
specific O
oligonucleotide O
( O
aso O
) O
method O
. O

results O
in O
persons O
at O
average O
risk O
for O
colorectal B-Disease
cancer I-Disease
, O
i1307k O
was O
found O
in O
5 O
. O

0 O
% O
of O
120 O
european O
and O
1 O
. O

6 O
% O
of O
188 O
non O
- O
european O
jews O
( O
p O
= O
0 O
. O
08 O
) O
. O

it O
occurred O
in O
15 O
. O

4 O
% O
of O
52 O
ashkenazi O
israelis O
with O
familial O
cancer B-Disease
( O
p O
= O
0 O
. O
02 O
) O
and O
was O
not O
detected O
in O
51 O
non O
- O
european O
jews O
at O
increased O
cancer B-Disease
risk O
. O

colorectal B-Disease
neoplasia I-Disease
occurred O
personally O
or O
in O
the O
families O
of O
13 O
of O
20 O
ashkenazi O
i1307k O
carriers O
, O
8 O
of O
whom O
also O
had O
a O
personal O
or O
family O
history O
of O
noncolonic O
neoplasia B-Disease
. O

conclusions O
the O
i1307k O
apc O
variant O
may O
represent O
a O
susceptibility O
gene O
for O
colorectal B-Disease
, I-Disease
or I-Disease
other I-Disease
, I-Disease
cancers I-Disease
in O
ashkenazi O
jews O
, O
and O
partially O
explains O
the O
higher O
incidence O
of O
colorectal B-Disease
cancer I-Disease
in O
european O
israelis O
. O

systematic O
analysis O
of O
coproporphyrinogen O
oxidase O
gene O
defects O
in O
hereditary B-Disease
coproporphyria I-Disease
and O
mutation O
update O
. O

hereditary B-Disease
coproporphyria I-Disease
( O
hc B-Disease
) O
is O
an O
acute O
hepatic B-Disease
porphyria I-Disease
with O
autosomal O
dominant O
inheritance O
caused O
by O
deficient B-Disease
activity I-Disease
of I-Disease
coproporphyrinogen I-Disease
iii I-Disease
oxidase I-Disease
( O
cpo O
) O
. O

clinical O
manifestations O
of O
the O
disease O
are O
characterized O
by O
acute O
attacks O
of O
neurological B-Disease
dysfunction I-Disease
often O
precipitated O
by O
drugs O
, O
fasting O
, O
cyclical O
hormonal O
changes O
, O
or O
infectious B-Disease
diseases I-Disease
. O

skin O
photosensitivity O
may O
also O
be O
present O
. O

the O
seven O
exons O
, O
the O
exon O
/ O
intron O
boundaries O
and O
part O
of O
3 O
noncoding O
sequence O
of O
the O
cpo O
gene O
were O
systematically O
analyzed O
by O
an O
exon O
- O
by O
- O
exon O
denaturing O
gradient O
gel O
electrophoresis O
( O
dgge O
) O
strategy O
followed O
by O
direct O
sequencing O
in O
seven O
unrelated O
heterozygous O
hc B-Disease
patients O
from O
france O
, O
holland O
, O
and O
czech O
republic O
. O

seven O
novel O
mutations O
and O
two O
new O
polymorphisms O
were O
detected O
. O

among O
these O
mutations O
two O
are O
missense O
( O
g197w O
, O
w427r O
) O
, O
two O
are O
nonsense O
( O
q306x O
, O
q385x O
) O
, O
two O
are O
small O
deletions O
( O
662de14bp O
; O
1168del3bp O
removing O
a O
glycine O
at O
position O
390 O
) O
, O
and O
one O
is O
a O
splicing O
mutation O
( O
ivs1 O
- O
15c O
- O
- O
> O
g O
) O
which O
creates O
a O
new O
acceptor O
splice O
site O
. O

the O
pathological O
significance O
of O
the O
point O
mutations O
g197w O
, O
w427r O
, O
and O
the O
in O
- O
frame O
deletion O
390delgly O
were O
assessed O
by O
their O
respective O
expression O
in O
a O
prokaryotic O
system O
using O
site O
- O
directed O
mutagenesis O
. O

these O
mutations O
resulted O
in O
the O
absence O
or O
a O
dramatic O
decrease O
of O
cpo O
activity O
. O

the O
two O
polymorphisms O
were O
localized O
in O
noncoding O
part O
of O
the O
gene O
1 O
) O
a O
c O
/ O
g O
polymorphism O
in O
the O
promotor O
region O
, O
142 O
bp O
upstream O
from O
the O
transcriptional O
initiation O
site O
( O
- O
142c O
/ O
g O
) O
, O
and O
2 O
) O
a O
6 O
bp O
deletion O
polymorphism O
in O
the O
3 O
noncoding O
part O
of O
the O
cpo O
gene O
, O
574 O
bp O
downstream O
of O
the O
last O
base O
of O
the O
normal O
termination O
codon O
( O
+ O
574 O
delattctt O
) O
. O

five O
intragenic O
dimorphisms O
are O
now O
well O
characterized O
and O
the O
high O
degree O
of O
allelic O
heterogeneity O
in O
hc B-Disease
is O
demonstrated O
with O
seven O
new O
different O
mutations O
making O
a O
total O
of O
nineteen O
cpo O
gene B-Disease
defects I-Disease
reported O
so O
far O
. O
. O

coincidence O
of O
two O
novel O
arylsulfatase O
a O
alleles O
and O
mutation O
459 O
+ O
1g O
> O
a O
within O
a O
family O
with O
metachromatic B-Disease
leukodystrophy I-Disease
: O
molecular O
basis O
of O
phenotypic O
heterogeneity O
. O

in O
a O
family O
with O
three O
siblings O
, O
one O
developed O
classical O
late O
infantile O
metachromatic B-Disease
leukodystrophy I-Disease
( O
mld B-Disease
) O
, O
fatal O
at O
age O
5 O
years O
, O
with O
deficient O
arylsulfatase O
a O
( O
arsa O
) O
activity O
and O
increased O
galactosylsulfatide O
( O
gs O
) O
excretion O
. O

the O
two O
other O
siblings O
, O
apparently O
healthy O
at O
12 O
( O
1 O
/ O
2 O
) O
and O
15 O
years O
, O
respectively O
, O
and O
their O
father O
, O
apparently O
healthy O
as O
well O
, O
presented O
arsa O
and O
gs O
values O
within O
the O
range O
of O
mld B-Disease
patients O
. O

mutation O
screening O
and O
sequence O
analysis O
disclosed O
the O
involvement O
of O
three O
different O
arsa O
mutations O
being O
the O
molecular O
basis O
of O
intrafamilial O
phenotypic O
heterogeneity O
. O

the O
late O
infantile O
patient O
inherited O
from O
his O
mother O
the O
frequent O
0 O
- O
type O
mutation O
459 O
+ O
1g O
> O
a O
, O
and O
from O
his O
father O
a O
novel O
, O
single O
basepair O
microdeletion O
of O
guanine O
at O
nucleotide O
7 O
in O
exon O
1 O
( O
7delg O
) O
. O

the O
two O
clinically O
unaffected O
siblings O
carried O
the O
maternal O
mutation O
459 O
+ O
1g O
> O
a O
and O
, O
on O
their O
paternal O
allele O
, O
a O
novel O
cytosine O
to O
thymidine O
transition O
at O
nucleotide O
2435 O
in O
exon O
8 O
, O
resulting O
in O
substitution O
of O
alanine O
464 O
by O
valine O
( O
a464v O
) O
. O

the O
fathers O
genotype O
thus O
was O
7delg O
/ O
a464v O
. O

mutation O
a464v O
was O
not O
found O
in O
18 O
unrelated O
mld B-Disease
patients O
and O
50 O
controls O
. O

a464v O
, O
although O
clearly O
modifying O
arsa O
and O
gs O
levels O
, O
apparently O
bears O
little O
significance O
for O
clinical O
manifestation O
of O
mld B-Disease
, O
mimicking O
the O
frequent O
arsa O
pseudodeficiency O
allele O
. O

our O
results O
demonstrate O
that O
in O
certain O
genetic O
conditions O
mld B-Disease
- O
like O
arsa O
and O
gs O
values O
need O
not O
be O
paralleled O
by O
clinical O
disease O
, O
a O
finding O
with O
serious O
diagnostic O
and O
prognostic O
implications O
. O

moreover O
, O
further O
arsa O
alleles O
functionally O
similar O
to O
a464v O
might O
exist O
which O
, O
together O
with O
0 O
- O
type O
mutations O
, O
may O
cause O
pathological O
arsa O
and O
gs O
levels O
, O
but O
not O
clinical O
outbreak O
of O
the O
disease O
. O
. O

human O
mlh1 O
deficiency O
predisposes O
to O
hematological B-Disease
malignancy I-Disease
and O
neurofibromatosis B-Disease
type I-Disease
1 I-Disease
. O

heterozygous O
germ O
- O
line O
mutations O
in O
the O
dna O
mismatch O
repair O
genes O
lead O
to O
hereditary B-Disease
nonpolyposis I-Disease
colorectal I-Disease
cancer I-Disease
. O

the O
disease O
susceptibility O
of O
individuals O
who O
constitutionally O
lack O
both O
wild O
- O
type O
alleles O
is O
unknown O
. O

we O
have O
identified O
three O
offspring O
in O
a O
hereditary B-Disease
nonpolyposis I-Disease
colorectal I-Disease
cancer I-Disease
family O
who O
developed O
hematological B-Disease
malignancy I-Disease
at O
a O
very O
early O
age O
, O
and O
at O
least O
two O
of O
them O
displayed O
signs O
of O
neurofibromatosis B-Disease
type I-Disease
1 I-Disease
( O
nf1 B-Disease
) O
. O

dna O
sequence O
analysis O
and O
allele O
- O
specific O
amplification O
in O
two O
siblings O
revealed O
a O
homozygous O
mlh1 O
mutation O
( O
c676t O
- O
- O
> O
arg226stop O
) O
. O

thus O
, O
a O
homozygous O
germ O
- O
line O
mlh1 O
mutation O
and O
consequent O
mismatch O
repair O
deficiency O
results O
in O
a O
mutator O
phenotype O
characterized O
by O
leukemia B-Disease
and O
/ O
or O
lymphoma B-Disease
associated O
with O
neurofibromatosis B-Disease
type I-Disease
1 I-Disease
. O
. O

missense O
mutations O
in O
the O
most O
ancient O
residues O
of O
the O
pax6 O
paired O
domain O
underlie O
a O
spectrum O
of O
human O
congenital B-Disease
eye I-Disease
malformations I-Disease
. O

mutations O
of O
the O
human O
pax6 O
gene O
underlie O
aniridia B-Disease
( O
congenital B-Disease
absence I-Disease
of I-Disease
the I-Disease
iris I-Disease
) O
, O
a O
rare O
dominant O
malformation B-Disease
of I-Disease
the I-Disease
eye I-Disease
. O

the O
spectrum O
of O
pax6 O
mutations O
in O
aniridia B-Disease
patients O
is O
highly O
biased O
, O
with O
92 O
% O
of O
all O
reported O
mutations O
leading O
to O
premature O
truncation O
of O
the O
protein O
( O
nonsense O
, O
splicing O
, O
insertions O
and O
deletions O
) O
and O
just O
2 O
% O
leading O
to O
substitution O
of O
one O
amino O
acid O
by O
another O
( O
missense O
) O
. O

the O
extraordinary O
conservation O
of O
the O
pax6 O
protein O
at O
the O
amino O
acid O
level O
amongst O
vertebrates O
predicts O
that O
pathological O
missense O
mutations O
should O
in O
fact O
be O
common O
even O
though O
they O
are O
hardly O
ever O
seen O
in O
aniridia B-Disease
patients O
. O

this O
indicates O
that O
there O
is O
a O
heavy O
ascertainment O
bias O
in O
the O
selection O
of O
patients O
for O
pax6 O
mutation O
analysis O
and O
that O
the O
missing O
pax6 O
missense O
mutations O
frequently O
may O
underlie O
phenotypes O
distinct O
from O
textbook O
aniridia B-Disease
. O

here O
we O
present O
four O
novel O
pax6 O
missense O
mutations O
, O
two O
in O
association O
with O
atypical O
phenotypes O
ectopia B-Disease
pupillae I-Disease
( O
displaced B-Disease
pupils I-Disease
) O
and O
congenital B-Disease
nystagmus I-Disease
( O
searching B-Disease
gaze I-Disease
) O
, O
and O
two O
in O
association O
with O
more O
recognizable O
aniridia B-Disease
phenotypes O
. O

strikingly O
, O
all O
four O
mutations O
are O
located O
within O
the O
pax6 O
paired O
domain O
and O
affect O
amino O
acids O
which O
are O
highly O
conserved O
in O
all O
known O
paired O
domain O
proteins O
. O

our O
results O
support O
the O
hypothesis O
that O
the O
under O
- O
representation O
of O
missense O
mutations O
is O
caused O
by O
ascertainment O
bias O
and O
suggest O
that O
a O
substantial O
burden O
of O
pax6 B-Disease
- I-Disease
related I-Disease
disease I-Disease
remains O
to O
be O
uncovered O
. O
. O

the O
chromosomal O
order O
of O
genes O
controlling O
the O
major O
histocompatibility O
complex O
, O
properdin O
factor O
b O
, O
and O
deficiency B-Disease
of I-Disease
the I-Disease
second I-Disease
component I-Disease
of I-Disease
complement I-Disease
. O

the O
relationship O
of O
the O
genes O
coding O
for O
hla O
to O
those O
coding O
for O
properdin O
factor O
b O
allotypes O
and O
for O
deficiency B-Disease
of I-Disease
the I-Disease
second I-Disease
component I-Disease
of I-Disease
complement I-Disease
( O
c2 O
) O
was O
studied O
in O
families O
of O
patients O
with O
connective O
tissue O
disorders O
. O

patients O
were O
selected O
because O
they O
were O
heterozygous O
or O
homozygous O
for O
c2 B-Disease
deficiency I-Disease
. O

12 O
families O
with O
15 O
matings O
informative O
for O
c2 B-Disease
deficiency I-Disease
were O
found O
. O

of O
57 O
informative O
meioses O
, O
two O
crossovers O
were O
noted O
between O
the O
c2 B-Disease
deficiency I-Disease
gene O
and O
the O
hla O
- O
b O
gene O
, O
with O
a O
recombinant O
fraction O
of O
0 O
. O

035 O
. O

a O
lod O
score O
of O
13 O
was O
calculated O
for O
linkage O
between O
c2 B-Disease
deficiency I-Disease
and O
hla O
- O
b O
at O
a O
maximum O
likelihood O
value O
of O
the O
recombinant O
fraction O
of O
0 O
. O

04 O
. O

18 O
families O
with O
21 O
informative O
matings O
for O
both O
properdin O
factor O
b O
allotype O
and O
hla O
- O
b O
were O
found O
. O

of O
72 O
informative O
meioses O
, O
three O
recombinants O
were O
found O
, O
giving O
a O
recombinant O
fraction O
of O
0 O
. O

042 O
. O

a O
lod O
score O
of O
16 O
between O
hla O
- O
b O
and O
factor O
b O
allotypes O
was O
calculated O
at O
a O
maximum O
likelihood O
value O
of O
the O
recombinant O
fraction O
of O
0 O
. O

04 O
. O

a O
crossover O
was O
shown O
to O
have O
occurred O
between O
genes O
for O
factor O
b O
and O
hla O
- O
d O
, O
in O
which O
hla O
- O
d O
segregared O
with O
hla O
- O
a O
and O
b O
. O

these O
studies O
suggest O
that O
the O
genes O
for O
factor O
b O
and O
c2 B-Disease
deficiency I-Disease
are O
located O
outside O
those O
for O
hla O
, O
that O
the O
order O
of O
genese O
is O
hla O
- O
a O
, O
- O
b O
, O
- O
d O
, O
factor O
b O
allotype O
, O
c2 B-Disease
deficiency I-Disease
, O
that O
the O
genes O
coding O
for O
c2 B-Disease
deficiency I-Disease
and O
factor O
b O
allotypes O
are O
approximately O
3 O
- O
- O
5 O
centimorgans O
from O
the O
hla O
- O
a O
and O
hla O
- O
b O
loci O
, O
and O
that O
the O
apparent O
lack O
of O
recombinants O
between O
the O
factor O
b O
gene O
and O
c2 B-Disease
deficiency I-Disease
gene O
suggests O
that O
these O
two O
genes O
lie O
in O
close O
proximity O
to O
one O
another O
. O

distribution O
of O
emerin O
and O
lamins O
in O
the O
heart O
and O
implications O
for O
emery B-Disease
- I-Disease
dreifuss I-Disease
muscular I-Disease
dystrophy I-Disease
. O

emerin O
is O
a O
nuclear O
membrane O
protein O
which O
is O
missing O
or O
defective O
in O
emery B-Disease
- I-Disease
dreifuss I-Disease
muscular I-Disease
dystrophy I-Disease
( O
edmd B-Disease
) O
. O

it O
is O
one O
member O
of O
a O
family O
of O
lamina O
- O
associated O
proteins O
which O
includes O
lap1 O
, O
lap2 O
and O
lamin O
b O
receptor O
( O
lbr O
) O
. O

a O
panel O
of O
16 O
monoclonal O
antibodies O
( O
mabs O
) O
has O
been O
mapped O
to O
six O
specific O
sites O
throughout O
the O
emerin O
molecule O
using O
phage O
- O
displayed O
peptide O
libraries O
and O
has O
been O
used O
to O
localize O
emerin O
in O
human O
and O
rabbit O
heart O
. O

several O
mabs O
against O
different O
emerin O
epitopes O
did O
not O
recognize O
intercalated O
discs O
in O
the O
heart O
, O
though O
they O
recognized O
cardiomyocyte O
nuclei O
strongly O
, O
both O
at O
the O
rim O
and O
in O
intranuclear O
spots O
or O
channels O
. O

a O
polyclonal O
rabbit O
antiserum O
against O
emerin O
did O
recognize O
both O
nuclear O
membrane O
and O
intercalated O
discs O
but O
, O
after O
affinity O
purification O
against O
a O
pure O
- O
emerin O
band O
on O
a O
western O
blot O
, O
it O
stained O
only O
the O
nuclear O
membrane O
. O

these O
results O
would O
not O
be O
expected O
if O
immunostaining O
at O
intercalated O
discs O
were O
due O
to O
a O
product O
of O
the O
emerin O
gene O
and O
, O
therefore O
, O
cast O
some O
doubt O
upon O
the O
hypothesis O
that O
cardiac B-Disease
defects I-Disease
in O
edmd B-Disease
are O
caused O
by O
absence O
of O
emerin O
from O
intercalated O
discs O
. O

although O
emerin O
was O
abundant O
in O
the O
membranes O
of O
cardiomyocyte O
nuclei O
, O
it O
was O
absent O
from O
many O
non O
- O
myocyte O
cells O
in O
the O
heart O
. O

this O
distribution O
of O
emerin O
was O
similar O
to O
that O
of O
lamin O
a O
, O
a O
candidate O
gene O
for O
an O
autosomal O
form O
of O
edmd B-Disease
. O

in O
contrast O
, O
lamin O
b1 O
was O
absent O
from O
cardiomyocyte O
nuclei O
, O
showing O
that O
lamin O
b1 O
is O
not O
essential O
for O
localization O
of O
emerin O
to O
the O
nuclear O
lamina O
. O

lamin O
b1 O
is O
also O
almost O
completely O
absent O
from O
skeletal O
muscle O
nuclei O
. O

in O
edmd B-Disease
, O
the O
additional O
absence O
of O
lamin O
b1 O
from O
heart O
and O
skeletal O
muscle O
nuclei O
which O
already O
lack O
emerin O
may O
offer O
an O
alternative O
explanation O
of O
why O
these O
tissues O
are O
particularly O
affected O
. O
. O

genetic O
mapping O
of O
the O
copper B-Disease
toxicosis I-Disease
locus O
in O
bedlington O
terriers O
to O
dog O
chromosome O
10 O
, O
in O
a O
region O
syntenic O
to O
human O
chromosome O
region O
2p13 O
- O
p16 O
. O

abnormal O
hepatic B-Disease
copper I-Disease
accumulation I-Disease
is O
recognized O
as O
an O
inherited B-Disease
disorder I-Disease
in O
man O
, O
mouse O
, O
rat O
and O
dog O
. O

the O
major O
cause O
of O
hepatic B-Disease
copper I-Disease
accumulation I-Disease
in O
man O
is O
a O
dysfunctional O
atp7b O
gene O
, O
causing O
wilson B-Disease
disease I-Disease
( O
wd B-Disease
) O
. O

mutations O
in O
the O
atp7b O
genes O
have O
also O
been O
demonstrated O
in O
mouse O
and O
rat O
. O

the O
atp7b O
gene O
has O
been O
excluded O
in O
the O
much O
rarer O
human O
copper B-Disease
overload I-Disease
disease O
non B-Disease
- I-Disease
indian I-Disease
childhood I-Disease
cirrhosis I-Disease
, O
indicating O
genetic O
heterogeneity O
. O

by O
investigating O
the O
common O
autosomal O
recessive O
copper B-Disease
toxicosis I-Disease
( O
ct B-Disease
) O
in O
bedlington O
terriers O
, O
we O
have O
identified O
a O
new O
locus O
involved O
in O
progressive O
liver B-Disease
disease I-Disease
. O

we O
examined O
whether O
the O
wd B-Disease
gene O
atp7b O
was O
also O
causative O
for O
ct B-Disease
by O
investigating O
the O
chromosomal O
co O
- O
localization O
of O
atp7b O
and O
c04107 O
, O
using O
fluorescence O
in O
situ O
hybridization O
( O
fish O
) O
. O

c04107 O
is O
an O
anonymous O
microsatellite O
marker O
closely O
linked O
to O
ct B-Disease
. O

however O
, O
bac O
clones O
containing O
atp7b O
and O
c04107 O
mapped O
to O
the O
canine O
chromosome O
regions O
cfa22q11 O
and O
cfa10q26 O
, O
respectively O
, O
demonstrating O
that O
wd B-Disease
cannot O
be O
homologous O
to O
ct B-Disease
. O

the O
copper O
transport O
genes O
ctr1 O
and O
ctr2 O
were O
also O
excluded O
as O
candidate O
genes O
for O
ct B-Disease
since O
they O
both O
mapped O
to O
canine O
chromosome O
region O
cfa11q22 O
. O

2 O
- O
22 O
. O

5 O
. O

a O
transcribed O
sequence O
identified O
from O
the O
c04107 O
- O
containing O
bac O
was O
found O
to O
be O
homologous O
to O
a O
gene O
expressed O
from O
human O
chromosome O
2p13 O
- O
p16 O
, O
a O
region O
devoid O
of O
any O
positional O
candidate O
genes O
. O

molecular O
analysis O
of O
the O
apc B-Disease
gene O
in O
205 O
families O
: O
extended O
genotype O
- O
phenotype O
correlations O
in O
fap B-Disease
and O
evidence O
for O
the O
role O
of O
apc B-Disease
amino O
acid O
changes O
in O
colorectal B-Disease
cancer I-Disease
predisposition O
. O

background O
/ O
aims O
the O
development O
of O
colorectal B-Disease
cancer I-Disease
and O
a O
variable O
range O
of O
extracolonic O
manifestations O
in O
familial B-Disease
adenomatous I-Disease
polyposis I-Disease
( O
fap B-Disease
) O
is O
the O
result O
of O
the O
dominant O
inheritance O
of O
adenomatous B-Disease
polyposis I-Disease
coli I-Disease
( O
apc B-Disease
) O
gene O
mutations O
. O

in O
this O
study O
, O
direct O
mutation O
analysis O
of O
the O
apc B-Disease
gene O
was O
performed O
to O
determine O
genotype O
- O
phenotype O
correlations O
for O
nine O
extracolonic O
manifestations O
and O
to O
investigate O
the O
incidence O
of O
apc B-Disease
mutations O
in O
non O
- O
fap O
colorectal B-Disease
cancer I-Disease
. O

methods O
the O
apc B-Disease
gene O
was O
analysed O
in O
190 O
unrelated O
fap B-Disease
and O
15 O
non O
- O
fap O
colorectal B-Disease
cancer I-Disease
patients O
using O
denaturing O
gradient O
gel O
electrophoresis O
, O
the O
protein O
truncation O
test O
, O
and O
direct O
sequencing O
. O

results O
chain O
terminating O
signals O
were O
only O
identified O
in O
patients O
belonging O
to O
the O
fap B-Disease
group O
( O
105 O
patients O
) O
. O

amino O
acid O
changes O
were O
identified O
in O
four O
patients O
, O
three O
of O
whom O
belonged O
to O
the O
non O
- O
fap O
group O
of O
colorectal B-Disease
cancer I-Disease
patients O
. O

genotype O
- O
phenotype O
correlations O
identified O
significant O
differences O
in O
the O
nature O
of O
certain O
extracolonic O
manifestations O
in O
fap B-Disease
patients O
belonging O
to O
three O
mutation O
subgroups O
. O

conclusions O
extended O
genotype O
- O
phenotype O
correlations O
made O
in O
this O
study O
may O
have O
the O
potential O
to O
determine O
the O
most O
appropriate O
surveillance O
and O
prophylactic O
treatment O
regimens O
for O
those O
patients O
with O
mutations O
associated O
with O
life O
threatening O
conditions O
. O

this O
study O
also O
provided O
evidence O
for O
the O
pathological O
nature O
of O
amino O
acid O
changes O
in O
apc O
associated O
with O
both O
fap B-Disease
and O
non O
- O
fap O
colorectal B-Disease
cancer I-Disease
patients O
. O
. O

inherited B-Disease
colorectal I-Disease
polyposis I-Disease
and O
cancer B-Disease
risk O
of O
the O
apc O
i1307k O
polymorphism O
. O

germ O
- O
line O
and O
somatic O
truncating O
mutations O
of O
the O
apc B-Disease
gene O
are O
thought O
to O
initiate O
colorectal B-Disease
tumor I-Disease
formation O
in O
familial B-Disease
adenomatous I-Disease
polyposis I-Disease
syndrome I-Disease
and O
sporadic O
colorectal O
carcinogenesis O
, O
respectively O
. O

recently O
, O
an O
isoleucine O
- O
- O
> O
lysine O
polymorphism O
at O
codon O
1307 O
( O
i1307k O
) O
of O
the O
apc B-Disease
gene O
has O
been O
identified O
in O
6 O
% O
- O
7 O
% O
of O
the O
ashkenazi O
jewish O
population O
. O

to O
assess O
the O
risk O
of O
this O
common O
apc B-Disease
allelic O
variant O
in O
colorectal O
carcinogenesis O
, O
we O
have O
analyzed O
a O
large O
cohort O
of O
unselected O
ashkenazi O
jewish O
subjects O
with O
adenomatous B-Disease
polyps I-Disease
and O
. O
or O
colorectal B-Disease
cancer I-Disease
, I-Disease
for O
the O
apc O
i1307k O
polymorphism O
. O

the O
apc O
i1307k O
allele O
was O
identified O
in O
48 O
( O
10 O
. O
1 O
% O
) O
of O
476 O
patients O
. O

compared O
with O
the O
frequency O
in O
two O
separate O
population O
control O
groups O
, O
the O
apc O
i1307k O
allele O
is O
associated O
with O
an O
estimated O
relative O
risk O
of O
1 O
. O

5 O
- O
1 O
. O

7 O
for O
colorectal B-Disease
neoplasia I-Disease
( O
both O
p O
= O
. O
01 O
) O
. O

furthermore O
, O
compared O
with O
noncarriers O
, O
apc O
i1307k O
carriers O
had O
increased O
numbers O
of O
adenomas B-Disease
and O
colorectal B-Disease
cancers I-Disease
per O
patient O
( O
p O
= O
. O
03 O
) O
, O
as O
well O
as O
a O
younger O
age O
at O
diagnosis O
. O

we O
conclude O
that O
the O
apc O
i1307k O
variant O
leads O
to O
increased O
adenoma B-Disease
formation O
and O
directly O
contributes O
to O
3 O
% O
- O
4 O
% O
of O
all O
ashkenazi O
jewish O
colorectal B-Disease
cancer I-Disease
. O

the O
estimated O
relative O
risk O
for O
carriers O
may O
justify O
specific O
clinical O
screening O
for O
the O
360 O
, O
000 O
americans O
expected O
to O
harbor O
this O
allele O
, O
and O
genetic O
testing O
in O
the O
setting O
of O
long O
- O
term O
- O
outcome O
studies O
may O
impact O
significantly O
on O
colorectal B-Disease
cancer I-Disease
prevention O
in O
this O
population O
. O

localization O
of O
human O
brca1 O
and O
its O
loss O
in O
high O
- O
grade O
, O
non B-Disease
- I-Disease
inherited I-Disease
breast I-Disease
carcinomas I-Disease
. O

although O
the O
link O
between O
the O
brca1 O
tumour B-Disease
- O
suppressor O
gene O
and O
hereditary B-Disease
breast I-Disease
and I-Disease
ovarian I-Disease
cancer I-Disease
is O
established O
, O
the O
role O
, O
if O
any O
, O
of O
brca1 O
in O
non B-Disease
- I-Disease
familial I-Disease
cancers I-Disease
is O
unclear O
. O

brca1 O
mutations O
are O
rare O
in O
sporadic B-Disease
cancers I-Disease
, O
but O
loss O
of O
brca1 O
resulting O
from O
reduced O
expression O
or O
incorrect O
subcellular O
localization O
is O
postulated O
to O
be O
important O
in O
non B-Disease
- I-Disease
familial I-Disease
breast I-Disease
and I-Disease
ovarian I-Disease
cancers I-Disease
. O

epigenetic O
loss O
, O
however O
, O
has O
not O
received O
general O
acceptance O
due O
to O
controversy O
regarding O
the O
subcellular O
localization O
of O
brca1 O
proteins O
, O
reports O
of O
which O
have O
ranged O
from O
exclusively O
nuclear O
, O
to O
conditionally O
nuclear O
, O
to O
the O
er O
/ O
golgi O
, O
to O
cytoplasmic O
invaginations O
into O
the O
nucleus O
. O

in O
an O
attempt O
to O
resolve O
this O
issue O
, O
we O
have O
comprehensively O
characterized O
19 O
anti O
- O
brca1 O
antibodies O
. O

these O
reagents O
detect O
a O
220 O
- O
kd O
protein O
localized O
in O
discrete O
nuclear O
foci O
in O
all O
epithelial O
cell O
lines O
, O
including O
those O
derived O
from O
breast B-Disease
malignancies I-Disease
. O

immunohistochemical O
staining O
of O
human O
breast O
specimens O
also O
revealed O
brca1 O
nuclear O
foci O
in O
benign O
breast O
, O
invasive B-Disease
lobular I-Disease
cancers I-Disease
and O
low B-Disease
- I-Disease
grade I-Disease
ductal I-Disease
carcinomas I-Disease
. O

conversely O
, O
brca1 O
expression O
was O
reduced O
or O
undetectable O
in O
the O
majority O
of O
high O
- O
grade O
, O
ductal B-Disease
carcinomas I-Disease
, O
suggesting O
that O
absence O
of O
brca1 O
may O
contribute O
to O
the O
pathogenesis O
of O
a O
significant O
percentage O
of O
sporadic B-Disease
breast I-Disease
cancers I-Disease
. O
